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Characteristics of late-life depression
Depression is characterized by depressed mood, loss of interest, rumination, feelings of guilt and 
shame, suicidal ideation, disturbed sleep and loss of appetite (1). It is associated with limitations 
in physical and social functioning and places a severe burden on patients and relatives (2).  
Compared to depression in middle age, late-life depression has some specifi c character-
istics. Depressive syndromes that escape the strict criteria of the Diagnostic and Statistical 
Manual of Psychiatric Disorders (DSM) for major depressive disorder and dysthymia are 
more common in the elderly (3-5). Many elderly have only some symptoms of depression. 
Such subthreshold depressive syndromes are considered clinically relevant, because they 
are related to increased disability and mortality, as are depressive disorders that meet DSM 
criteria (6-10). Moreover, depression is more common in the old age than in midlife. Th e 
prevalence ranges from 9 to 18 % in the general elderly population, to more than 30% in 
long-term care residents (3, 5, 11, 12). Depression in late life often has a chronic course (3, 
5, 11, 13) Only 60% of patients recover in one year and 70-80% in two years (7, 9, 14-19).
A number of risk factors for depression has been established, which predispose, pre-
cipitate, or perpetuate the disease. Female gender, adverse life events, and poverty are the 
most well known. Late-life depression has some additional specifi c risk factors. Depressive 
symptoms are very much related to cognitive decline, which occur as part of neurodegen-
erative brain diseases, such as Alzheimer’s disease, and Parkinson’s disease. Vascular brain 
damage, such as stroke and white matter lesions, are associated with late-life depression as 
well. Depression is also common in elderly patients with chronic disabling diseases. 
Th e focus of this thesis is to further assess the association between cardio- and cerebro-
vascular diseases and depression in late life.
Vascular heart disease and late-life depression
Once, mind, spirit and emotion were thought to center in the heart. Th at it is the heart 
which suff ers pain and feels anxiety. (Bible Isaiah 65:14, Jeremiah 24:7, Luke 2:19; Rom 
5:5; Anonymous writer (Hippocrates?) On the Sacred Disease, c. 425 BCE) In modern 
times, the relationship between heart and emotional well-being is still topic of many 
studies (20). Cross-sectional studies show that depression is more common in patients 
with cardiovascular disease than in the general population (20-23). Th is was found for 
heart failure, myocardial infarction and atrial fi brillation. However, little is known about 
the longitudinal relationship between these diseases and depression. Th ere may be an 
increased risk of depression in individuals with cardiac disease, an increased risk of cardiac 
disease in individuals with depression, or both. Only few prospective studies have been 
performed to test these hypotheses.
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Introduction
Depression has also been associated with medications that are prescribed for these cardiac 
diseases, such as beta-blockers (24, 25). What is known about the use of cardiovascular 
medication and the risk of depression has been studied in clinical populations primarily. 
Moreover, elderly patients are rarely included in randomized trials. Yet, approximately 
60% of elderly persons take one ore more of these drugs regularly. A drug-induced de-
pressive disorder would be a preventable or treatable disease in those patients who are 
vulnerable to this adverse eff ect, especially because alternative drugs are usually available. 
Vascular brain disease and late-life depression
Interest in the relationship between cerebrovascular disease and depression has grown 
since the early 19th century (26). Atherosclerotic lesions to brain circuits responsible for 
aff ective regulation are assumed to form the central mechanism (26-29). Such damage 
might also aff ect treatment success and the course of illness. Th is so called ‘vascular de-
pression hypothesis’ has been tested primarily in cross-sectional studies. Neuro-imaging 
and autopsy studies showed that lesions in frontal deep white matter, basal ganglia and 
gray matter, as well as atrophy were more prevalent in depressed patients than in healthy 
controls (30). Prospective studies are needed that assess the eff ect of cerebrovascular risk 
factors and disease on the risk of incident late-life depression. 
Aim and outline 
Th e aim of this research project was to assess whether cardiac diseases, cardiovascular 
medication, and cerebrovascular disease increase the risk of incident late-life depression in 
a population-based cohort study. 
Th is thesis is structured as follows. First, data on depressions that occurred newly during 
follow-up were collected in a population of community-dwelling elderly. We analyzed the 
rate of new-onset depression in persons without a history of depression (incidence rate) 
and those with a history of depression (recurrence rate) (Chapter 2). Next, we studied the 
risk of incident depression related to chronic heart failure and loop-diuretics (Chapter 
3), as well as atrial fi brillation (Chapter 4). We went on to assess whether the use of 
beta-blockers, the most commonly used group of cardiovascular medication, increases the 
risk of depression (Chapter 5). Subsequently, we examined the longitudinal association 
between risk factors generally regarded as cerebrovascular risk factors, such as smoking, 
hypertension and diabetes, and incident depression (Chapter 6). We also assessed the 
association between the retinal microcirculation, which shares many features with cerebral 
vessels, and incident depression (Chapter 7). In the next study, vascular brain disease was 
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visualized with neuro-imaging (Chapter 8). We assessed whether brain atrophy, white 
matter lesions and brain infarcts predicted the onset of depression. In the fi nal study, we 
investigated the eff ect of transient neurological attacks, clinical indicators of atheroscle-
rotic brain disease, on the risk of depression (Chapter 9). Th e thesis closes with a general 
discussion of methodology and fi ndings (Chapter 10).
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Abstract
Context. Depression is common in old age. Nevertheless, few incidence studies have 
established how often depression occurs in elderly persons with and without a history of 
depression.
Objective. To determine the incidence and recurrence rates of depression in an elderly 
population. 
Design. A cohort study performed between 1993 and 2005, encompassing baseline and 
two follow-up examinations, as well as continuous procedures.
Setting. Community-dwelling elderly persons, aged 56 or older, residing in Rotterdam, 
the Netherlands.
Participants and data assessment methods. Th e study population consisted of 5,653 par-
ticipants free of dementia. Depressions were identifi ed through standardized psychiatric 
examinations, monitoring of medical records, registration of anti-depressant use, and self-
reported histories of depression. We categorized the depressions as depressive syndromes, 
including DSM-IV defi ned major depression, or clinically relevant depressive symptoms. 
Main Outcome Measure(s). Incidence and recurrence rates for depressive syndromes, as 
well as for depressive syndromes and symptoms combined. Besides overall rates, sex- and 
age-specifi c rates were calculated.
Results. During the follow-up period of 8 years on average, 566 depressive syndromes and 
1073 episodes of clinically relevant depressive symptoms occurred. For depressive syn-
dromes, the incidence rate was 7 (95% CI: 6-8) per 1,000 person-years and the recurrence 
rate was 28 (95% CI: 24-32) per 1,000 person-years. Th e incidence and recurrence rate 
more than doubled when episodes of depressive symptoms were included. Th e recurrence 
rate of depressive syndromes was equal for women and men, but all other rates were 
almost twice as high for women compared to men. None of the rates changed with age.
Conclusions. Th e incidence rate of depression in the elderly is low, except when episodes 
of clinically relevant depressive symptoms are accounted for. Most late-life depressions 
occur in persons with a history of depression. Moreover, the recurrence rate of depressive 
syndromes does not diff er between men and women.
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Incidence and recurrence of late-life depression 
Introduction
Depression in old age places a severe burden on patients and relatives, and it occurs 
frequently.(1-4) Numerous studies have shown that the prevalence of clinically relevant 
depressive syndromes ranges from 9-18 % in the general elderly population, to more than 
30% in nursing home residents.(1-3, 5) To further assess risk and establish risk factors for 
late-life depression, incidence studies are needed. However, incidence studies that focus 
on cohorts of elderly persons are scarce.(6, 7) Incidence studies in mixed age populations 
often involved only small elderly subgroups and were not geared to the specifi c character-
istics of late-life depression.(8-10) 
In elderly people, depressive syndromes that escape the strict criteria of the Diagnostic 
and Statistical Manual of Psychiatric Disorders (DSM) for major depressive disorder 
(MDD) and dysthymia are more common.(1, 3, 11) Such sub threshold depressive syn-
dromes are often considered clinically relevant, because they are related to increased dis-
ability and mortality, like DSM-defi ned depressive disorders are.(12-15) Th erefore, these 
sub threshold depressions need to be included when estimating incidence rates.  Finally, 
incidence studies to date have typically been based on sequential psychiatric examinations 
in consecutive follow-up rounds.(2, 9, 10, 16) Depressions that developed and remitted 
in the interval between follow-up rounds could have easily been missed due to recall 
problems and loss-to-follow-up.(17, 18) Th erefore, methods to identify depressions in the 
interval period are needed to validly estimate incidence rates. 
To our knowledge, two studies have estimated incidence rates of DSM-defi ned depres-
sive disorders in non-demented elderly cohorts. However, the observed incidence rates 
varied substantially, ranging between 8 per 1,000 person-years in an American cohort 
and 23 per 1,000 person-years in a Swedish cohort.(19, 20) Case-fi nding methods as 
well socio-economic background of the study populations diff ered signifi cantly and 
might explain the diff erence. Neither of these studies, nor any other population-based 
study, presented the rate of recurrent depression. Recurrence rates represent the risk of 
new depressive episodes in persons who already experienced one or more depressions. In 
clinical studies, 13-88% of elderly patients had a recurrence, depending on whether they 
received maintenance treatment, and on the duration of follow-up.(21-26) Information 
on recurrence rates of depression would complement information on incidence rates of 
new-onset depression in the general population. 
Our objective was to determine incidence and recurrence rates of depression in a 
population-based cohort study of non-demented elderly persons. We used a combination 
of assessment methods, including continuous monitoring procedures, to identify new-
onset depressions. 
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Methods
Setting
Th is investigation was embedded in the Rotterdam Study, a prospective population-based 
study on incidence and determinants of diseases in late life. In 1990, all inhabitants of a 
district of Rotterdam aged 55 years and over were invited and 7983 agreed to participate 
(response 78%). (27) Th e Medical Ethics Committee of the Erasmus Medical Center 
Rotterdam approved the study and written informed consent was obtained from all 
participants.
So far, four examination rounds have taken place from 1990-1993, 1993-1995, 1997-
1999, and 2002-2004. Participants underwent an extensive home interview and a physical 
examination at the research centre. Continuous monitoring for major events that oc-
curred during follow-up was achieved through linkage with the medical fi les from general 
practitioners. Th ese fi les contain all medical information as the Dutch health care system 
requires all residents to be registered with a general practitioner (GP) and specialists report 
back to the GP. Information on vital status was obtained bimonthly from the municipal 
authorities in Rotterdam. 
Study population
During the fi rst examination round of the Rotterdam Study, 7983 persons participated. 
Of these participants, 771 died before the second examination round, and 736 were lost 
to follow-up or refused further participation in any subsequent rounds. In total, 6476 
participants participated in the second examination of the Rotterdam Study; this exami-
nation constituted the baseline of the present study (fi gure 1). 
Of these 6476 participants, 4940 were screened for depressive symptoms, 1372 did not 
receive a questionnaire containing the screening instrument for depressive symptoms and 
164 did not complete the screening questionnaire. However, 829 of these 1536 non-screened 
persons were successfully screened in the next examination round. Of the remaining 707 
persons, 339 had died before this round and 395 were lost to follow-up or refused further 
participation. Th us, 5769 persons (4940+829) were screened for depressive symptoms.
We excluded 105 persons with dementia at baseline according to earlier published crite-
ria (28), 9 persons that had been diagnosed with bipolar disorder before or after baseline, 
and 2 persons who died on the day they had been screened. Th is resulted in a cohort of 
5,653 persons for the analysis. 
Persons with dementia were excluded because they cannot report depressive symptoms 
validly, and without information from primary caregivers, estimates of the incidence of 
depression in persons with dementia are invalid.(3)
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Incidence and recurrence of late-life depression 
Assessment of depression
Screening for depressive symptoms was introduced as a pilot project in the Rotterdam 
Study. At baseline, 48% of the participants fi lled out the validated Dutch version of the 
Center for Epidemiologic Studies Depression Scale (CES-D), and 52% the validated 
Dutch version of the Hospital Anxiety and Depression Scale (HADS).(29, 30) Th e CES-
D consists of 20 questions with possible scores of 0 to 3. A score of 16 or higher on the 
CES-D is considered indicative of a depressive disorder. 10.5% of participants scored 
above this cut-off . Th e HADS contains a subscale of 7 questions on depressive symptoms 
with possible scores of 0 to 3. We applied ³ 9 as the cut-off  for the HADS as it yielded a 
percentage of screen-positives similar to that of the CES-D (9.9%). Among community 
populations, the sensitivity of the HADS was 90% and the specifi city 91%, and that of the 
CES-D 100% and 88% respectively. (30, 31) In order to enhance case-fi nding during the 
follow-up period, information on the occurrence of new-onset depressions was collected 
with multiple assessment methods. 
Psychiatric examination. During the two follow-up rounds, we used a two-step procedure 
to assess whether participants were going through a depressive episode. First, all partici-
pants were screened with the CES-D as part of the home-interview. Th e screen-positive 
participants were invited for a clinical interview. A psychiatrist (WO), psycho-geriatrician 
Figure 1 Flow diagram 
































0RQLWRULQJRI
PHGLFDOILOHV
5HJLVWUDWLRQRI
DQWLGHSUHVVDQWV


([DPLQDWLRQ
URXQGV





EDVHOLQH




















2FW
HQGRIVWXG\
6HOIUHSRUWHGKLVWRU\
RIGHSUHVVLRQ
6FUHHQLQJ
	SV\FKLDWULFLQWHUYLHZ
OLIHWLPH

OLIHWLPH


VFUHHQHG
VFUHHQSRVLWLYHVLQWHUYLHZHG
'HSUHVVLRQDVVHVVPHQWVGXULQJH[DPLQDWLRQURXQGV

VFUHHQHG
VFUHHQSRVLWLYHVLQWHUYLHZHG
VWXG\SRSXODWLRQ
&RQWLQXRXVGHSUHVVLRQDVVHVVPHQWV


















GLHGQRQSDUWLFLSDQWV
GLHGQRQSDUWLFLSDQWV
VFUHHQHG
VFUHHQHG

QRWVFUHHQHG
GLHGQRQ
SDUWLFLSDQWV
H[FOXGHG

SDUWLFLSDQWV
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Chapter 2 
20
(HJL) or clinical psychologist (HJT), each with extensive clinical experience, conducted 
the interview using the Dutch version of the Present State Examination (PSE-10). Th is is a 
semi-structured psychiatric interview included in the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN).(32) Scoring of items is conservative and relies on clinical judg-
ment instead of the participant’s answer only. Each interviewer was trained in the certifi ed 
Dutch WHO centre. With a computerized diagnostic algorithm based on the item scores, 
major and minor depressive disorders and dysthymia were classifi ed according to DSM-IV 
criteria. Th e psychiatric examination data were complete for 97% of the participants of 
the fi rst follow-up round, and 97 % of the participants of the second follow-up round. 
Continuous monitoring of medical records.  Active surveillance for the occurrence of de-
pressions took place from baseline onward. Trained research-assistants systematically scru-
tinized all information contained in the medical records of the GPs, for instance hospital 
discharge letters, specialist reports, and notes of the GP, for a number of predefi ned cues 
such as symptoms of depression, prescriptions of psychiatric medication, the occurrence 
of major life events and psychosocial problems. Th ey copied information that indicated 
a potential depression. By October 1, 2005, this information was complete for 85% of 
the follow-up period. Next, two physicians (HL, MD), and a research psychologist (JB) 
independently read all copied information. Th ey categorized each depression according to 
a predefi ned protocol. Instances of bipolar depressive disorder were ascertained as well. All 
discordant categorizations were discussed in consensus meetings. 
Registration of antidepressant drug use. Th e seven fully computerized pharmacies that 
serve the study area routinely store information on drugs dispensed to participants in an 
online database. Ninety-fi ve percent of the participants of the Rotterdam Study fi ll their 
prescriptions at one of the pharmacies in the study district. Th e other 5% either moved 
out of the study district, or resided in a nursing home that have their own pharmacies. 
Files were updated from the start of the Rotterdam Study up till October 1, 2005. For 
this study we used the information on antidepressants to identify potential depressive 
symptoms or specify the date-of-onset of a depressive episode. 
Self-reported history of depression. At baseline and during each follow-up round, all 
participants were interviewed by a physician to establish their medical history, including 
depression and certain somatic diseases. Participants were asked standardized questions 
to assess whether they had suff ered from a depression since the previous examination 
round, and if so whether (s)he had been treated, and at what age the episode had occurred. 
Baseline data were complete for 95% of the participants.
Categorization of depression
We recorded depressions that fulfi lled DSM-IV criteria, as well as depressive episodes that 
were clinically relevant but that did not meet DSM-criteria. GPs frequently diagnosed 
depressions without using or documenting the formal DSM-criteria. We applied a cat-
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egorization of depression that refl ects this variation in severity and diagnostic approach. 
Our categorization consisted of two categories: depressive syndromes, including DSM-IV 
depressive disorders, and clinically relevant depressive symptoms. 
1- Th e category depressive syndromes consisted of ‘MDD and dysthymia’ and ‘other 
depressive syndromes’. ‘MDD and dysthymia’ encompassed depressive episodes that 
clearly met the DSM-IV criteria for these disorders. Furthermore, the episodes were 
diagnosed by a psychiatrist or another mental health professional - be it in special-
ist health care or by psychiatric interview as part of the Rotterdam Study. Th e group 
‘other depressive syndromes’ covered a) depression recorded by a GP or physician, b) 
self-reported depression for which the participant consulted a GP or a mental health 
professional, and c) DSM-IV minor depression. 
2- Th e category clinically relevant depressive symptoms included a) one clinically relevant 
core symptom of major depression recorded during the psychiatric interview or in the 
medical record, b) self-reported depression of a participant who did not consult a GP 
or a mental health professional, and c) initiation of anti-depressant drug treatment 
(without documentation of clinical symptoms).
We applied the same criteria to categorize depressions that preceded the study period. 
Grief, adjustment disorder and burnout, characterized by emotional exhaustion, and 
reduced satisfaction in personal accomplishment (33), were not regarded depressions.
Recurrent episodes. We assumed that a person had recovered fully if no depressive symp-
toms had been recorded nor any anti-depressant had been used for a period of at least two 
years.(34) Th is two-year criterion not only refl ects a conservative approach, but was also 
deemed appropriate because depression  often has a chronic course, with only 60% of 
patients recovering in one year and 70-80% in two years.(6, 12, 21, 22, 35-38) Th is way, 
we took into account that ongoing depressive episodes are frequently poorly documented 
in primary care medical records, and that a long lag time exists between the onset of a 
depressive episode and its presentation to a GP. Ideally, actual cessation dates are used, but 
these are diffi  cult to ascertain in population-based studies.
Date-of-onset. We defi ned the date-of-onset of a depressive episode as (a) the self-
reported date-of-onset as provided in the psychiatric interview or the self-reported history 
of depression, (b) the fi rst occurrence of a depressive symptom in the medical records, 
or (c) the day at which the fi rst prescription of an antidepressant drug was dispensed. 
Duplicate reports. When an episode was identifi ed with two or more assessment methods, 
we used the most specifi c assessment method to determine the diagnosis, i.e. the psychi-
atric interview overrules the medical records, which in turn overrules the self-reported 
histories and prescription data. We took the earliest date to defi ne the date-of-onset, with 
the exception that a date reported retrospectively in the history of depression  could not 
overrule a date from any other assessment method.
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Data-analysis
We analyzed incidence and recurrence rates. Persons with no history of depression could 
experience a fi rst-ever depression during follow-up (incidence rate). Persons with a history 
of depression or prevalent depression at baseline were at risk of a recurrent depression 
(recurrence rate). 
First, we calculated the incidence and recurrence rate of all depressions combined, 
including MDD, dysthymia, other depressive syndromes and clinically relevant depressive 
symptoms. Th e incidence rate was calculated in 3,459 participants who did not have 
depressive symptoms at baseline nor a history of depression, and who were therefore at risk 
of a fi rst-ever depression. Th e recurrence rate was calculated in a total of 2,753 participants 
who were at risk of recurrent depression: 1,645 participants had a positive history of 
depression and 549 participants had a prevalent depression at baseline; 559 participants 
were at risk after they had experienced a fi rst-ever episode during follow-up. 
Secondly, we calculated incidence and recurrence rates of depressive syndromes only, 
including MDD and other depressive syndromes. For this analysis the fi rst follow-up 
examination served as baseline, because this was the fi rst round during which prevalent 
depressive syndromes were formally diagnosed (N=4,343). Th ere were 3,461 participants 
who were at risk of a fi rst-ever depression, and 1,158 participants at risk of a recurrent 
depression. In addition, we calculated the incidence and recurrence rate of MDD and 
dysthymia in this study population. 
All rates were obtained by dividing the number of new-onset episodes by the number of 
person-years at risk. Participants were censored when one of the following events occurred: 
dementia, death, loss-to-follow-up, or October 1, 2005 (end of the study). Individuals did 
not contribute person-time to the analyses of the recurrence rates as long as they used 
antidepressants, nor during the two years after the last prescription. . Age-specifi c rates 
were calculated per 10-year age-stratum (<65, 65-74, 75-84, >85) for men and women 
separately. Th e 95% confi dence intervals were based on the Poisson distribution. Female-
to-male ratios for the rates were calculated using Cox’ proportional hazards analysis 
adjusted for baseline age. To assess the impact of the two-year criterion in our defi nition 
of a recurrent episode, we recalculated the recurrence rates using a one- and a three-year 
criterion.
Finally, we compared the 736 persons who refused to participate at baseline to the 6476 
responders. Similarly, we compared the 1536 participants who were not screened in the 
1993-1995 baseline examination round to the 4940 screened participants.
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Results
At baseline, the study population consisted of 2,945 (59%) women and 2,159 men. Th e 
mean age was 70 years (range of 56 to 102 years), 63 % of the participants were married 
or living together, and 20% had primary school only. Th e participants lived independently 
(97%) or in an assisted living facility (3%). In total, 1,744 persons died during the follow-
up period. Th e mean follow-up period was 8.0 years.
In the follow-up period, 2,093 new-onset depressions were identifi ed. After discarding 
454 duplicate reports, 1,639 episodes remained. Table 1 displays the number of episodes 
that were identifi ed with each assessment method. All methods contributed considerably 
to the number of episodes identifi ed. Of these episodes 174 were categorized as MDD 
or dysthymia, 392 as another depressive syndrome, and the remaining 1,073 as clini-
cally relevant depressive symptoms. Two-thirds of the episodes (1080) involved recurrent 
episodes. 216 persons experienced more than one episode during the follow-up period.
Table 2 presents the overall and sex-specifi c incidence and recurrence rates for episodes 
of depressive syndromes and clinically relevant depressive symptoms combined. Th e 
overall incidence rate was 19.3 per 1,000 person-years (95% CI: 17.8-21.0). Th e Cox’ 
proportional hazards regression generated an age-adjusted female-to-male ratio of 1.56 
(95% CI: 1.31-1.86). Th e recurrence rate was 65.6 per 1,000 person-years (95% CI: 
61.8-69.7). Th us, the rate of any new-onset depression in participants with a positive 
history is more than three times higher than the rate in participants with no history. Th e 
age-adjusted female-to-male ratio was 1.39 (95% CI: 1.21-1.59) for the recurrence rate. 
Figure 2 shows that the incidence and recurrence rates  appeared to be relatively stable 
across 10-year age groups. 
Table 3 shows the overall and sex-specifi c incidence and recurrence rates for depressive 
syndromes only. Th e overall incidence rate was 7.0 per 1,000 person-years (95% CI: 6.0-
Table 1 Number of depressions by assessment method (n= 5,653)*
Assessment method Depressive syndromes Depressive 
symptoms
All depressive 
episodes (%)
MDD and 
dysthymia
Other depressive 
syndromes
Psychiatric examination 133 83 178 394 (24)
Medical records 41 89 122 252 (15)
Self-reported history NA 220 115 335 (20)
Anti-depressant use NA NA 658 658 (40)
Total 174 392 1073 1639 (100)
* Only unique episodes are reported. When duplicate reports existed the episode is reported under the most accurate assessment 
method. For instance, 35 duplicate reports of depressive syndromes in medical records were ignored. MDD stands for major depressive 
disorder according to DSM-IV criteria; NA stands for not applicable. 
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8.3). Using Cox’ regression, we found an age adjusted female-to-male ratio of 1.95 (95% 
CI: 1.49-2.56). Th e overall recurrence rate was 27.5 per 1,000 person-years (95% CI: 
23.7-32.1). Th e female-to-male ratio was 1.18 (95% CI: 0.84-1.65). Similarly, incidence 
and recurrence rates appeared to be relatively stable across 10-year age groups. 
Th e incidence rate for MDD and dysthymia was 2.1 (95% CI: 1.6-2.8) per 1,000 person-
years, with a female-to-male ratio of 2.44 (1.47-4.06). Th e recurrence rate was 10.2 per 
1,000 person-years (95% CI: 8.0-13.0), with a female-to-male ratio of 0.95 (0.56-1.60). 
Th e rates were relatively stable with age.
Figure 2 Incidence and recurrence rates of episodes of depressive syndromes and symptoms combined per age group 
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Table 3 Sex-specifi c and overall incidence and recurrence rates of depressive syndromes per 1,000 person-years 
Cases Person-years Rate 95% CI
Incidence (n=3,461) Men   40   8932 4.5 3.3-6.1
Women 107 11990 8.9 7.4-10.8
Overall 147 20922 7.0 6.0-8.3
Recurrence (n=1,158) Men   47   1914 24.6 18.5-32.7
Women 120   4149 28.9 24.2-34.6
Overall 167   6063 27.5 23.7-32.1
Total 314 26985 11.6 10.4-12.9
Table 2 Overall and sex-specifi c incidence and recurrence rates of episodes of depressive syndromes and depressive 
symptoms combined per 1,000 person-years 
Cases Person-years Rate 95% CI
Incidence (n=3,459) Men 198 13500 14.7 12.8-16.9
Women 361 15431 23.4 21.1-25.9
Overall 559 28932 19.3 17.8-21.0
Recurrence (n=2,753) Men 295   5712 51.6 46.1-57.9
Women 785 10745 73.1 68.1-78.4
Overall 1080 16457 65.6 61.8-69.7
Total 1639 45389 36.1 34.4-37.9
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When re-estimating the recurrence rates using a one- and three-year criterion instead 
of a two-year criterion for the defi nition of a recurrent episode, the overall rate for all 
episode combined changed from 65.6 (95% CI: 61.8-69.7) to 76.9 (95% CI: 73.0-81.1) 
and 60.8 (95% CI: 57.0-64.8) per 1,000 person-years, respectively. Likewise, the overall 
rate of 27.5 (95% CI: 23.7-32.1) for depressive syndromes only, became 30.1 (95% CI: 
26.2-34.6) using a one-year and 21.0 (95% CI: 17.4-25.4) per 1,000 person-years using 
a two-year criterion. 
Non-participants at baseline were on average older (75.8 versus 68.6 years), and more 
likely to be female (70% versus 60%) and have primary school education only (39% 
versus 23%). Th e 1536 participants who were not screened in the 1993-1995 round did 
not diff er from the 4940 participants who were screened for depressive symptoms at that 
time.
Discussion
In this study of community-dwelling elderly persons, incidence rates were 19 per 1,000 
person-years for fi rst-ever depressive syndromes and clinically relevant depressive symp-
toms combined, and 7 per 1,000 person-years for depressive syndromes only. However, 
most episodes occurred in persons with a history of depression, with recurrence rates being 
more than three times as high as incidence rates. In women, as compared to men, the inci-
dence and recurrence rate of depressive syndromes and symptoms combined were almost 
twice as high, but women and men had  similar risks of a recurrent depressive syndrome.
Before discussing our fi ndings, we point out the strengths and weaknesses of our study. 
First, this is a large study population with a long follow-up time, which enhances the 
accuracy of the estimates. Second, in order to overcome recall problems, we combined 
several assessment methods to enhance the detection of incident cases. During the follow-
up rounds an extensive psychiatric assessment was applied, and a self-reported history of 
depression was recorded. As older patients are less likely to acknowledge having aff ective 
symptoms (39), we chose the CES-D as screening instrument; it has been validated in 
elderly populations, and yields small numbers of false-negatives when using a cut-off  of 
16.(30, 40) Th e SCAN interview method has a high sensitivity compared to the DIS and 
CIDI, especially in elderly populations, and provides accurate DSM-IV defi ned diagnoses.
(41-43) 
Furthermore, we identifi ed depressions that occurred between the follow-up rounds by 
monitoring medical records and registration of antidepressant use. Th e major advantage of 
these prospectively gathered data is that recall and selection bias are reduced. People tend to 
forget or undervalue past depressions, and report only those episodes that occurred in the 
fi ve years preceding the assessment.(18, 44) Moreover, as depression is related to mortality 
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and loss-to-follow-up, episodes will be missed especially in elderly persons.(12) However, 
abstracting diagnoses from medical records also has some limitations. Th e information in 
the records is recorded for the purpose of patient care, not for epidemiological research. 
Symptoms of depression may have been incompletely recorded or omitted. Even though 
we applied a broad range of cues that indicate depression, this drawback cannot be fully 
overcome. Moreover, depression often remains unrecognized, as many elderly patients 
tend to present somatic complaints masking emotional symptoms.(35, 45-47) General 
practitioners diagnose between 30 to 60% of depressions, with lower recognition for more 
milder cases.(48-50) However, when a general practitioner diagnoses a depression, this 
probably refl ects actual depressions(51), but the reports of other health professionals to 
the GPs were often elaborate with substantiated DSM-classifi ed diagnoses.
Automatic registration of fi lled prescriptions not only has the advantages of prospective 
methods, the data are also particularly useful to specify the date-of-onset of episodes. 
In some etiological studies, antidepressant use is used as an indicator of a depressive 
syndrome.(52, 53) However, modern antidepressants are commonly prescribed for other 
indications such as anxiety disorders, sleeping disorders, migraine, or neuropathic pain.
(54, 55) Population surveys and family practices studies have shown that 43-56% of 
patients receiving an antidepressant do not fulfi ll the criteria of depression.(54, 56-58) 
Hence, we regarded antidepressant use as a marker of depressive symptoms only.
Th e psychiatric assessment during the examination rounds yielded more valid diagnoses 
than the other methods. Th e main rationale for using data from other sources, albeit 
with diff erent diagnostic certainty and reliability, was to identify the depressive episodes 
that occurred and remitted in the intervals between follow-up examination rounds. In-
formation from the diff erent sources is thus additive. At the same time, many depressions 
successfully with antidepressants are not recalled and certainly not screened positive if 
assessed only with the CES-D. In addition, depressions for which a participant has not 
sought help will have been missed more easily. Th e category ‘clinically relevant depres-
sive symptoms’ probably covers the most diverse types of depression. One core symptom 
of major depression recorded in the psychiatric interview or in the medical record, was 
considered a suffi  ciently valid indication of the presence of ‘clinically relevant depressive 
symptoms’. In addition, even though the use of an anti-depressant drug provides less 
diagnostic certainty, it indicates a depression in 50% of users.(54, 56-58)
Our study yielded lower incidence rates than those presented by other studies in elderly 
populations. In our study the incidence rate for major depression and dysthymia was 2 per 
1,000 person-years (95% CI: 2-3), while the Cache County study presented an incidence 
rate for major depression of 8 per 1,000 person-years (95% CI: 6-11). To some extent, 
this higher incidence rate is explained by the diagnoses of depression that were made in 
interviews with family and caregivers of deceased participants (20% of total). Similarly, 
in our study the incidence rate for depressive syndromes, including major depression, 
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dysthymia and minor depression, was 7 per 1,000 person-years (95% CI: 6-8), whereas 
the Göteborg study yielded an incidence rate for major depression, dysthymia and depres-
sion NOS of 23 per 1,000 person-years (95% CI: 18-29). Th is study diff ered from ours 
in that it was performed more than 20 years ago in a relatively small birth cohort of 322 
persons born in 1901-1902. Most likely though, our lower estimates resulted from our 
conservative approach in categorizing depressive episodes as being a depressive syndrome. 
In addition, our study population may have included fewer participants with misclassi-
fi ed negative histories, because data was available on the occurrence of depression in the 
period between the start of the study and the fi rst follow-up examination, which served 
as baseline for our analysis of depressive syndromes. Indeed, the incidence rate of depres-
sive syndromes and symptoms combined that we found seems more in line with that of 
the abovementioned Cache County study: 19 per 1,000 person-years (95% CI: 18-21) 
compared to 24 per 1,000 person-years (95% CI: 20-27) respectively.(20) In particular as 
20% of the depression cases in the latter study involved bereavement. Finally, some studies 
have found that late-life depression is more often characterized by somatic and cognitive 
symptoms, even though others found no diff erences.(59-62) As the conventional core 
symptoms of depression in the DSM are important for our categorization, the incidence 
and recurrence rates that we present are probably conservative estimates.
Some landmark studies performed among mixed-age populations in North-America 
and Scandinavia, such as the Epidemiologic Catchment Area Study, the Lundby Study, 
and the Stirling County Study have also estimated incidence rates of major depression 
in the elderly subgroups. Th e most recently published analyses show incidence rates for 
major depression between 0.9 and 4.5 per 1,000 person-years.(8-10) We found an inci-
dence rate for major depression and dysthymia of 2 per 1,000 person-years (95% CI: 2-3). 
Th e results seem similar to ours, even though in the cited studies psychiatric assessments 
were generally based on the DIS, intervals between follow-up rounds were much longer 
(11 to 40 years), continuous monitoring during the intervals was generally lacking, and 
demented participants were not excluded.
In the present study we found particularly high recurrence rates for both depressive syn-
dromes and clinically relevant depressive symptoms, even though we discounted all events 
occurring within two years of the previous episode. To our knowledge, no other study to 
date has estimated recurrence of depression in a general elderly population. In clinical 
elderly populations, the risk of recurrence increased with the number of lifetime episodes 
and decreased as the duration of recovery increased.(21, 63, 64) A few population-based 
studies, all conducted in predominantly middle-aged adults, consistently found that about 
half of the depressed persons had a recurrence if followed for longer periods.(38, 65, 66) 
Our study showed that the recurrence rates of MDD and dysthymia were fi ve times as 
high as the fi rst ever incidence rates in later life. Th is suggests that clinicians must not 
only be aware that many depression in later life will be chronic or recurrent but that few 
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depressive episodes diagnosed are fi rst ever episodes. Th is emphasizes the importance of 
maintenance treatment and close monitoring after recovery from depression.
We found that men had similar risks for a recurrent depressive syndrome as women, 
even though the female-to-male ratios of the other rates that we studied were in line with 
the well-known ratio of 1.5-3.0.(67, 68) In adult populations no signifi cant sex diff erences 
in the course of major depressive disorder were found as well.(65, 69) Prospective studies 
among adult populations have shown rather consistently that psychological and social risk 
factors such as higher levels of anxiety, lower self-confi dence, lack of power, role strain and 
sexual abuse contribute to the higher risk of fi rst-ever depression in women.(70, 71) In 
addition, men seem to recollect less episodes of depression and underreport the severity 
of symptoms compared to women.(72, 73) Studies that investigated gender diff erences 
in late-life depression are scarce. One study suggested that depressed older men were less 
likely to endorse core depressive symptoms or to be referred for treatment.(74) Appar-
ently, risk factors for incident depressions do not always predict the course of depression 
as well.  Th e risk factors for recurrent late-life depression are possibly less gender related, 
and recurrent depressive syndromes might be as easily recognized in men as in women. 
In conclusion, if a person has never had a depression in middle age, his risk of devel-
oping a fi rst-ever episode in old age may be lower than estimated before. Conversely, 
if someone has experienced a depression before, the risk of a recurrent episode in old 
age is high. In fact, the majority of new episodes in our study were recurrent episodes. 
Th ese fi ndings, in addition to the chronic nature of depression, could explain the well-
known discrepancy between the high prevalence and low incidence of late-life depression. 
Community-dwelling elderly persons have a much higher risk of developing a recurrent 
than a fi rst ever depression. To enhance diagnostic accuracy, it is thus important that 
clinicians become aware of this a priori risk. More research is needed to clarify the etiology 
of recurring late-life depression, given that recurring episodes contribute substantially to 
the impact of depression on public health. 
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Abstract
Background. Depression is common in patients with heart failure and associated with 
recurrent cardiac events and increased mortality. It is still unclear whether heart failure 
is a risk factor for developing depression. Th e aim of this study was to determine the 
association between heart failure and incident depression, and assess whether the use of 
loop diuretics in persons with heart failure alters this risk.
Methods. We performed a cohort study between 1993 and 2005 among 5,095 elderly 
inhabitants of Rotterdam, the Netherlands. Th ey were free of depression at baseline. 
Detailed information on heart failure and depression was collected during examination 
rounds, and through continuous monitoring of medical and pharmaceutical records. 
Heart failure was defi ned according to the criteria of the European Society of Cardiology. 
Depressive episodes were categorized as depressive syndromes, including DSM-IV defi ned 
major depressive disorder, or clinically relevant depressive symptoms. We used multivari-
ate Cox’ proportional hazard regression to calculate hazard ratios (HR). 
Results. Heart failure was associated with an increased risk of depressive symptoms and 
syndromes combined (HR 1.41; 95% CI 1.03-1.94). It also increased the risk of depres-
sive syndromes (HR 1.66; 95% CI 1.09-2.52). In participants with heart failure, the use 
of loop diuretics more than halved the risk of depressive symptoms and syndromes (HR 
0.46; 95% CI 0.22-0.96) and depressive syndromes only (HR 0.41; 95% CI 0.16-1.00). 
Conclusions. Heart failure is an independent risk factor for incident depression in elderly 
persons. Eff ective treatment of the debilitating symptoms of heart failure may prevent 
depression.
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Introduction
High rates of depression among patients with heart failure have been reported in nu-
merous studies.(1) Depression is present in one out of fi ve patients with heart failure. 
Th e proportion rises to one out of three patients if episodes of depressive symptoms that 
do not meet the criteria of major depression are included. Moreover, the prevalence of 
depression increases with the severity of heart failure (11% in New York Heart Association 
Class I vs. 42% in Class IV). Co-morbid depression in heart failure complicates eff ective 
treatment. It is associated with a greater than 2-fold risk of recurrent cardiac events and 
mortality.(1-4) Th is fi nding is consistent for subthreshold and major depressions. In ad-
dition, depression in heart failure is associated with signifi cant increases in functional 
disability and health care utilization.(5)
Th e high rates of depression in heart failure in cross-sectional studies (1, 2, 6, 7) might 
be explained by an increased risk of heart failure in individuals with depression, by an 
increased risk of depression in individuals with heart failure, or by both. Only few studies 
have investigated the temporal relationship between heart failure and depression. Th e risk 
of incident heart failure in depressed patients varied from a hazard ratio of 1.5 in a general 
elderly population followed for 14 years (8), to 2.6 in a group of patients with systolic hy-
pertension followed for 4.5 years.(9) To our knowledge, no study has investigated whether 
heart failure is associated with an increased risk of developing depression. Diff erentiating 
between already existent and incident depression in patient with heart failure can be of 
clinical importance. For example, in myocardial infarction only incident depression is as-
sociated with an impaired cardiovascular prognosis, not already prevalent depression.(10)
Undoubtedly, a life event such having a failing heart, which is potentially fatal, might 
lead to depression in a patient. Moreover, heart failure is associated with impaired daily 
functioning, a known risk factor for depression.(11) A biological link might be that re-
duced cardiac output as a result of heart failure could lead to insuffi  cient cerebral perfusion. 
Loop-diuretics, which are often prescribed for heart failure, deplete circulating volume 
and thus decrease blood pressure even further.(12-14) On the other hand, loop diuretics 
eff ectively diminish the debilitating symptoms of heart failure, and might decrease the risk 
of depression.
Prior studies that examined heart failure as a risk factor for depression have been limited 
by their cross-sectional design and clinical study population. Th e aim of this population-
based study was to estimate the eff ect of heart failure and loop-diuretics on the risk of 
incident depression in the elderly. Detailed information on heart failure and depression 
was collected for 5,095 participants during on average eight years of follow-up.
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Methods
Setting 
Th is study was part of the Rotterdam Study, a prospective study that started in 1990 
among 7,983 inhabitants of Ommoord, a district of Rotterdam.(15) Th e participants 
were 55 years of age or older at that time. Th e study focuses on the occurrence and de-
terminants of common chronic diseases in the elderly. Th e Medical Ethics Committee of 
the Erasmus Medical Center Rotterdam approved the study and written informed consent 
was obtained from all participants. 
So far, four examination rounds have taken place (1989-1993, 1993-1995, 1997-1999, 
and 2002-2004). Participants underwent an extensive home interview and a physical 
examination at the research centre. Blood was drawn and electrocardiography (ECG) was 
carried out. In addition, continuous monitoring for major cardiovascular and psychiatric 
events took place through automated linkage with the medical fi les from the general 
practitioners (GPs) from baseline onwards. Th e Dutch health care system requires all 
residents to be registered with a GP, and clinicians report back to the GP. Furthermore, 
the pharmacies that serve the neighborhood provided complete online information on all 
fi lled prescriptions for virtually all participants. Th is information included the Anatomical 
Th erapeutic Chemical code; total number of delivered units (e.g. tablets/capsules); pre-
scribed daily number of units; date of delivery and drug dosage. Finally, information on 
vital status was obtained bimonthly from the municipal authorities in Rotterdam. 
Study population
During the second visit, the baseline of the current analysis, 5,769 participants were 
screened for depressive symptoms. Participants fi lled out either the validated Dutch ver-
sion of the Center for Epidemiologic Studies Depression Scale (CES-D) or the validated 
Dutch version of the Hospital Anxiety and Depression Scale (HADS-D).(16, 17) A score 
of 16 or higher out of 60 on the CES-D and 9 or higher out of 21 on the HADS-D 
was considered screen-positive for depressive symptoms.(16, 17) At baseline, we excluded 
549 persons with depressive symptoms, 105 persons with dementia (18), 9 persons with 
bipolar disorder diagnosed before or after baseline, 9 persons with missing heart failure 
status and 2 persons who were lost-to-follow-up on the day they had been screened. Th is 
resulted in a study population of 5,095 persons who were free of depression at baseline. 
Assessment of incident depression
Th e assessment of depression in the Rotterdam Study has been described in detail before.
(19) Information on the occurrence of incident depressions during follow-up was ob-
tained from (1) psychiatric examinations, (2) self-reported histories of depression, and (3) 
medical records. Th e psychiatric examination consisted of a two-step procedure during 
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examination rounds. First, all participants were screened with the CES-D as part of the 
home-interview. Next, the screen-positive participants were invited for a clinical interview, 
in which trained clinicians administered a semi-structured psychiatric interview included 
in the Schedules for Clinical Assessment in Neuropsychiatry (SCAN).(20) Major and mi-
nor depressive disorders and dysthymia were ascertained with a computerized algorithm 
that refl ected DSM-IV criteria.(21) Th e self-reported history of depression was solicited 
at baseline and during follow-up rounds. Participants were asked standardized questions 
to assess whether they had suff ered from a depressive episode up to that time, and if so 
whether they had been treated, and at what age the episode had occurred. Th e GPs’ medi-
cal records were scrutinized by trained research-assistants. Th ey copied the information 
that indicated a potential depression. Two research physicians independently assessed this 
information, and categorized each depressive episode according to a predefi ned protocol 
(see below). 
Based on these sources, we categorized depressive episodes into depressive syndromes, 
and clinically relevant depressive symptoms. Th e category ‘depressive syndromes’ con-
sisted of major depressive disorder and dysthymia that clearly met the DSM-IV criteria for 
either of these disorders, and that were diagnosed by a psychiatrist or other mental health 
professional. Th e category also covered other depressive syndromes, that is depression 
recorded by a GP, self-reported depression for which the participant consulted a health 
professional, and DSM-IV minor depression. Th e category ‘clinically relevant depressive 
symptoms’ included a report of one core symptom of major depression in the psychiatric 
interview or medical record, and self-reported depression without consultation of a health 
professional. We applied the same criteria to categorize depressive episodes that preceded 
the study period.
We defi ned the date-of-onset of as the day of the reported fi rst occurrence of symptoms 
of depression, or the fi rst prescription date of an antidepressant drug (tricyclic antidepres-
sants, (non)selective serotonin reuptake inhibitors, or other), whichever came fi rst.
Assessment of heart failure
Th e assessment procedures for heart failure have been described in detail previously.(22, 
23) In brief, during the fi rst examination round of the Rotterdam Study, information on 
the presence of symptoms and signs of heart failure and the use of medication for heart 
failure was obtained.(23) Additionally, virtually all medical records of GPs were screened 
for the occurrence of incident cases of heart failure during follow-up.(22) Furthermore, a 
database with discharge diagnoses from the hospitals in the Rotterdam area was linked to 
the study database, and copies of discharge letters of potential cases were requested. Two 
research physicians independently classifi ed the information and discussed all diff ering 
classifi cations in a consensus meeting. Finally, a cardiologist judged decisively about the 
probable and discordant cases. 
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Defi nite heart failure was defi ned as a combination of (1) the presence of at least one of 
the typical signs or symptoms of heart failure, i.e. breathlessness at rest or during exertion, 
ankle oedema and pulmonary crepitations, and (2) confi rmation of cardiac dysfunc-
tion on chest X-ray or echocardiography. Symptoms could not be attributed to another 
underlying disease, such as chronic obstructive pulmonary disease. Th is defi nition is in 
accordance with the criteria of the European Society of Cardiology.(24) For defi nite heart 
failure, the diagnosis had to be ascertained by a medical specialist. A case was classifi ed 
as probable when a medical specialist’ diagnosis was missing, but two or three typical 
symptoms suggestive of heart failure were present, as well as a history of cardiovascular 
disease (e.g., myocardial infarction, hypertension), response to treatment for heart failure, 
or objective evidence of cardiac dysfunction. Th e current study is based on probable and 
defi nite cases of heart failure.
Th e date-of-onset was defi ned as the day of the fi rst reported occurrence of symptoms 
of heart failure, or the fi rst prescription date for a loop diuretic or angiotensin-converting-
enzyme-inhibitor, whichever came fi rst.
Covariates
Th e following baseline characteristics were considered as potential confounders of the as-
sociation between heart failure and depression: age, sex, socio-economic status, disability 
in activities of daily living, history of depression, smoking, hypertension, and history 
of ischemic heart disease. In addition, as dates-of-onset had been ascertained, diabetes 
mellitus, myocardial infarction, atrial fi brillation, and use of loop diuretics and (other) 
antihypertensive medication could be included as time-varying covariates.
Socio-economic status was determined in terms of highest education attained and net 
income.(25) Disability in activities of daily living was assessed with the Modifi ed Stanford 
Health Assessment Questionnaire.(26) Th is scale ranges between 1.0 and 4.0 and higher 
scores represent more disability. Self-reported smoking was categorized into never, former, 
and current. For blood pressure, the average of two measurements in sitting position at 
the right upper arm with a sphygmomanometer, was used for our analysis. Hypertension 
was defi ned as diastolic blood pressure of 100 mmHg or above, or systolic blood pressure 
of 160 mmHg or above (27), or the use of antihypertensive drugs for the indication hy-
pertension. History of ischemic heart disease encompassed angina pectoris and claudicatio 
intermittens, both established with the Rose questionnaire, as well as a history of coronary 
artery bypass graft, percutaneous transluminal coronary angioplasty and peripheral artery 
bypass graft. 
Th e criteria for diabetes mellitus were: fasting plasma glucose level of ≥ 7.0 mmol/l, 
non-fasting glucose or an oral glucose tolerance test result of ≥ 11.1 mmol/L, or treat-
ment with an antidiabetic medication or diet.(28) A history of  myocardial infarction was 
defi ned as self-reported myocardial infarction confi rmed by information from medical 
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records, or an ECG characteristic of prior myocardial infarction according to the ICD-10 
(code I21) as verifi ed by a cardiologist.(29) A diagnosis of atrial fi brillation according 
to ICD-10 (code I48) required an ECG that verifi ed the diagnosis.(30) Th e medical or 
pharmaceutical records yielded the date-of-onset of these events. 
Information on the use of loop diuretics and other antihypertensive medication was 
obtained from the pharmaceutical database. Th e other antihypertensive medication 
included low-ceiling diuretics, beta-blockers, angiotensin-converting-enzyme-inhibitors, 
reserpine, methyldopa, and clonidine. Th e duration of a prescription was calculated as the 
total number of delivered units divided by the prescribed daily number of units. Th us, we 
were able to distinguish between non-use and current use on the index date if this date fell 
within a prescription period. 
Statistical analysis
To study the eff ect of heart failure on the risk of incident depression, we performed a Cox’ 
proportional hazard analysis. Heart failure was entered in the model as a time-varying 
exposure variable. We performed the analysis with the outcome depressive symptoms 
and syndromes combined, as well as depressive syndromes only. (Given the low number 
of depressive disorders, we expected insuffi  cient power for this outcome.) We fi tted two 
multivariate models for both outcomes. In the fi rst model, we adjusted for age and sex 
only, in the second additionally for all other confounders. Next, we reran the two models 
in the subsample of persons without a history of depression at baseline to estimate the 
risk of fi rst-ever incident depression. In this way, we further reduced bias due to reversed 
causality in the estimated association between heart failure and depression. Finally, in 
order to assess the eff ect of loop diuretics on the risk of depression, we compared the risk 
of depression in current users to that in non-users in the participants with heart failure. 
In these analyses we included the same co-variates, except diabetes, because it is not a 
(contra-)indication for use of loop diuretics.
In all of the analyses, the participants contributed person-years from the date of the 
baseline interview until follow-up ended either when a depression occurred or when a par-
ticipant was censored due to dementia, death, loss-to-follow-up, or the end of the study 
on October 1, 2005. Missing values for the baseline covariates were imputed using the 
last observation carried forward, i.e. the measurements from the fi rst examination round 
of the Rotterdam Study. For the variables income and hypertension, means were imputed 
and, to adjust for the potential confounding eff ect of these imputations, dummies that 
indicated the missing values were included in the multivariate models. Two-sided p-values 
of <0.05 were considered statistically signifi cant. For all statistical analyses we used SPSS 
for Windows, version 15.0.
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Results 
Table 1 presents the baseline characteristics of the study sample. Th e average age was 70 
years with a range of 56 to 101 years and 58 % of the participants were female. Th e most 
prevalent cardiovascular risk factor was history of smoking with 51% former smokers and 
17 % current smokers. At baseline, 1641 participants had a history of depression, and 206 
participants had heart failure. Another 423 persons developed heart failure after baseline 
during follow-up. In our study population, a total of 736 incident depressions occurred 
during 42,090 person-years. Of these depressions, 407 were depressive syndromes, includ-
ing 103 DSM-defi ned major depressive disorders and dysthymias. Th e mean time between 
onset of heart-failure and onset of depression was 3.5 years (SD 2.9), counting cases of 
heart failure present at baseline from that time onward.
Figure 1 depicts the Kaplan-Meier survival curves by heart failure status. After 12 years 
of follow-up, twice as many participants with heart failure had developed depression than 
Table 1 Baseline characteristics of the study population (N=5,095)
Characteristic Descriptives
Socio-demographic factors
Age, mean (SD) 70.0 (8.3)
Female, n (%) 2939 (57.7)
Education, primary school only, n (%) 934 (18.3)
Income, mean (range), in euros/month 1220 (350-3200)
Cardiovascular risk factors
Smoking 
- former smoker, n (%)
- current smoker, n (%)
2598 (51.0)
868 (17.0)
Hypertension, n (%) 1140 (22.4)
Diabetes, n (%) 537 (10.5)
Cardiac disease
Heart failure, n (%) 206 (4.0)
Myocardial infarction, n (%) 348 (6.8)
History of other ischemic heart disease*, n (%) 1006 (19.7)
Atrial fi brillation, n (%) 430 (8.4)
Other health related factors
Disability in ADL†, mean (SD) 1.3 (0.6)
History of depression, n (%) 1641 (32.2)
Medication use
Loop diuretics, n (%) 223 (4.4)
Other antihypertensive medication, n (%) 1505 (29.6)
Digoxin, n (%) 235 (4.6)
* This encompasses a history of angina pectoris, claudicatio intermittens, coronary artery 
bypass graft, percutaneous transluminal coronary angioplasty and peripheral artery bypass 
graft. † ADL stands for activities of daily living.
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those without heart failure. A similar diff erence was seen for depressive syndromes only. 
Table 2 shows the risk of depression associated with heart failure. Heart failure was associ-
ated with a signifi cantly increased risk of depressive symptoms and syndromes combined 
(HR 1.36; 95% CI 1.03-1.81) and depressive syndromes only (HR 1.54; 95% CI 1.06-
2.24) when age and sex were the sole factors adjusted for. Th e risk estimates were similar, 
that is 1.41 (95% CI 1.03-1.94) for depressive symptoms and syndromes and 1.66 (95% 
CI 1.09-2.52) for depressive syndromes, in the models that adjusted for all confounders 
and the associations remained signifi cant. 
Figure 1 Kaplan-Meier curves of depression-free survival by heart failure status 
Table 2 Heart failure and the risk of depression estimated with Cox’ regression
Depressive symptoms and syndromes†
  HR (95%CI)  p-value
Depressive syndromes only‡
 HR (95%CI)  p-value
Complete sample (n=5,095)
Heart failure, age and sex adjusted        1.36 (1.03-1.81)   .033  1.54 (1.06-2.24)      .024
Heart failure, fully adjusted*        1.41 (1.03-1.94)         .036  1.66 (1.09-2.52)      .019
Persons without history of depression (n=3,454)
Heart failure, age and sex adjusted        1.41 (0.93-2.13)         .103  1.79 (1.05-3.04)      .033
Heart failure, fully adjusted*        1.64 (1.04-2.58)         .033  2.07 (1.15-3.72)      .015
* adjusted for age, sex, SES, ADL, history of depression, smoking, hypertension, diabetes, myocardial infarct, history of other ischemic 
cardiovascular 
disease, atrial fi brillation, and use of loop diuretics and other antihypertensive medication.
† episodes of clinically relevant depressive symptoms and depressive syndromes, including DSM-defi ned depressive disorders, 
combined.
‡ includes DSM-defi ned depressive disorders
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Next, we estimated the risk of fi rst-ever incident depression in the persons without 
a history of depression at baseline (n=3,454). In the multivariate model, heart failure 
again carried an increased risk of depressive symptoms and syndromes (HR 1.64; 95% CI 
1.04-2.58), and depressive syndromes (HR 2.07; 95% CI 1.15-3.72). Moreover, persons 
with heart failure had a three-fold, almost signifi cant, risk of fi rst-ever depressive disorders 
(HR 3.00; 95% CI 0.86-10.50; not in table) compared to the others. 
Table 3 presents the risk of depression related to the use of loop diuretics in persons with 
heart failure. In the models adjusted for age and sex only, current use of loop diuretics was 
not signifi cantly associated with depressive symptoms and syndromes (HR 0.59; 95% CI 
0.30-1.15), nor with depressive syndromes only (HR 0.48; 95% CI 0.22-1.06). However, 
the multivariate models indicated similar but just signifi cant associations for both out-
comes, with a more than 50% reduced risk of depressive symptoms and syndromes (HR 
0.46; 95% CI 0.22-0.96) and depressive syndromes only (HR 0.41; 95% CI 0.16-1.00) 
in current users of loop diuretics.
Discussion
Th e present study demonstrates that people with heart failure had an increased risk of devel-
oping incident depression. Th e risk remained similarly high when persons with a history of 
depression were excluded. Our fi ndings also suggest that the use of loop diuretics in persons 
with heart failure decreased the risk of incident depression. Many cross-sectional studies 
have shown that depression is very common in heart failure. Our study demonstrated that 
heart failure is also a risk factor for incident depression. To the best of our knowledge, there 
is only one other prospective study. It showed that 21% of 245 outpatients with heart 
failure had depressive symptoms one year later.(31) Patients living alone, reporting alcohol 
abuse, perceiving medical care as an economic burden, and those with impaired health 
status were more likely to develop depressive symptoms. However, the lack of a control 
group forestalled a conclusion about the risk of incident depression in that study. 
Table 3 Current use of loop diuretics and risk of depression in persons with heart failure (n= 629)
Depressive symptoms and syndromes† Depressive syndromes 
only‡
        HR (95%CI)      p-value        HR (95%CI)      p-value
Diuretic use, age and sex adjusted        0.59 (0.30-1.15)      .122       0.48 (0.22-1.06)      .068
Diuretic use, fully adjusted*        0.46 (0.22-0.96)      .039       0.41 (0.16-1.00)      .050
* adjusted for age, sex, SES, ADL, history of depression, smoking, hypertension, myocardial infarct, history of other ischemic 
cardiovascular disease, atrial fi brillation, and use of other antihypertensives.
† episodes of clinically relevant depressive symptoms and depressive syndromes, including DSM-defi ned depressive disorders, 
combined.
‡ includes DSM-defi ned depressive disorders
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Heart failure is a fatal disease, with only 35%-50% of patients surviving more than 
5 years.(22, 32) Experiencing the symptoms of such a life-threatening disease may pro-
voke a psychological reaction, and when coping mechanisms fail, a patient may become 
depressed. Reversely, individuals with high levels of perceived self-control are better able 
to manage their cardiac disease, which in turn leads to improvement of functional status 
and thereby to a decrease in depression.(6) In addition, biological mechanisms might 
explain the increased risk of depression related to heart failure. For instance, reduced 
cardiac output as a result of heart failure could lead to insuffi  cient cerebral perfusion 
and the drugs prescribed for it may cause hypotension, dizziness and fatigue that may in 
turn lead to psychological discomfort.(14) In the current study, use of loop diuretics was 
associated with a protective eff ect against depression. As loop diuretics eff ectively diminish 
the debilitating symptoms of heart failure, this fi nding suggests that the symptoms of the 
disease themselves may account for the increased risk of depression. Finally, evidence exists 
of a common genetic vulnerability for risk factors of heart failure, such as atherosclerosis 
and myocardial infarction, and depression.(33) 
Our study was based on a large population-based cohort and long follow-up period. It 
is unlikely that information bias occurred in our study. Data were gathered prospectively 
and without prior knowledge of the research hypothesis. In addition, detailed informa-
tion on the occurrence of heart failure and depression was collected. As heart failure and 
depression show some overlap in symptoms, such as lack of energy and listlessness, clear 
and mutually exclusive defi nitions needed to be used.(2) Th e core symptoms of heart 
failure and depression in our case defi nitions did not include any overlapping symptoms. 
Moreover, the results of the analyses based on a more stringent defi nition of depression 
(depressive syndromes only) remained signifi cant despite the smaller number of cases. Th is 
is suggestive of a true increase in risk. However, the dates-of-onset of heart failure and 
depression need to be precise. For both diseases, we used all available information from 
interviews, prescriptions, and medical records. Given that the mean lag-time between the 
onset of heart failure and the onset of depression was more than three years, we consider 
it unlikely that pre-existent depressions were taken for incident depressions in our study, 
even if they had a long prodromal period. Moreover, when we performed the analyses in 
the participants without a history of depression in order to further reduce this type of 
misclassifi cation, the results did not change substantially.
A potential source of selection bias might be that patients with heart failure died before 
their depression was diagnosed and recorded. Depressions in terminally ill patients are 
often not diagnosed or recorded by the treating physician.(34) We have probably missed 
some of these episodes. However, this would have led to an underestimation of the true 
risk and it would mean that our risk estimates are conservative. 
We minimized potential confounding by adjusting for a considerable number of socio-de-
mographic and health related factors. However, some confounding by severity of heart failure 
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might have occurred, because we did not have baseline information such as left ventricular 
systolic function. Current users of loop diuretics probably have more severe heart failure than 
non-users, and the prevalence of depression increases with the severity of heart failure.(1) Th is 
would have resulted in an underestimation of the protective eff ect of loop diuretics. 
Recently, clinicians have begun to pay greater attention to the treatment of co-morbid 
depression in patients with cardiovascular disorders such as heart failure, because depres-
sion confers an increased risk of recurrent cardiac event and mortality. Th e present study 
shows that heart failure is also associated with a more than two-fold increased risk of 
new-onset depression. Our fi ndings additionally emphasize the need for eff ective interven-
tions to prevent depression in patients with heart failure. As, in our study, the use of loop 
diuretics seemed to protect heart failure patients against the development of depression, 
somatic and psychological treatments with a focus on improvement of functional status 
might prove eff ective. 
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Abstract
Objective. In cross-sectional studies, atrial fi brillation (AF) is common in depressed pa-
tients, but whether AF causes depression is unclear. We assessed whether AF increases the 
risk of incident late-life depression. 
Methods. In 4,750 elderly persons from the Rotterdam Study, detailed information on the 
occurrence of AF and depression was collected between 1993 and 2005. AF was identifi ed 
by electrocardiography. We categorized depressive episodes as clinically relevant depressive 
symptoms or as depressive syndromes including DSM-IV defi ned depressive disorders. 
We calculated hazard ratios with multivariate Cox regression.  
Results. AF was not associated with an increased risk of depressive symptoms and syn-
dromes combined. It was associated with depressive syndromes (HR 1.63; 95% CI 1.04-
2.55) when adjusted for age and sex, but this association lost statistical signifi cance when 
adjusted for all confounders (HR 1.49; 95% CI 0.94-2.37). 
Conclusions. In this prospective study, AF was not an independent risk factor for incident 
late-life depression.
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Objective
Depressive symptoms occur frequently in the elderly, and even more frequently in patients 
with atrial fi brillation (AF), the most common cardiac arrhythmia. In a study among 
101 patients with AF, 38% had depressive symptoms, which typically had persisted more 
than 6 months.(1) Also, patients with major depression have AF and related conductive 
abnormalities on electrocardiography (ECG) more often than healthy controls.(2-4)
Little is known about the temporal relationship between AF and depression. It has been 
suggested that AF increases the risk of depression because disturbances of heart rate and 
heart-rate variability have consequences for blood fl ow to the brain, and may interfere 
with brain function.(5) Alternatively, stroke and heart failure, the major causes of morbid-
ity in patients with AF, can give rise to depression. To our knowledge, AF has not been 
studied as a risk factor for incident depression before. Th e aim of this prospective study 
was to assess the association between AF and late-life incident depression. 
Methods
Setting
Th is study was part of the Rotterdam Study, a population-based cohort study that started 
in 1990 among 7,983 inhabitants of Rotterdam, aged ≥ 55 years.(6) Th e Medical Ethics 
Committee of the Erasmus Medical Center Rotterdam approved the study and all par-
ticipants provided written informed consent. So far, four visits have taken place in which 
participants underwent a home interview and physical examination. 
Study population
During the second visit, the baseline of the current analysis, 5,769 participants were 
screened for depressive symptoms. Participants fi lled out either the validated Dutch ver-
sion of the Center for Epidemiologic Studies Depression Scale (CES-D) or the validated 
Dutch version of the Hospital Anxiety and Depression Scale (HADS-D). A score of 16 or 
higher out of 60 on the CES-D and 9 or higher out of 21 on the HADS-D was considered 
screen-positive.(7) At baseline, we excluded 549 persons with depressive symptoms, 105 
with dementia, 9 with bipolar disorder, 2 who were lost to follow-up directly after screen-
ing, and 354 persons with unknown AF status. Th is resulted in a study population of 
4,750 persons, who were free of depression at baseline. 
Assessment of incident depression
Information on incident depressions was obtained from (1) psychiatric examinations, 
(2) self-reported histories of depression, and (3) medical records.(7) Th e psychiatric 
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examination during follow-up visits consisted of a screening with the CES-D, and in the 
screen-positive participants a semi-structured interview performed by a trained clinician 
(Schedules for Clinical Assessment in Neuropsychiatry). Th e self-reported history of de-
pression, solicited during the visits, included standardized questions to ascertain whether 
and when participants had had a depressive episode, and if they had been treated. To 
continuously monitor incidence of depression throughout follow-up, trained research-
assistants scrutinized the medical records of the general practitioners (GPs) and copied the 
information about a potential depression. Two research physicians independently assessed 
this information according to a predefi ned protocol, and discussed discordant assessments.
We categorized the depressive episodes into (1) depressive syndromes, including  DSM-
defi ned major depressive disorder and dysthymia, and other depressive syndromes, such 
as depressions recorded by a GP, self-reported depression for which a health professional 
had been consulted, and DSM-IV minor depression; or (2) ‘clinically relevant depressive 
symptoms’, if at least one core symptom of major depression had been reported. 
We defi ned the date-of-onset as the day of the fi rst report of symptoms, or the fi rst 
prescription date of an antidepressant drug, whichever came fi rst. 
Assessment of atrial fi brillation (AF)
AF was ascertained using 3 methods.(8) (1) At baseline and during follow-up visits, 
ECGs were recorded and analyzed with the Modular ECG Analysis System. Two research 
physicians blinded to the MEANS diagnosis recoded all ECGs with a diagnosis of AF, 
atrial fl utter, or any other rhythm disorder independently. A cardiologist’s judgment was 
decisive in those cases in which disagreement persisted between the coding physicians. 
(2) Medical records were also screened for the occurrence of AF by research assistants. A 
senior physician examined the information that had been copied. (3) Information on AF 
was acquired from the National Medical Registration system, which accumulates validated 
discharge diagnoses of all Dutch hospitals. 
A diagnosis of AF according to ICD-10 (code I48) required an ECG that verifi ed the 
diagnosis. We did not distinguish between AF and atrial fl utter, or between paroxysmal AF 
and chronic AF. If AF was identifi ed from the medical fi les, the earliest date was considered 
the date of onset. If AF was detected exclusively during one of the follow-up rounds, the 
midpoint between the date of that round and the date of the previous round was taken. 
Covariables
Th e following baseline characteristics were considered as potential confounders: age, sex, 
socio-economic status, disability in activities of daily living, history of depression, smok-
ing, hypertension, diabetes, history of ischemic heart disease, myocardial infarction, heart 
failure, stroke, transient ischemic attacks, and use of antihypertensive medication . 
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Statistical analysis
We performed a Cox’ proportional hazard analysis for the outcome ‘depressive symptoms 
and syndromes together’, and depressive syndromes only. A multivariate model with all 
confounders mentioned above was fi tted for each outcome. Th e models were repeated 
in the subsample of persons without a history of depression at baseline. In this way, we 
further ascertained the chronological relationship between AF and depression.
In all analyses, the participants contributed person-years from baseline until follow-up 
ended, either when a depression occurred or when a participant was censored due to 
dementia, death, loss-to-follow-up, or the end of the study on October 1, 2005. Two-
sided p-values of <0.05 were considered statistically signifi cant. For all statistical analyses 
we used SPSS for Windows, version 16.0.
Results
At baseline, the average age was 70 years with a range of 56 to 101 years and 57 % of 
the participants were female. Th e most prevalent cardiovascular risk factor was history of 
smoking with 52% former smokers and 17 % current smokers. 1535 participants had a 
history of any depression, and 128 a history of stroke. 255 persons had AF at baseline, and 
another 311 developed AF during follow-up.
In our study population, a total of 699 incident depressive episodes occurred during 
39,840 person-years. Of these episodes, 388 were depressive syndromes, including 99 
DSM-defi ned major depressive disorders and dysthymias. Table 1 presents the risk of 
incident late-life depression related to AF. AF was not associated with depressive symp-
toms and syndromes combined. When adjusting for age and sex only, AF was related 
to depressive syndromes in the complete sample (HR 1.63; 95% CI 1.04-2.55), as well 
as the subsample of persons without a history of depression (HR 2.00; 95% CI 1.06-
Table 1 Atrial fi brillation (AF) and the risk of incident depression estimated with Cox’ regression
Depressive symptoms and 
depressive syndromes
 HR (95%CI)            p-value
Depressive syndromes
only 
 HR (95%CI)            p-value
Complete sample (n=4,750)
AF, age and sex adjusted  1.21 (0.83-1.75)             .32  1.63 (1.04-2.55)             .03
AF, adjusted for all confounders*  1.18 (0.81-1.72)             .40  1.49 (0.94-2.37)             .09
Persons without history of depression (n=3,215)
AF, age and sex adjusted  1.51 (0.92-2.49)             .11  2.00 (1.06-3.75)             .03
AF, adjusted for all confounders*  1.51 (0.90-2.54)             .12  1.60 (0.81-3.15)             .18
* adjusted for baseline age, sex, SES, ADL, history of depression, smoking, hypertension, history of ischemic cardiovascular disease, 
diabetes, 
myocardial infarct, heart failure, stroke, transient ischemic attacks, use of antihypertensive medication
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3.75). However, when all confounders were adjusted for, AF was not associated with these 
outcomes in either the complete sample or the subsample of persons without a history of 
depression. Moreover, in an additional time-varying analysis, that took changes in AF or 
confounder status after baseline into account, the risk estimates decreased even more: HR 
1.18 (95% CI 0.88-1.57) for depressive symptoms and syndromes combined, and HR 
1.25 (95% CI 0.85-1.83) for depressive symptoms only (complete sample). 
Discussion
In this population-based cohort study, AF was not associated with an increased risk of 
incident depression anymore when all potential confounders were taken into account. A 
cross-sectional association between AF and depression has previously been established in 
four clinical populations.(1-4) Several prospective studies examined the risk of depression 
associated with (the cumulative burden of ) a set of cardiovascular risk factors, including 
AF.(9-11) Th e results were, however, inconsistent for both any depression (9, 11), as well as 
DSM-defi ned depression.(9, 10) As these studies were not focused on AF, many potential 
confounders were not taken into account. To our knowledge, this is the fi rst prospective 
study that specifi cally addressed the association between AF and incident depression. 
Th e current study was based on a large cohort of community-dwelling elderly. Moreover, 
detailed information on the occurrence of AF and depression was collected continuously 
throughout the follow-up period. It is unlikely that information bias explains our results. 
If persons with cardiac disorders visited their GP or cardiologist more often, so that 
depressions were identifi ed more easily, this would have led to an overestimation of the 
true risk. A potential source of selection bias might be that patients with cardiac disorders 
died before their depression was diagnosed, but this seems less likely as atrial fi brillation 
is mostly not an acute cause of mortality. We minimized confounding by adjusting for a 
substantial number of potential confounders. Some residual confounding may still have 
occurred, since we did not have baseline information on hyperthyroidism. Finally, we 
assessed whether lack of power could explain the results. However, the most parsimonious 
model, based on the criterium of 10% change in risk estimate, that included sex, age, 
history of depression and heart failure, did not yield materially diff erent results.
We conclude that AF is not an independent risk factor for incident late-life depression. 
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Abstract
Objective. Th e aim of this study was to prospectively assess whether highly lipid-soluble, 
non-selective, or serotonergic receptor binding beta-blockers are associated with incident 
depression. 
Methods. Between 1993 and 2005, 5,104 elderly persons were followed for incident de-
pressions, identifi ed by regular interview and continuous monitoring of medical records. 
Pharmacies provided online information on fi lled beta-blockers. We used multivariate 
Cox proportional hazard models to analyze the data.
Results. Overall, beta-blockers were not associated with depressive symptoms or syndromes. 
Highly lipid-soluble beta-blockers were associated with depressive symptoms during the 
fi rst three months of use (HR 3.31; 95% CI 1.03-10.6). Non-selective beta-blockers con-
veyed an increased risk (HR 2.13; 95% CI 1.05-4.33), but only if also highly lipid-soluble 
(HR 3.45; 95% CI 1.08-11.0). Serotonergic receptor affi  nity was not signifi cantly associ-
ated with depressive symptoms (HR 2.56; 95% CI 0.80-8.20). No group of beta-blockers 
was associated with incident depressive syndromes. 
Conclusion. We conclude that lipophilic beta-blockers, mostly propranolol in our study, 
were associated with depressive symptoms.
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Introduction
Soon after propranolol was marketed, physicians became concerned about depression in 
users of beta-adrenergic blockers. In 1967, a report indicated that 20 out of 89 patients 
receiving propranolol for cardiac arrhythmias developed depressive symptoms (1). Since 
then, numerous cases of depression in beta-blocker users were described in medical 
journals (2). Th ese case reports were suggestive of a strong causal relationship between 
propranolol and depression (2). 
Th e most widely proposed explanation for the relationship between beta-blockers and 
depression is that the drugs decrease noradrenergic activity in the brain.(3, 4) Th is suggests 
that non-selective beta-blockers, blocking beta-2 in addition to beta-1 adrenoceptors, may 
be more likely to induce depression than selective beta-blockers. Indeed, all beta-blockers 
that have ever been individually associated with an increased risk of depression are also 
non-selective: propranolol, oxprenolol, nadolol, sotalol and timolol (2, 5, 6). However, 
to our knowledge, this hypothesis has been investigated in only one study. Th is cross-
sectional study yielded an odds ratio of 1.8 for DSM-defi ned major depression (95%CI: 
1.1-3.1) for non-selective beta-blockers (7). Another hypothesis is that the affi  nity with 
serotonergic (5-HT1A) receptors forms the actual iatrogenic mechanism of action. More-
over, independent of the actual mechanism involved, lipophilic beta-blockers may be the 
most likely candidates for conveying an increased risk of depression because they pass the 
blood brain barrier most easily. Propranolol and oxprenolol, both lipophilic beta-blockers, 
have in fact been associated with an increased risk of depression (2, 6). 
Th e objective of the current study was to examine the association between lipid-solu-
bility, serotonergic receptor affi  nity, and non-selectiveness of beta-blockers and incident 
depression in a large cohort study among community-dwelling elderly. Participants were 
assessed prospectively and systematically for the occurrence of depressions.
Methods
Setting 
Th e study was embedded in the Rotterdam Study, a prospective cohort study among 7,983 
inhabitants of Ommoord, a district of Rotterdam, who were 55 or older at the start of 
the study in 1990. Th e Rotterdam Study focuses on the occurrence of common diseases 
in the elderly.(8) Th e Medical Ethics Committee of the Erasmus Medical Center Rot-
terdam approved the study and all participants provided written informed consent. Up 
till 2004, four examination rounds have taken place during which participants underwent 
an extensive interview and a physical examination. Continuous monitoring for major 
cardiovascular, neurological, and psychiatric diseases such as depression was achieved 
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through linkage with the medical fi les from general practitioners (GPs). Information on 
vital status was obtained from the municipal authorities. 
Study population
Th e study population consisted of persons at risk for incident depression and was selected 
as follows. During the second examination round in the Rotterdam Study, the baseline 
of the current analysis, 5769 participants were screened for depressive symptoms. Partici-
pants fi lled out either the validated Dutch version of the Center for Epidemiologic Studies 
Depression Scale (CES-D) or the validated Dutch version of the Hospital Anxiety and 
Depression Scale (HADS)(9, 10). Persons with a score of 16 or higher on the CES-D or 
9 or higher on the HADS were considered screen-positive. At baseline, we excluded 549 
persons with depressive symptoms, 105 persons with dementia, 9 persons with bipolar 
disorder, and 2 persons lost to follow-up directly after screening. Th is resulted in a study 
population of 5104 persons free of depression at baseline.
Assessment of incident depression
Assessment of depression in the Rotterdam Study has been described in detail before 
(11). Information on the occurrence of incident depressions during follow-up was ob-
tained from (1) psychiatric examinations, (2) self-reported histories of depression, and (3) 
medical records. Th e psychiatric examination during examination rounds consisted of a 
screening with the CES-D. Subsequently, a trained clinician conducted a semi-structured 
interview in screen-positive participants (Schedules for Clinical Assessment in Neuro-
psychiatry).(12) Th e self-reported history of depression, solicited during examination 
rounds, included standardized questions to ascertain whether and when participants 
had suff ered from a depressive episode, and if so whether they had been treated. Trained 
research-assistants scrutinized the GPs’ medical records and copied the information about 
a potential depression. Two research physicians and a psychologist independently assessed 
this information according to a predefi ned protocol, and discussed discordant assessments.
Based on these sources, we defi ned two categories of depressive episodes: (1) clinically 
relevant depressive symptoms, if at least one clinically relevant core symptom of major 
depression had been reported, and (2) depressive syndromes, which included depressive 
disorders that met DSM-IV criteria for major depression or dysthymia (13) and were 
diagnosed by a psychiatrist or another mental health professional, and other depressive 
syndromes that involved a depression recorded by a GP or other physician, self-reported 
depression for which the participant consulted a GP or a mental health professional, and 
DSM-IV minor depression.  We defi ned the date-of-onset as the day of the fi rst report 
of symptoms according to one of the sources described above, or the date of the fi rst 
prescription  of an antidepressant drug, whichever came fi rst. 
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Exposure defi nition
Th e seven fully computerized pharmacies that serve the study area routinely store digitized 
information on all drugs dispensed to participants. More than 95 percent of the participants 
fi ll their prescriptions at one of these pharmacies. For each prescription, the ATC-code, 
prescribed daily dosage and number of tablets is registered. For each prescription, the dura-
tion was calculated by dividing the number of fi lled tablets by the prescribed daily number 
plus a carry-over period of seven days. We included all orally administered beta-blockers, 
as well as beta-blockers in combination-drugs. Participants were assigned the status of cur-
rent user of a beta-blocker at the time a depression occurred, if the depression fell within 
the calculated prescription period. We distinguished two levels of lipid-solubility: low 
(atenolol, carteolol, practolol, nadolol, sotalol, timolol)/ moderate (acebutolol, bisoprolol, 
celiprolol, esmolol, labetalol, levobunolol, medroxalol, mepindolol, metoprolol, oxpreno-
lol, pindolol), and high (alprenolol, betaxolol, bopindolol, bucindolol, bupranolol, cara-
zolol, carvedilol, metipranolol, nebivolol, penbutolol, propranolol, talinolol, tertatolol).
(14) Th e following beta-blockers were considered serotonergic antagonists: alprenolol, 
bopindolol, penbutolol, pindolol, and propranolol (15-17). Non-selective beta-blockers 
were: alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, metipranolol, 
nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol. 
Covariates
Th e following potential confounders were considered. We considered the socio-demo-
graphic variables age, sex, socio-economic status, and disability in activities of daily living 
in the analyses. Cardiovascular diseases were assessed as these are indications for beta-
blocker use: hypertension, myocardial infarction, and heart failure. Finally, the following 
(relative) contraindications for beta-blocker use were accounted for: hypotension, chronic 
obstructive pulmonary disease, claudicatio intermittens, and a history of depression.
Socio-economic status was determined in terms of highest education attained and 
net income.(18) Disability in activities of daily living was assessed with the Modifi ed 
Stanford Health Assessment Questionnaire.(19) Higher scores on this scale with a range 
of 1.0 to 4.0 represent more disability. Blood pressure was measured twice, after a mini-
mum of 5 minutes rest, in sitting position at the right upper arm using a random zero 
sphygmomanometer. Th e average of the two measurements was used for our analysis. 
Hypertension was defi ned as diastolic blood pressure of 100 mmHg or above, or systolic 
blood pressure of 160 mmHg or above (20), or the use of antihypertensive drugs for the 
indication hypertension. Hypotension was defi ned as systolic blood pressure of 90 mmHg 
or below. Claudicatio intermittens was established with the Rose questionnaire during 
home-interviews.
A history of  myocardial infarction was defi ned as self-reported myocardial infarc-
tion confi rmed by information from medical records, or an ECG characteristic of prior 
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myocardial infarction according to the ICD-10 (code I21) as verifi ed by a cardiologist 
(21). Heart failure was defi ned in accordance with the criteria of the European Society of 
Cardiology.(22) It required the presence of the typical signs or symptoms of heart failure, 
and confi rmation of cardiac dysfunction on chest X-ray or echocardiography. Chronic ob-
structive pulmonary disease (COPD) was defi ned with an algorithm based on spirometry 
reports and information from medical fi les (23). Th e medical and pharmacy records also 
provided information on the date-of-onset of these events.
Statistical analysis
For the calculation of adjusted risk estimates with their 95% confi dence intervals, we 
used Cox proportional hazards analyses with the outcomes ‘depressive symptoms’ and ‘de-
pressive syndromes’, respectively. We defi ned the following exposures as time-dependent 
determinants of interest and compared them to no use: 1) use of any beta-blocker, 2) use 
of low/moderately and highly lipid-soluble beta-blockers, 3) use of serotonergic receptor 
non-binding and binding beta-blockers, and 4) use of selective and non-selective beta-
blockers. We tested whether these exposures were associated with depression especially in 
the fi rst three months of use, because in earlier reports depression began within a couple of 
weeks after starting treatment (2). Moreover, it is likely that patients who develop depres-
sion in the fi rst months of treatment stop or switch to other drugs (potentially causing 
‘depletion of susceptibles’). We fi tted a multivariate model for each outcome and exposure 
variable, adjusting for age, sex, and dosage expressed in terms of lower or higher than the 
Defi ned Daily Dose, which is the recommended dose for the main indication in an adult. 
Subsequently, we assessed whether the other confounders mentioned above changed the 
risk estimate by 1 percent or more. Only history of depression, and the time-varying 
variables myocardial infarction, heart failure, and chronic obstructive pulmonary disease 
changed the point estimate and these variables were included in the multivariate models.
In the analyses, each participant contributed person-years until follow-up ended either 
with an episode of depressive symptoms or a depressive syndrome, dementia, death, 
loss-to-follow-up, or the end of study on October 1, 2005, whichever came fi rst. For all 
statistical analyses we used SPSS for Windows, version 15.0.
Results
We identifi ed 736 new-onset depressive episodes in 42,145 person-years, of which 329 
were episodes of depressive symptoms, and 407 depressive syndromes. Table 1 presents the 
baseline characteristics of the study sample. Th e average age was 70 years with a range of 56 
to 101 years and 58 % of the participants were female. Th e most prevalent cardiovascular 
risk factor was smoking (49% former smoker, 18 % current smoker). 
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During the study period, 39 % of the study population fi lled at least one prescription 
for a beta-blocker. More than two third of fi lled prescriptions for beta-blockers consisted 
of atenolol and metroprolol (see table 2). Propranolol was the most frequently prescribed 
highly lipid-soluble and serotonergic receptor binding beta-blocker. Table 2 shows that 
lipid-solubility and serotonergic receptor affi  nity are highly correlated.  
Table 3 shows the results of the multivariate Cox proportional hazard analyses. Overall, 
use of a beta-blocker was not associated with depressive symptoms or syndromes, either 
in the fi rst 90 days of use or afterwards. Highly lipid-soluble beta-blockers were associated 
Table 1 Baseline characteristics of the study population (N=5,104)
Characteristic Descriptive
Age, mean (SD) 70.0 (8.3)
Female sex, no (%) 2941 (57.7)
Education, primary school only, no (%) 936 (18.6)
Income, median (range) 2749 (750-7000)
Disability, mean (range) 1.31 (1.00-4.00)
History of depression, no (%) 1643 (32.2)
Smoking, 
- former smoker, no (%)
- current smoker, no (%)
2420 (48.6)
931 (18.3)
Diastolic blood pressure, mean (range) 77 (40-128)
Systolic blood pressure, mean (range) 141 (70-242)
Myocardial infarction, no (%) 563 (11.0)
Chronic heart failure, no (%) 206 (4.0)
Chronic obstructive pulmonary disease, no (%) 175 (3.4)
Table 2 Characteristics of the beta-blockers used during the study period*
Generic name Lipid-solubility Serotonergic affi  nity Non-selectivity Percentage
Atenolol L N N 37%
Metoprolol M N N 32%
Bisoprolol M N N 12%
Sotalol L N Y 11%
Propranolol H Y Y 3%
Pindolol M Y Y 1%
Labetolol M N Y 1%
Penbutolol H N Y <1%
Nebivolol M N N <1%
Celiprolol M N N <1%
Oxprenolol M N Y <1%
Timolol L N Y <1%
Acetobutolol M N N <1%
Alprenolol H Y Y <1%
Bevantolol M N N <1%
* L stands for low, M for intermediate, H for high, N for no and Y for Yes
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with depressive symptoms in the fi rst 90 days of use (HR 3.31; 95% CI 1.03-10.6), as 
were non-selective beta-blockers (HR 2.13; 95% CI 1.05-4.33). Serotonergic binding also 
conveyed an increased, albeit non-signifi cant, risk of depressive symptoms in the fi rst 90 
days of use (HR 2.56; 95% CI 0.80-8.20). Th ere were no associations when these groups 
of beta-blockers were used longer than three months. Nor was there a relation between 
these groups of beta-blockers and depressive syndromes. 
Due to collinearity between lipid-solubility and serotonergic receptor affi  nity, we could not 
fi t one statistical model with all three groups of beta-blockers in order to test whether one group 
in particular accounted for the increase in the risk of depressive symptoms. However, non-selec-
tive, highly lipid-soluble beta-blockers carried a risk of depressive symptoms in the fi rst 90 days 
of use (HR 3.45; 95% CI 1.08-11.0) similar that of all highly lipid-soluble beta-blockers (HR 
3.31; 95% CI 1.03-10.6). Non-selective beta-blockers with low to moderate lipid-solubility 
were not associated with an increased risk of depressive symptoms in the fi rst 90 days of use 
(HR 1.70; 95% CI 0.73-3.96). When we restricted exposure further to highly lipid-soluble, 
non-selective beta-blockers with serotonergic affi  nity, that is propranolol and alprenolol, the 
risk of depressive symptoms in the fi rst 90 days of use was 3.81 (95% CI 1.19-12.2). 
Table 3 Beta-blocker use and the risk of incident depression using multivariate Cox’ regression (n=5104)*
Exposure Depressive symptoms Depressive syndromes
HR (95%CI)     p-value
Age and sex adjusted
HR (95%CI)      p-value
Fully adjusted
HR (95%CI)      p-value
Age and sex adjusted
HR (95%CI)      p-value
Fully adjusted
HR (95%CI)      p-value
All beta-blocker:
   No use (ref )
   Use during 1-90 days 
   Use during > 90 days
-
0.78 (0.38-1.62)      .502
0.85 (0.44-1.63)      .623
-
0.76 (0.37-1.59)      .469
0.87 (0.45-1.66)      .661
-
1.02 (0.54-1.91)     .957
0.79 (0.44-1.40)     .415
-
0.99 (0.53-1.84)     .967
0.80 (0.45-1.43)     .455
Highly lipophilic beta-
blocker: 
   no use (ref )
   use during 1-90 days
   use during > 90 day
-
3.60 (1.13-11.5)     .031
1.51 (0.37-6.17)     .568
-
3.31 (1.03-10.6)       .044
1.47 (0.36-6.02)       .592
-
1.96 (0.48-8.00)    .347
-**
-
1.77 (0.43-7.23)     .429
-**
Serotonergic binding 
beta-blocker:
   no use (ref )
   use during 1-90 days
   use during > 90 day
-
2.93 (0.92-9.36)     .069
1.67 (0.52-5.32)     .388
-
2.56 (0.80-8.20)       .112
1.58 (0.50-5.06)       .437
-
1.65 (0.40-6.72)     .487
0.47 (0.07-3.36)     .450
-
1.42 (0.35-5.79)       .628
0.43 (0.06-3.12)       .407
Non-selective beta-
blocker:
   no use (ref )
   use during 1-90 days
   use during > 90 day
-
2.25 (1.11-4.56)     .025
0.76 (0.31-1.91)     .564
-
2.13 (1.05-4.33)       .036
0.75 (0.30-1.88)       .543
-
1.51 (0.69-3.29)     .304
0.91 (0.42-1.99)     .811
-
1.38 (0.36-3.01)       .423
0.89 (0.41-1.94)       .766
 * All models are adjusted for treatment dosage (<= 1 DDD versus > 1 DDD). The fully adjusted models also included age, sex, history 
of depression, myocardial infarction, heart failure, and chronic obstructive pulmonary disease. 
** The model could not be fi tted due to too few observations.
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Discussion
In this prospective study, we found that highly lipid-soluble beta-blockers were associated 
with a more than threefold increased risk of incident depressive symptoms in the fi rst three 
month of use. Th e risk was particularly high for highly lipid-soluble beta-blockers that also 
bind to serotonergic receptors. Non-selective beta-blockers were only associated with an 
increased risk of depressive symptoms if they were also highly lipid-soluble. Beta-blockers 
in general were not associated with an increased risk of depressive symptoms or syndromes. 
Th e association between depression and beta-blockers is controversial. With respect 
to beta-blockers in general, a prospective population-based study reported a risk of 2.6 
for anti-depressant use (6), but this result has not been replicated since in prospective 
observational studies (24-26), or in a meta-analysis of randomized studies (27). Th e results 
of our study are in line with the null fi ndings of the latter studies. With respect to highly 
lipid-soluble beta-blockers in particular, a review of 24 published case reports suggested 
a likely causal relationship between propranolol and depression.(2) Nine reports met the 
Naranjo criteria for causality (28). In all nine case described, depression began within a 
couple of weeks after treatment had started. Moreover, in a large Canadian cohort study, 
the risk of antidepressant use within 12 months after the start of propranolol was 4.8 times 
that of non-users and 2.1 times that of other study drug users (6). Th ree quarters of the 
depressions had occurred within the fi rst half year of treatment. When patients are closely 
followed for the eff ect of stopping and restarting the use of a drug, as is common for a case 
report, an eff ect will probably be noted sooner. Another cohort study found a signifi cantly 
increased standardized mortality ratio due to suicide of 2.7 in users of beta-blockers with 
high lipid-solubility, but not with low or medium lipid-solubility.(29) Th e results of our 
study also confi rm the hypothesis that lipophilic beta-blockers cause more depression 
than do hydrophilic beta-blockers. Lipophilic beta-blockers more readily pass the blood-
brain-barrier. However, previous prospective studies did not show an association between 
propranolol and depressive symptoms (25, 26). Insuffi  cient power may have contributed 
to these results. In one cohort study, antidepressant drug use served as an indicator of 
depression(26), but in later studies, this indicator has been shown to represent a depres-
sion in only 43-56% of users (30-33). Medical records were used to verify the diagnosis of 
depression in antidepressant users in the other cohort study, but this yielded only 28 cases.
(25) No association was found either with lipid-solubility or propranolol in particular 
in meta-analyses of controlled clinical trials (2, 27), but trials often lack systematic and 
timely assessment of depression (2, 3, 29). 
Lipid-solubility is not a pathophysiological mechanism of action in itself, but rather 
a prerequisite for the depressogenic eff ect of beta-blockers. Th erefore, we also studied 
whether a serotonergic (5-HT1A) or beta-2 adrenergic receptor antagonism that some 
beta-blockers exert could be involved. Overall, beta-blockers with serotonergic receptor af-
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fi nity were not signifi cantly associated with incident depression in our study. On the other 
hand, non-selective (beta-2 blocking) beta-blockers were associated with an increased risk 
of incident depression. An odds ratio of 1.8 for DSM-defi ned major depression (95%CI: 
1.1-3.1) has been found before in a cross-sectional study (7). In animal research, the 
beta-1 and beta-2 adrenoceptor antagonists alprenolol, pindolol, propranolol, and sotalol 
were found to block the action of nortriptyline, as shown by Yalcin et al in a study in 
mice (34). Conversely, salbutamol, a beta-2 adrenergic stimulant had been found to be 
as eff ective as clomipramine in a small trial with depressed inpatients (35). Positive cor-
relations were also observed between the number of lymphocyte beta-adrenoceptors and 
the rating on the Beck and Hamilton depression questionnaires in patients with major 
depressive disorder (36). Yet, we also found that non-selective beta-blockers with high 
lipid-solubility, i.e. propranolol, penbutolol and alprenolol in our study population (see 
table 2), have a similar risk of depressive symptoms as the whole group of highly lipid-
soluble beta-blockers. Th is suggests that the increased risk that we found for non-selective 
beta-blockers may be explained by the fact that many of these beta-blockers are highly 
lipid-soluble. Moreover, non-selective beta-blockers with low to moderate lipid-solubility 
were not related to depression in our study. When we studied highly lipid-soluble beta-
blockers with serotonergic affi  nity, in our study consisting of alprenolol and in most users 
propranolol, the risk was similar to that of the whole group of highly lipid-soluble beta-
blockers as well. Given the abundance of studies that have implicated a depressogenic 
eff ect of propranolol, it is possible that propranolol itself explains our fi ndings. 
It has been suggested that drug-induced depressions present with a diff erent phenom-
enology (37). For instance, medication may cause depressive symptoms instead of depres-
sions that meet DSM criteria. Our fi ndings are compatible with this suggestion. We found 
an increased risk for episodes of depressive symptoms in the fi rst three months of use, but 
not for depressive syndromes. Given that prescription and treatment protocols that were 
in use during the study period required physicians to evaluate the eff ect of a drug within 
three months, it is likely that adverse eff ects such as depressive symptoms are identifi ed 
within this period.
Strengths of our study are the large study population, long follow-up time, and sys-
tematic psychiatric work-up. Incident depressions were identifi ed from multiple sources, 
among which medical records. Moreover, our fi ndings apply to the heterogeneous sample 
of ambulatory elderly patients that, in our view, are typical of today’s beta-blocker users. A 
limitation of our study is that some information bias might have occurred. It is conceivable 
that treating physicians are alert to the adverse eff ect of depression in users of beta-blockers, 
especially propranolol (25). However, we did not fi nd that people with a history of depres-
sion received propranolol less or more often than people without such a history. Finally, it 
cannot be ruled out that in some instances propranolol was prescribed for conditions that 
are risk factors for depression such as anxiety, migraine, alcoholism and thyroid disease. 
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We conclude that the use of high lipid-soluble beta-blockers, possibly propranolol in 
particular, may give rise to depressive symptoms in late life, and that this adverse eff ect is 
usually detected in the fi rst months of treatment. As depressive symptoms and beta-blocker 
use are both very common in the elderly, physicians should be alert to this adverse eff ect.
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Abstract
Introduction. Th e ‘vascular depression’ hypothesis suggests that late-life depression results 
from vascular brain damage. We studied the longitudinal association between cerebrovas-
cular risk factors and incident depression in a large population-based study. 
Methods. 2,931 persons aged 61 or older were followed. Data on a comprehensive set of 
cerebrovascular risk factors was collected at baseline. Participants received a psychiatric 
assessment fi ve years later to establish DSM-IV diagnoses. 
Results. Only current smoking and anti-hypertensive drug use were independently associ-
ated with incident depressive symptoms. Diabetes mellitus, and the Framingham stroke 
risk score were related to incident depressive disorder. No relation with depression was 
observed for cholesterol, diastolic and systolic blood pressure, history of cardiovascular 
disease, atrial fi brillation, left ventricular hypertrophy, or the use of statins and antico-
agulants.
Conclusion. Th ese results moderately support the ‘vascular depression’ hypothesis. 
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Introduction
According to the vascular depression hypothesis, cerebrovascular disease may predispose, 
precipitate or perpetuate late-life depression (1, 2). Atherosclerotic lesions to brain circuits 
responsible for aff ective regulation are assumed to form the central mechanism (3). Such 
damage might also aff ect treatment success and the course of illness. 
When comparing depressed geriatric patients with controls, neuroimaging and autopsy 
studies showed that lesions in frontal deep white matter, basal ganglia and gray matter, 
as well as atrophy were more prevalent (4). One prospective study showed that lesions on 
magnetic resonance imaging were also associated with incident depression (5). To further 
test the vascular depression hypothesis, the longitudinal association between risk factors 
of vascular brain damage and late-life depression can be examined. Th e following cerebro-
vascular risk factors (CVRFs) have been established: smoking, hypertension, dyslipidemia, 
diabetes mellitus, history of cardiovascular disease, and atrial fi brillation (4, 6-12). 
To date only two population-based cohort studies have studied this relationship. Th ey 
present confl icting results. In a Korean population, after two years of follow-up, low 
and high total cholesterol, low HDL cholesterol and a history of heart disease were as-
sociated with incident depression (GMS), but hypertension and diabetes were not (13). 
In an American study, none of the risk factors included was associated with depressive 
symptoms (CES-D) after one year of follow-up (14). Both studies relied on self-reported 
vascular disease and had a relatively short follow-up period. Furthermore, the potential 
bias introduced by the use of cardiovascular medication has received little attention. Th ey 
are the most widely prescribed drugs in the elderly (15) and have been associated with 
depression as well (16, 17). 
Th e purpose of this study was to examine whether CVRFs at baseline were associated 
with incident depressive symptoms and depressive disorders in the general elderly popula-
tion. CVRFs were systematically assessed and the follow-up period covered more than fi ve 
years.
Methods
Setting
Th is investigation was embedded in the Rotterdam Study, a prospective study in a cohort 
of community-dwelling elderly residing in Ommoord, a district of Rotterdam. Th e Rotter-
dam Study focuses on the determinants of vascular, neuro-degenerative, ophthalmologic, 
locomotor and psychiatric diseases in the elderly (18). Th e Medical Ethics Committee 
of the Erasmus Medical Center Rotterdam approved the study, and written informed 
consent was obtained from all participants.
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Th e third examination round, which took place from March 1997 to December 1999, 
served as the baseline for the current study. Th e participants were 61 years or older at 
that time. Trained interviewers administered an extensive questionnaire covering current 
health status, health related behavior, medication use, medical history and socio-economic 
background. As part of the home interview, a cabinet check of actual medication use was 
carried out. During the visit to the study center, laboratory assessments and clinical ex-
aminations were performed. In the third round an assessment of depressive disorders was 
added to the study protocol (see below). Th e occurrence of incident depressive symptoms 
and depressive disorders was assessed again at follow-up, i.e. during the fourth round, 
which was conducted between January 2002 and October 2004.
In order to complement the data retrieved from the examination rounds, from the start 
of the Rotterdam Study all participants were continuously monitored for the occurrence 
of disease. Automated linkage with fi les from general practitioners provided information 
on clinical diseases such as myocardial infarction, atrial fi brillation, and diabetes mellitus. 
Two research physicians independently classifi ed all information. If they could not reach 
consensus, the judgment of a specialist was considered decisive. 
Study population
Of 5,990 invited participants, 4,797 people took part in the baseline examination (80%). 
We excluded 362 participants with depressive symptoms and 196 participants who did 
not answer enough items of the depression screening instrument to calculate a valid score 
(see fi gure 1). As the use of anti-depressive medication within six months before the in-
terview might have infl uenced the number and severity of reported depressive symptoms, 
we also excluded the 142 participants who did not report depressive symptoms but used 
an antidepressant at baseline. After the baseline examination, 572 individuals died, so that 
3,525 participants could be invited for the follow-up examination. 3,020 of them took 
part (86%). Eventually, 2,931 participants provided valid data about depressive symptoms 
at follow-up and comprise the study sample for the current analysis. 
Assessment of depressive symptoms and depressive disorders
During the baseline and follow-up examination round, we used the same two-step proce-
dure to assess depressive symptoms and depressive disorders. First, the participants were 
screened for depressive symptoms during the home-interview with a Dutch, validated 
version of the Center for Epidemiologic Studies Depression Scale (CES-D) (19). Th is 
questionnaire contains 20 questions with possible scores of 0 to 3. Participants with 
scores of 16 or higher were considered screen-positive. Th is cut-off  represents clinically 
signifi cant depressive symptoms.
Next, the screen-positive participants were invited for a clinical interview. A trained psy-
chiatrist, geriatrician or psychologist conducted the psychiatric work-up using the Dutch 
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version of the Present State Examination, a semi-structured psychiatric interview included 
in the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (20). Major and 
minor depressive disorders as well as dysthymia were classifi ed according to the DSM-IV 
criteria, with an algorithm based on the item-scores. 
As explicated above, our study population consisted of participants who were free of 
depressive symptoms (CES-D <16) at baseline and were at risk of incident depressive 
symptoms (CES-D >= 16) or an incident DSM-IV defi ned depressive disorder.
Assessment of cerebrovascular risk factors (CVRFs)
We studied the following CVRFs: smoking, diastolic and systolic blood pressure, diabetes 
mellitus, total and HDL-cholesterol, history of cardiovascular disease, atrial fi brillation, 
and left ventricular hypertrophy on ECG. 
Self-reported smoking was categorized into never, former, and current. Blood pressure 
was measured twice, after a minimum of fi ve minutes rest, in sitting position at the right 
upper arm using a random zero sphygmomanometer. Th e average of the two measurements 
was calculated. Th e criteria for diabetes mellitus were: fasting plasma glucose level of 7.0 
mmol/l or over, non-fasting glucose or an oral glucose tolerance test of 11.1 mmol/L or 
Figure 1: fl ow diagram of study population 
 
Baseline examination:   4,797 participants screened with CES-D for depressive symptoms 
700 excluded 
Ź 362 CES-D positive 
Ź 142 CES-D negative but using anti-depressant medication 
Ź 196 not screened validly 
572 died  
428 refused further participation 
  77 lost to follow-up 
 
Follow-up examination:  3,020 participants  
2,628 CES-D negative                                  
    303 CES-D positive                  
Ź 46 major depression 
Ź 41 minor depression 
Ź 7 dysthymia 
Ź 80 depressive complaints 
Ź 79 no depressive disorder or depressive complaints 
Ź 50 no SCAN interview available 
     89 not screened validly with CES-D 
¾  Final study population: 2,931 ¾  Final study population: 2,931 
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over, or treatment with an antidiabetic medication or diet. Total serum cholesterol and 
HDL-cholesterol were determined with an automated enzymatic procedure. 
Angina pectoris and claudicatio intermittens were established with the Rose question-
naire. Other ‘signs’ of coronary insuffi  ciency were a history of coronary artery bypass 
grafting, and percutaneous transluminal coronary angioplasty. History of myocardial 
infarction was defi ned as self-reported myocardial infarction confi rmed by a physician, 
or myocardial infarction on the echocardiography (ECG) made during the centre visit. 
A diagnosis of heart failure was classifi ed as defi nite, probable, possible, or unlikely in 
accordance with the criteria of the European Society of Cardiology (21), and we included 
only defi nite and probable cases included in the analysis. 
For the diagnosis of atrial fi brillation or atrial fl utter, an ECG that verifi ed the diagnosis 
was required. Th e ECGs that were recorded at the research centre were analyzed with 
the Modular ECG Analysis System (22). Th e ECGs were also used to assess the presence 
of left ventricular hypertrophy. Cases with left ventricular hypertrophy were defi ned as 
having a left ventricular mass index ≥ 104 g/m2 in women and 116 g/m2 in men.
Information on medication use was derived from the seven fully computerized pharma-
cies that serve the neighborhood. Ninety percent of the participants of the Rotterdam 
Study fi ll their prescriptions at one of these pharmacies. With regard to the use of anti-
hypertensive medication, statins, coumarines or salicylates, we assumed that a participant 
was a current user when the data from the home interviews or pharmacies showed that 
(s)he had fi lled a prescription for either of these drugs within three months before the 
date of the home-interview of the third round. Th e following antihypertensive drugs 
were included: diuretics, beta-blockers, ace-inhibitors, calcium channel blockers, and 
a miscellaneous group including reserpine. We also checked whether participants used 
antidepressants (tricyclic antidepressants, (non)selective serotonin reuptake inhibitors, or 
other) within six months before the baseline and follow-up examination, because this 
might have infl uenced the number and severity of reported depressive symptoms.
On the basis of the abovementioned information we computed the 10-year Framingham 
stroke risk score. Th is composite score was developed to identify persons at substantially 
increased stroke risk, resulting from their vascular risk profi le (12). It encompasses age, 
systolic blood pressure, antihypertensive treatment, history of cardiovascular disease 
(including myocardial infarction, angina pectoris, coronary insuffi  ciency, claudicatio 
intermittens, and chronic heart failure), diabetes mellitus, smoking, atrial fi brillation and 
left ventricular hypertrophy. Diff erent weights are attributed to these risk factors for men 
and women. Men can be assigned up to 30 and women up to 27 points, corresponding 
with 10-year probabilities of stroke of 87.9% and 84.4% respectively.
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Assessment of confounders
Age, sex, socio-economic status, disability in activities of daily living, cognitive function 
and body mass index were assumed to confound the association between CVRFs and both 
depressive symptoms and depressive disorders (23, 24). We adjusted for highest education 
attained as well as net income per month in order to adjust as fully as possible for the 
eff ect of socio-economic status (25). Disability in activities of daily living was assessed 
with the Modifi ed Stanford Health Assessment Questionnaire (26), and cognitive status 
with the Mini Mental State Examination (27). Height and weight were measured with 
the participant in light underclothing and the body mass index (kg/m2) was calculated.
Data analysis
We examined the longitudinal relationship between CVRFs and incident depressive 
symptoms with linear regression. Th ese symptoms were measured with the CES-D on 
a continuous scale from 0 to 60. First, we determined the association between the indi-
vidual CVRFs at baseline and depressive symptoms at follow-up adjusted for age and sex. 
Although blood pressure was measured continuously, we used quintiles of diastolic and 
systolic blood pressure in the models of this risk factor in order to facilitate the interpreta-
tion of the results. When blood pressure was added as a confounder in the multivariate 
models of the other risk factors, we corrected for blood pressure levels using the continu-
ous measure in order to enhance the precision of the correction. We also analyzed with 
an F-test the eff ect of adding the quadratic terms of diastolic blood pressure and total 
cholesterol to these models, because other studies have found u-shaped relationships 
between these variables and cerebrovascular disease or depression (11, 13). Th e regression 
models were adjusted for antidepressant use at follow-up, but this did not change the 
coeffi  cients materially.
We used logistic regression to analyze the association between the individual CVRFs 
and the depressive disorders diagnosed in the clinical interviews. Participants with a major 
or minor depression or dysthymia were considered incident cases. Persons with some 
depressive complaints but not enough to fulfi ll the criteria of minor or major depression 
or dysthymia were restricted from this analysis. Again, we started with analyzing the as-
sociation between the individual CVRFs and the depressive syndromes adjusting for age 
and sex, and subsequently analyzed with a likelihood ratio-test the eff ect of adding the 
quadratic terms of diastolic blood pressure and total cholesterol to these models.
Finally, for both outcomes, multivariable models were fi tted, in which all risk factors, 
including the quadratic terms of diastolic blood pressure, and the presumed confounders 
were included. For the Framingham stroke risk score, a separate multivariable model was 
fi tted, because this score encompasses almost all other individual risk factors. Th e variables 
education and (log-transformed) income were entered as continuous variables in the mul-
tivariable models.  None of the abovementioned models was adjusted for baseline CES-D 
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in order to avoid bias as a result of regression to the mean in CES-D scores. Nor did we 
adjust for history of depression, as this would eliminate any possible eff ect of CVRFs on 
depression in the years prior to baseline. 
Two-sided p-values of <0.05 were considered statistically signifi cant. For all statistical 
analyses we used SPSS for Windows, version 13.0.
Results
After a follow-up of on average fi ve years, there were 303 persons with a positive CES-D 
score among the 2,931 participants who formed the study population for the analyses 
relating to depressive symptoms (see fl ow diagram). 253 of the 303 screen-positive persons 
received a psychiatric work-up. Th ere were 94 subjects with an incident depressive disor-
der: 46 persons fulfi lled the DSM-IV-criteria for a major depression, 41 those for a minor 
depression, and 7 those for dysthymia. In 80 participants, no diagnosis of a depressive 
disorder according to DSM criteria was made using the psychiatric interview due to insuf-
fi ciently severe depressive symptoms. Th ese 80 persons with ‘depressive complaints’ and 
another 50 with no psychiatric work-up were excluded. Th e analyses relating to depressive 
disorders were based on the remaining 2,801 participants.
Table 1 presents the baseline characteristics of the study sample. Th e average age was 
71 years with a range of 61 to 95 years and 58% of the participants was female. Th e 
most prevalent cerebrovascular risk factor was smoking (51% former smoker, 15.6% 
current smoker). Th e average 10-year Framingham stroke risk score was 12 in both men 
and women, which is equivalent to a 10-year probability of stroke of 12.9% and 9.2%, 
respectively.
Table 2 shows the results for the association between CVRFs at baseline and incident 
depressive symptoms after fi ve years of follow-up. Increasing age (beta=0.16; 95% 
CI=0.12-0.20), female sex (beta=1.60; 95% CI=1.12-2.09), current smoking (beta=1.53; 
95% CI=0.79-2.28), a history of cardiovascular disease (beta=0.96; 95% CI=0.33-1.59), 
the use of antihypertensives (beta=1.14; 95% CI=0.65-1.64), and the use of antico-
agulants (beta=0.73; 95% CI=0.12-1.34) were statistically signifi cantly associated with 
reporting depressive symptoms at follow-up. Th e 10-year Framingham stroke risk score 
was also associated with the occurrence of incident depressive symptoms (beta=0.14; 95% 
CI=0.07-0.20). In the multivariate model, only increasing age (beta=0.10; 95% CI=0.05-
0.15), female sex (beta=1.43; 95% CI=0.75-2.11), current smoking (beta=1.68; 95% 
CI=0.83-2.53), and use of anti-hypertensives (beta=1.04; 95% CI=0.42-1.65) remained 
signifi cantly associated with incident depressive symptoms at follow-up. 
In a post-hoc analysis of smoking, we examined the association between pack-years and 
depressive symptoms in current and former smokers. We found a statistically signifi cant 
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association between packyears and depressive symptoms only in former smokers (beta = 
0.023; 95% CI= 0.01-0.04; p=0.004), but no signifi cant association in current smokers 
(beta =0.027; 95% CI= -0.12-0.07; p=0.17) in the multivariable analyses.
Table 3 shows the results for incident DSM-defi ned depressive disorders at fi ve year fol-
low-up. Besides increasing age (OR=1.05; 95% CI=1.02-1.08) and female sex (OR=2.40; 
95% CI=1.47-3.89), the 10-year Framingham stroke risk score was the only variable that 
was associated with the occurrence of depressive disorders (OR=1.06; 95% CI=1.00-1.11). 
In the multivariable model, however, apart from female sex (OR=2.40; 95% CI=1.21-
4.76), diabetes (OR=2.07; 95% CI=1.11-3.85) increased the risk of depressive disorders. 
To assess the potential eff ect of excluding the 50 participants who did not agree to a 
psychiatric interview, we performed an additional analysis in which we included the 50 
participants in the logistic regression as if they had a depressive disorder. In the models 
for individual risk factors, the point estimates for sex, diabetes, atrial fi brillation and anti-
hypertensive medication were attenuated by more than 10%. In the multivariable model, 
the point estimates for sex, former smoking, current smoking, and diabetes were attenuated.
Table 1 Baseline characteristics of the study population (N=2,931)
Characteristic Descriptives
Age, mean (SD) 71.0 (6.3)
Female sex, no (%) 1699 (58.0)
Education, primary school only, no (%) 419 (14.5)
Income, median (range) 2550 (750-7000)
Disability, mean (range) 0.4 (0.0-2.8)
MMSE, mean (SD) 27.9 (1.65)
BMI, mean (SD) 26.9 (3.9)
Cerebrovascular risk factors
Smoking, 
former smoker, no (%)
current smoker, no (%)
1496 (51.0)
457 (15.6)
Diastolic blood pressure, mean (SD) 76 (11.0)
Systolic blood pressure, mean (SD) 143 (20.8)
Diabetes mellitus, no (%) 391 (13.4)
Total cholesterol, mean (SD) 5.8 (1.0)
HDL-cholesterol, mean (SD) 1.4 (0.4)
Cardiovascular disease, no (%) 522 (17.8)
Atrial fi brillation, no (%) 139 (4.9)
Left ventricular hypertrophy on ECG, no (%) 71 (2.5)
Medication
Anti-hypertensive treatment, no (%) 1147 (39.1)
Statines, no (%) 330 (11.3)
Anti-coagulant use, no (%) 576 (19.7)
Framingham stroke risk score, mean (SD) 12 (4.8)
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Discussion
Th is prospective study showed that besides smoking and the use of antihypertensive medi-
cation no vascular risk factor was independently associated with the occurrence of incident 
depressive symptoms in a cohort of community-dwelling elderly. Diabetes mellitus and 
the Framingham stroke risk score were the only variables that were independently associ-
ated with the occurrence of a major or minor depressive disorder. 
Table 2 The association between cerebrovascular risk factors and incident depressive symptoms estimated with linear 
regression (N=2,931)
Variables Models for individual risk factors* 
    Beta                  95% CI                p-value
Multivariable model# 
   Beta                  95% CI                p-value
Age, in yrs 0.20 0.17 – 0.25 .000 0.11 0.06 – 0.16 .000
Female sex 2.27 1.76 – 2.77 .000 1.73 1.03 – 2.43 .000
Cerebrovascular risk factors
Smoking, 
- former smoker
- current smoker
0.10 
1.74 
-0.51 – 0.71
0.95 – 2.52
.741
.000
0.07 
1.92 
-0.59 – 0.74
1.04 – 2.80
.832
.000
Diastolic blood pressure, mmHg
- quintile 1: 42 - 66
- quintile 2: 67 - 72
- quintile 3: 73 - 77 (reference group)
- quintile 4: 78 - 84
- quintile 5: 85 - 146
0.17
-.49
0.00
-.44
0.03
-0.64 – 1.00
-1.30 – 0.32
-
-1.26 – 0.38
-0.78 – 0.84
.68
.23
-
.30
.94
0.06
-0.73
0.00
-0.34
-0.08
-0.86 – 0.98
-1.60 – 0.14
-
-1.23 – 0.55
-1.01 – 0.85
.901
.101
-
.456
.870
Systolic blood pressure, mmHg
- quintile 1: 87 - 125 (reference group)
- quintile 2: 126 - 136
- quintile 3: 137 - 146
- quintile 4: 147 - 159
- quintile 5: 160 - 236
0.00
-0.11
-0.27
-0.29
-0.34
-
-0.91 – 0.70
-1.09 – 0.55
-1.10 – 0.51
-1.15 – 0.47
-
.794
.517
.477
.412
0.00
-0.25
-0.31
-0.33
-0.48
-
-1.14 – 0.64
-1.25 – 0.64
-1.31 – 0.65
-1.52 – 0.57
-
.583
.527
.506
.372
Diabetes mellitus 0.76 0.02 – 1.50 .043 0.73 -0.10 – 1.57 .085
Total cholesterol -0.03 -0.35 – 0.21 .609 0.01 -0.31 – 0.30 .981
HDL-cholesterol -0.52 -1.21 – 0.16 .134 0.39 -0.39 – 1.17 .326
Cardiovascular disease 1.17 0.50 – 1.84 .001 0.28 -0.51 – 1.07 .486
Atrial fi brillation 0.66 -0.53 – 1.84 .278 -0.19 -1.50 – 1.12 .774
Left ventricular hypertrophy on ECG 0.08 -1.63 – 1.62 .992 -0.60 -2.36 – 1.17 .508
Medication
Anti-hypertensives 1.23 0.71 – 1.75 .000 1.10 0.46 – 1.74 .001
Statines 0.58 -0.21 – 1.36 .153 0.20  -0.72 – 1.12 .674
Anti-coagulants 0.83 0.19 – 1.48 .011 0.33  -0.45 – 1.10 .406
Framingham stroke risk score 0.16 0.09 – 0.23 .000 0.06 -0.04 – 0.15 .261$
* Adjusted for age and gender; # adjusted for age, sex, education, income, disability, cognitive function, BMI, all other CVRFs and 
medication; $ adjusted for age, sex, education, income, disability, cognitive function, BMI.
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Th e positive association that we found between current smoking and depressive symp-
toms is in line with results of many cross-sectional (28, 29) and prospective studies (30, 
31). If a relationship exists between smoking and depression through vascular damage, as 
suggested by the vascular depression hypothesis, one would expect to fi nd an association 
in current as well as former smokers. As endothelial function may improve after stopping 
smoking, it is likely that the risk in former smokers is lower. When testing the ‘dose-
response’ relationship between packyears and depressive symptoms in former and current 
smokers, we found a statistically signifi cant association for the former smokers only. It 
seems that, although strong, the link between smoking and major depression is not very 
Table 3 The association between cerebrovascular risk factors and incident depressive disorders estimated with logistic 
regression (N=2,801)
Variables Models for individual risk factors* 
     OR                 95% CI               p-value
Multivariable model# 
     OR                95% CI              p-value
Age, in yrs 1.05 1.02 – 1.08 .002 1.03 0.98 – 1.07 .289
Female sex 2.40 1.47 – 3.89 .000 2.40 1.21 – 4.76 .012
Cerebrovascular risk factors
Smoking, 
- former smoker
- current smoker
1.18
1.57
0.72 – 1.92
0.85 – 2.90
.512
.149
1.22
1.89
0.70 – 2.24
0.91 – 3.92
.445
.087
Diastolic blood pressure, mmHg
- quintile 1: 42 - 66
- quintile 2: 67 - 72
- quintile 3: 73 - 77 (reference group)
- quintile 4: 78 - 84
- quintile 5: 85 - 146
1.05
0.79
1.00
0.65
1.21
0.57 – 1.93
0.41 – 1.52
-
0.32 – 1.33
0.65 – 2.24
.882
.474
-
.240
.543
1.06
0.66
1.00
0.82
1.36
0.51 – 2.20
0.29 – 1.49
-
0.37 – 1.82
0.63 – 2.93
.886
.315
-
.631
.434
Systolic blood pressure, mmHg
- quintile 1: 87 - 125 (reference group)
- quintile 2: 126 - 136
- quintile 3: 137 - 146
- quintile 4: 147 - 159
- quintile 5: 160 - 236
1.00
0.90
0.86
0.95
0.75
-
0.46 – 1.73
0.44 – 1.68
0.50 – 1.81
0.38 – 1.48
-
.742
.652
.882
.409
1.00
1.00
0.74
0.97
0.68
-
0.46 – 2.14
0.31 – 1.75
0.42 – 2.22
0.28 – 1.70
-
.993
.488
.936
.414
Diabetes mellitus 1.31 0.75 – 2.29 .340 2.07 1.11 – 3.85 .022
Total cholesterol 0.89 0.70 – 1.13 .327 1.00 0.76 – 1.32 .992
HDL-cholesterol 0.69 0.38 – 1.27 .238 1.02 0.52 – 2.02 .947
Cardiovascular disease 1.54 0.93 – 2.55 .094 0.92 0.46 – 1.84 .816
Atrial fi brillation 2.09 1.01 – 4.31 .048 2.03 0.88 – 4.66 .096
Left ventricular hypertrophy on ECG 2.31 0.89 – 5.99 .085 1.19 0.33 – 4.30 .791
Medication
Anti-hypertensives 1.51 0.99 – 2.31 .054 1.57 0.89 – 2.75 .117
Statines 1.28 0.69 – 2.38 .441 1.51 0.73 – 3.15 .271
Anti-coagulants 1.15 0.70 – 2.92 .597 0.92 0.47 – 1.78 .801
Framingham stroke risk score 1.06 1.00 – 1.11 .039 1.07 1.00 – 1.14 .021$
* Adjusted for age and gender; # adjusted for age, sex, education, income, disability, cognitive function, BMI, all other CVRFs and 
medication; $ adjusted for age, sex, education, income, disability, cognitive function, BMI.
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straightforward (32). First, nicotine may act as an antidepressant because it stimulates 
the release of many diff erent neurotransmitters, but tolerance may develop quickly (32). 
Second, it can cause the symptoms of depression when smokers try to quit (32). Finally, 
twin studies have suggested that tobacco dependence is determined by a gene that makes 
carriers vulnerable to depression as well (32). 
Th at antihypertensive drugs may cause depressive disorders was recognized more than 
40 years ago (16). Reserpine and methyldopa are established causes of depressive disor-
ders. We found that antihypertensive treatment at baseline was associated with depressive 
symptoms at follow-up.  In another community-based study, low diastolic blood pressure 
at baseline was also associated with incident positive CES-D scores at follow-up (33). 
Th ese fi ndings suggest that lowering blood pressure itself might be causative, rather than 
the pharmacological entities. A strong decline of blood pressure may cause serious malaise 
and lassitude and this may be misclassifi ed as depressive disorder. Th e fact that certain 
antihypertensives such as thiazide diuretics and calcium antagonists are less frequently 
associated with depressive disorder despite their similar eff ect on blood pressure reduction 
solves this question only partly (34-39). More detailed studies are needed in which the 
diff erent kinds of antihypertensive drugs are compared. Clarifi cation of the relationship 
with depression may have substantial clinical implications. 
In adults and elderly, the onset of depression seems to be independent of the onset 
of type 2 diabetes; for type 1 diabetes, it is less clear (40-45). Th e risk of developing 
depression did not seem to be higher in patients with diabetes once complications and 
co-morbid diseases were accounted for (40-45). Our fi nding that diabetes is associated 
with an incident episode of minor or major depression does not concord with these earlier 
fi ndings, and could thus be a chance fi nding. We did not fi nd an association between total 
and HDL-cholesterol level and depressive symptoms or depressive disorders. Th is result is 
in line with the results of the cohort study performed by Blazer et al (46). Moreover, high 
total and low HDL are associated with an increased of stroke in elderly men, but not in 
elderly women (7). However, Kim et al found that low and high total cholesterol as well 
as low HDL cholesterol were associated with incident depression at two-year follow-up 
(13). Th e authors assumed that low cholesterol is associated with frailty and poor health, 
and thereby with depression. It is possible that our study did not have suffi  cient power to 
detect an association between serum cholesterol and depression, because statin use is high 
in our study population and this might give rise to a skewed distribution of total serum 
cholesterol levels. 
Even though most individual CVRFs were not associated with depressive symptoms 
or depressive disorders, the Framingham stroke risk score – a composite score which 
encompasses the majority of the CVRFs that we studied – was associated with depressive 
symptoms and depressive disorders in the models for individual risk factors, and with 
depressive disorders in the multivariate model. Th is fi nding renders some support to the 
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vascular depression hypothesis. However, Lyness et al did not fi nd a positive association 
between the Framingham stroke risk score and depressive disorders in a prospective study 
among primary care patients. Th is may have been due to insuffi  cient power resulting from 
a small sample (N=247), a higher cut-off  for depressive symptoms (21 on CES-D) and a 
short follow-up period of one year (47). Two other studies yielded mixed results as well for 
a cumulative score of vascular burden. In the population-based study, a history of two or 
more risk factors, i.e. self-reported heart disease, hypertension, diabetes or atherosclerosis, 
was not associated with depressive symptoms after one year of follow-up (14), whereas in 
a study among rehabilitation inpatients, two or more risk factors reported in the medical 
records, i.e. hypertension, diabetes or atrial fi brillation, increased the risk of depressive 
symptoms at 6- and 18-months of follow-up (48). 
Our study allowed examination of the association between a comprehensive set of 
CVRFs and depression in a general elderly population. Depressive symptomatology was 
assessed not only with the use of a dimensional symptom rating scale but also during 
a clinical interview in which DSM-IV classifi ed depressive syndromes were diagnosed. 
Moreover, the percentage of participants followed up was relatively high in our study. 
Furthermore, studies among patients presenting for treatment, be it for their depressive 
symptoms or other diseases, might suff er from information bias. Th e medical records may 
provide diff erential information on the CVRFs depending on the patient’s psychiatric 
status. Our study avoids the information bias inherent in such studies, because all partici-
pants were assessed in the same way. 
Nevertheless, a potential limitation of our study is that selection bias cannot be ruled 
out. Th e probability that a participant drops out is higher if he has more vascular health 
problems at baseline, or if he is depressed at the time of the follow-up examination. We 
excluded the 50 participants with no psychiatric work-up and this could have introduced 
bias and might explain some discrepancies between the multivariate models. Another limi-
tation is that risk factors that occurred between baseline and follow-up measurement were 
not captured. Th is might have led to an underestimation of the associations. In addition, 
depressive episodes that occurred after baseline and disappeared before the follow-up as-
sessment were not identifi ed. As depressive syndromes often have a chronic and recurrent 
nature (49-52), these episodes most probably consisted of on average shorter episodes. 
Th ere is some evidence that vascular depression episodes are less likely to be of short 
duration (4, 5), so that the bias as a result of missing these episodes would have yielded 
stronger positive associations between vascular risk factors and incident depression. None-
theless, the limited number of incident depressive disorders could have been responsible 
for the negative fi ndings with regard to this outcome. Finally, as we did not fi t a separate 
multivariable model for each individual risk factor, our multivariable models might have 
been overadjusted with respect to some of these factors, such as atrial fi brillation.
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In conclusion, we found that current smoking, the use of anti-hypertensive medication 
and diabetes mellitus were the only CVRFs that were associated with an increased risk of 
depressive symptoms or depressive disorders in the multivariable analyses. Apart from an 
ischemic eff ect on cerebral small vessels, these factors have also been hypothesized to cause 
abnormalities in neurotransmitter metabolism. All in all, we found no strong and consis-
tent relationship between individual CVRFs and depression. On the other hand, there was 
a positive association between the Framingham stroke risk score and depressive disorders. 
Th is composite score encompasses many of the individual risk factors. Hence, the fi ndings 
of this study provide only moderate support for the ‘vascular depression’ hypothesis.
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Abstract
Objectives. In order to test the “vascular depression” hypothesis, we investigated whether 
smaller retinal arteriolar or larger venular calibers, which are markers of cerebral microvas-
cular disease, were associated with incident late-life depression.
Methods. We included 3,605 participants (>55 years) from the population-based Rot-
terdam Study, who were free of depression at baseline (1993-1995) and had gradable 
fundus photographs for retinal vascular caliber measurements. We identifi ed persons with 
incident depressive symptoms and syndromes using psychiatric interviews during follow-
up visits and continuous monitoring. Follow-up was complete until October, 2005.
Results. After a mean follow-up of 9.0 years, 555 participants developed depressive symp-
toms, including 243 with depressive syndrome. Neither smaller arteriolar (age- and sex-
adjusted hazard ratio (HR): 1.01; 95%-confi dence interval (CI): 0.93-1.10), nor larger 
venular calibers (HR: 1.02; 95%-CI: 0.94-1.12) were associated with incident depressive 
symptoms or syndromes. 
Conclusions. Our present data showed no evidence of an association between retinal vascu-
lar calibers and incident late-life depression.
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Retinal vascular calibers
Introduction
According to the “vascular depression” hypothesis cerebral vascular pathology has been 
implicated in the pathogenesis of late-life depression.(1) Previous studies reported an 
association between depression and vascular risk factors, including white matter lesions 
on magnetic resonance imaging (MRI) and stroke.(1-3) However, not all studies have 
consistently demonstrated these associations.(4) Furthermore, it remains unclear whether 
macrovascular or microvascular processes are related to depression.(1-5) 
Th e retinal microcirculation, which can be assessed non-invasively,(6) shares similar 
anatomical, physiological, and embryological features with the cerebral microcirculation. 
Studies suggest that retinal arteriolar and venular calibers are markers of cerebral micro-
vascular disease.(6) Moreover, changes in the retinal microcirculation such as arteriolar 
narrowing or venular dilatation have been linked to cerebral white matter lesions on MRI 
scans.(6) Data both on retinal microcirculation and depression were collected in the Rot-
terdam Study, thereby providing an ideal opportunity to examine possible associations 
between microvascular disease and depression. Previously, two cross-sectional studies 
could not fi nd any association between retinal vascular abnormalities (e.g. retinal vascular 
caliber, retinopathy signs) and prevalent depression.(7,8) Th us far, there are no prospective 
data on these associations. In the present study, we examined associations between retinal 
vascular calibers and incident late-life depression in a large prospective population-based 
study.
Methods
Study sample
Th e present study was performed as part of the Rotterdam Study, a population-based, 
cohort study on chronic and disabling diseases in the elderly.(9) A total of 7,983 partici-
pants aged 55 years and older and living in one district of Rotterdam agreed to participate. 
Th e study was conducted according to the tenets of the Declaration of Helsinki, and the 
Medical Ethics Committee of the Erasmus Medical Center approved the study protocol. A 
written informed consent was obtained from all participants. Up till now four visits have 
taken place during which participants underwent an extensive interview and a physical ex-
amination (1989-1993, 1993-1995, 1997-1999, 2002-2004). During the fi rst visit, 5,674 
participants had gradable fundus photographs and during the second visit, the baseline of 
the present study, 4,940 participants were screened for depressive symptoms. Th e study 
sample for the present study consisted of 3,605 persons who were free of depression at 
baseline and had gradable fundus transparencies for retinal vascular caliber measurement. 
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Retinal vascular caliber measurements
Th e ophthalmic examination consisted of taking fundus photographs centered on the op-
tic disc of both eyes with a telecentric fundus camera (pharmacological mydriasis, 20° fi eld, 
Topcon Optical Company, Tokyo, Japan). Th ese photographs were digitized with a high-
resolution scanner (Nikon LS-4000, Nikon Corporation, Japan) and for each participant 
the eye with the best image quality was analyzed with a semi-automated system (Retinal 
Analysis, Optimate, WI; Department of Ophthalmology and Visual Science, University 
of Wisconsin-Madison). Per eye one summary value was calculated for the caliber of the 
blood column of the arterioles and one for the venules (in micrometers). As eyes may 
have diff erent magnifi cations in case of refractive changes due to corneal curvature, lens 
and axial length diff erences, we additionally adjusted these summary vessel measures with 
Littmann’s formula to approximate absolute measures. Four trained graders performed all 
measurements masked for participant characteristics. Both inter- and intragrader studies 
showed good to excellent agreement (intraclass correlation coeffi  cient = 0.49–0.95).(6)
To examine whether we could extrapolate caliber measurements from the fi rst to the 
second examination round (baseline of present study), we examined diff erences in vascular 
calibers over time. We measured the calibers in a random subset of 303 participants who 
had gradable fundus photographs from the fi rst and the third examination round that 
covered a mean interval of six years. Th e mean diff erences were -0.82 μm (95% confi dence 
interval (CI): -2.40; 0.77) for arteriolar calibers and -0.31 μm (95% CI: -2.47; 1.86) for 
venular calibers.
Assessment of depression
At baseline, participants were screened for depressive symptoms with either the validated 
Dutch version of the Center for Epidemiologic Studies Depression Scale (CES-D) or 
the validated Dutch version of the Hospital Anxiety and Depression Scale (HADS).(10) 
Persons with a score of 16 or higher on the CES-D or 9 or higher on the HADS were 
considered screen-positive.
During follow-up visits, information on incident depressions was obtained from psy-
chiatric examinations that consisted of a screening with the CES-D, and subsequent semi-
structured interviews of the screen-positive participants (Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN)). Additionally, the self-reported history of depression was 
solicited. Moreover, the general practitioner’s medical records and pharmacy records were 
continuously monitored for depressions and use of anti-depressants by automated linkage 
of these records with the study database.(10)
We categorized depressions as (1) episodes of clinically relevant depressive symptoms, if 
at least one clinically relevant core symptom of major depression (feeling depressed or loss-
of-interest) had been reported during the psychiatric interview or in the medical record, or 
as (2) depressive syndromes, which included major and minor depression and dysthymia 
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according to the criteria of Diagnostic and Statistical Manual of Mental Disorders of the 
American Psychiatric Association (fourth edition), as well as depressions diagnosed by a 
general practitioner or other physician, and self-reported depressions that had been treated 
by a health professional.(10) Follow-up was complete until October 1st, 2005. We defi ned 
the date-of-onset as the day of the fi rst report of symptoms, or the fi rst prescription date 
of an antidepressant drug, whichever came fi rst.  
Cardiovascular risk factors
Confounders such as age, sex, smoking, blood pressure, diabetes mellitus, body mass 
index, carotid artery plaques and serum cholesterol levels were measured as described 
previously.(6)
Statistical analyses
Associations of retinal vascular calibers with incident late-life depression were analyzed by 
means of Cox proportional hazards models. Hazard ratios (HR), 95% confi dence intervals 
(CI) and Wald chi-square (χ2) test statistics with one degree of freedom for depression 
were calculated by analyzing retinal vascular calibers both linearly (per standard deviation 
(SD)) and in quartiles. Persons were followed-up until onset of depressive symptoms or 
depressive syndromes, dementia, death, loss to follow-up, or October 1st, 2005, whichever 
came fi rst. All analyses were performed using SPSS (Windows version 15.0).
Results
After a mean follow-up of 9.0 years, 555 persons (15.4%) developed an incident late-life 
depression, of whom 312 (8.7%) suff ered from depressive symptoms and 243 (6.7%) 
had a depressive syndrome. Table 1 presents characteristics of the participants that were 
obtained at the time of the retinal vascular caliber measurements. 
Neither smaller retinal arteriolar (age- and sex-adjusted HR per SD decrease: 1.01; 
95% CI: 0.93-1.10; Wald χ2: 0.036; p-value: 0.85) nor larger venular calibers (age- and 
sex-adjusted HR per SD increase: 1.02; 95% CI: 0.94-1.12; Wald χ2: 0.262; p-value: 
0.61) were associated with an increased risk of depressive symptoms. Th e correspond-
ing age- and sex-adjusted HR for depressive syndromes were 1.08 (95% CI: 0.94-1.22; 
Wald χ2: 1.242; p-value: 0.27) for arteriolar caliber and 1.00 (95% CI: 0.88-1.14; Wald 
χ2: 0.001; p-value: 0.97) for venular caliber. Categorizing retinal vascular calibers into 
quartiles did not show a consistent trend towards a higher risk of incident depression. 
Additional adjustment for other cardiovascular risk factors did not alter the associations. 
Also, excluding persons with history of depression before the second examination round 
(n=1,092) did not change the above-mentioned results.
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Discussion
In this prospective population-based cohort study of elderly persons, we did not fi nd an 
association between retinal vascular calibers and incident late-life depressive symptoms or 
depressive syndromes. 
So far, studies examining the associations between microvascular processes and depression 
used MRI-markers such as white matter lesions and brain infarcts. Th ese studies produced 
inconsistent fi ndings probably due to diff erences not only in assessment of depression, 
source population or study design, but also diff erences in MRI acquisition and grading.(2-4)
Two recent studies used retinal microvasculature to explore the association between 
microvascular disease and depression.(7,8) Population-based data from the Cardiovascular 
Health Study among 2,420 persons aged 65 years and older showed that persons with 
generalized arteriolar narrowing or generalized venular dilatation were not more likely to 
have depression.(7) Also, other microvascular signs were not related to the presence of 
depression either.(7) More recently, a clinic-based study including 99 participants showed 
Table 1 Characteristics of the study population at time of retinal vascular caliber measurements (1990-1993) 
Participants Non-participants* Adjusted diff erences†
(95% CI)‡
Number (n) 3,605 2,069
Age (years) 66.1 (7.1) 71.4 (8.9) 5.3 (4.9; 5.7)§
Gender (% women) 55 66 9.5 (6.7; 12.3)§
Institutionalized (%) 1 8 2.6 (1.7; 3.6)§
Diabetes mellitus (%) 8 13 2.0 (0.0; 3.6)§
Smoking (% current) 22.6 25.4 8.1 (5.7; 10.5)§
Body mass index (kg/m2) 26.3 (3.5) 26.4 (3.9) -0.02 (-0.19; 0.23)
Systolic blood pressure (mmHg) 137.3 (21.4) 140.7 (23.1) 0.27 (-1.51; 0.96)
Diastolic blood pressure (mmHg) 74.0 (11.1) 73.0 (11.8) -0.30 (-0.95; 0.35)
Number of carotid artery plaques ≥ 4 (%) 13.3 21.1 4.6 (2.3; 6.8)§
Serum total cholesterol (mmol/l) 6.63 (1.17) 6.65 (1.26) 0.05 (-0.02; 0.11)§
Serum HDL|| cholesterol (mmol/l) 1.35 (0.36) 1.35 (0.37) -0.02 (-0.04; 0.00)
Retinal arteriolar caliber (μm) 147.0 (14.2) 146.5 (14.9) 0.66 (-0.17; 1.47)
Retinal venular caliber (μm) 222.7 (20.3) 220.6 (21.8) 0.97 (-0.20; 2.13)
Presented as means (standard deviation) or percentages
* Non-participation at the second examination round, including prevalent depression cases (1993-1995)
† Age and sex adjusted if applicable
‡ CI = confi dence interval
§ Statistically signifi cant (p<0.05)
||High-density lipoprotein
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that diabetic patients with major depression (n=34; 145.3μm) had statistically signifi cantly 
larger retinal arteriolar caliber compared to diabetic patients without depression (n=27; 
139.2μm) and healthy persons (n=38; 132.6μm).(8) However, after additional adjustment 
for vascular risk factors this trend became non-signifi cant. Findings from these cross-
sectional studies are in accordance with the results we found in the current prospective 
study.
Th e lack of an association should be interpreted within the context of several possible 
limitations of the present study. Firstly, the retinal vascular caliber measurements were 
performed on average two years prior to the initial assessment of prevalent depression. 
Th is might have introduced selection bias if the retinal vascular calibers were diff erent at 
the time of the baseline assessment of depression compared to the actual measurements. 
However, in the random subset, we did not fi nd any signifi cant diff erences in vascular 
calibers over a six-year period, suggesting a limited role for selection bias. Secondly, some 
persons who developed depression during follow-up already had a history of depression. 
As depression is a risk factor for vascular disease as well as for recurrent depression any pos-
sible true eff ect would most likely have been overestimated. However, excluding persons 
with history of depression did not alter our fi ndings. Th irdly, other retinal microvascular 
signs such as arteriovenous nicking and focal arteriolar narrowing were not examined 
in the present study. Finally, as depression is a remitting and relapsing disease, it is a 
challenge to ascertain all episodes of this disease which occur in between follow-up exami-
nation rounds. We attempted to limit the underdetection of depression by continuously 
monitoring the general practitioner’s medical records and pharmacy records.
Strengths of our study include the population-based setting, the longitudinal design of the 
study with on average nine years of follow-up and standardized procedures for retinal vascular 
caliber measurements. Due to the close collaboration with general practitioners and other 
health care institutions, the follow-up for depressive episodes was virtually complete. Finally, 
with a two-sided alpha of 0.05 and a sample size of 3,605, we had a power of 80% to show 
a signifi cant relative risk of at least 1.2 per standard deviation change in vascular calibers.
In conclusion, our present data show no evidence of an association between retinal 
vascular calibers and incident late-life depression.
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Abstract
 Background. Whereas cross-sectional studies show an association between vascular brain 
disease and depression, longitudinal data are scarce. In a population-based study we inves-
tigated this relationship both cross-sectionally and longitudinally.
Methods. 479 persons (60-90 years) underwent brain MRI. Brain atrophy, white matter 
lesions (WML) and brain infarcts refl ected vascular brain disease. At baseline (1995-1996) 
and follow-up examinations we identifi ed persons with depressive symptoms and syn-
dromes using CES-D and psychiatric interview. Moreover, medical records were continu-
ously monitored to identify incident depression. Follow-up was complete until October 
2005.
Results. At baseline 36 persons had depressive symptoms. Brain atrophy, WML, and in-
farcts were associated with presence of depressive symptoms. During follow-up 92 persons 
developed depressive symptoms, of whom 35 depressive syndrome. Th ere was no associa-
tion of any MRI-marker with incident depressive symptoms or syndromes.
Conclusions. Markers of vascular brain disease were associated with depression cross-
sectionally. However, no relationship was present between these markers and risk of 
depression longitudinally.
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MRI-markers of vascular brain disease
Introduction
Vascular disease and depression in the elderly are closely related.1,2 Th is has fuelled the 
‘vascular depression’ hypothesis,3 which postulates a vascular basis of late-life depression.4-6 
With magnetic resonance imaging (MRI) markers of vascular brain disease can be visual-
ized, including white matter lesions (WML), brain infarcts, and brain atrophy. Various 
cross-sectional studies reported an association of several MRI-markers with depression.4,7-10 
Longitudinal studies thus far only investigated the relationship of WML with depression 
longitudinally, and found inconsistent results.9,11-13 We investigated the relationship of 
several MRI-markers of subclinical vascular brain disease both cross-sectionally with 
prevalent depression, and longitudinally with new-onset depression
Methods
Study population
Th is study is based on an age-stratifi ed (60-90 years) sample of 563 participants from the 
population-based Rotterdam Study,14 who underwent multi-sequence brain MR-imaging 
in 1995-1996.15 Th e institutional medical-ethics committee approved the study and all 
participants gave written informed consent. Of the 563 participants, 73 did not com-
plete MRI-examination due to claustrophobia or technical reasons, and 4 persons did 
not undergo psychiatric assessment at baseline. Furthermore, of the eleven persons using 
anti-depressants at baseline seven had no depressive symptoms. Th ese seven persons were 
excluded, because we could not determine whether the indication for using this medica-
tion was still present. Th erefore, a total of 479 persons were available for the analysis.
MRI measures at baseline
Image acquisition, classifi cation algorithm, and validation steps have been described 
elsewhere.15 In summary, we used the k-nearest-neighbor classifi er to classify voxels into 
cerebrospinal fl uid, grey matter, normal white matter, and WML. Using non-rigid trans-
formation, non-cerebral tissues were stripped. For measurement of lobar and deep central 
brain volumes, we created an atlas, in which the lobes were labeled according to a slightly 
modifi ed version of the segmentation protocol as described by Bokde et al.16 Subsequently, 
we used validated non-rigid transformation to transform this atlas to each brain. Brain 
infarcts were rated visually as focal hyperintensities on T2-weighted images, 3 mm in size 
or larger and with a corresponding prominent hypointensity on T1-weighted images.15
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Chapter 8 
98
Assessment of depression
Th e assessment of depression has been described elsewhere.17 At the baseline visit and during 
three follow-up rounds (1997-1999, 1999-2000, 2000-2001) the Center for Epidemio-
logical Studies Depression Scale (CES-D) was used as screening tool with a cut-off  of 16. 
Screen-positive individuals then underwent the Present State Examination 18 to diagnose 
major depression, dysthymia, and minor depression. Th e response rate at each of the three 
follow-up rounds was 95% (437 of the 461 eligible), 81% (336 of 414 eligible), and 81% 
(309 of 381 eligible). Moreover, medical and pharmacy records of participants (e.g. hospital 
discharge letter, specialists’ reports, and notes of general practitioners) were continuously 
monitored for depressive episodes and for start of anti-depressants during the follow-up 
period by automated linkage of the general practitioners’ and pharmacists’ records with the 
database. Th ese data ensured virtually complete follow-up among care-seeking participants.
Depressive episodes were classifi ed as depressive symptoms if persons were CES-D posi-
tive; or had at least one core symptom of depression recorded in medical fi les; or started 
anti-depressants (without documentation of clinical symptoms). Depressive symptoms 
were further classifi ed as depressive syndrome if persons were diagnosed as suff ering from 
major depression, minor depression, or dysthymia according to the psychiatric interview 
or medical fi les. Follow-up for incident depressive symptoms and syndromes was complete 
until October 1st 2005.
Covariates
Covariates included education, smoking, blood pressure, diabetes mellitus, body-mass 
index, and intima-media thickness.15
Statistical analysis
All volumes were expressed as percentage of intra-cranial volume. Total white matter was 
the sum of normal white matter and WML. WML were analyzed as ln(WML volume), 
because of the skewed untransformed measures. We used logistic regression to calculate 
odds ratios for presence of depressive symptoms associated with brain imaging markers. 
We also performed cross-sectional analyses with linear regression using CES-D score con-
tinuously. For the longitudinal analyses, we excluded persons with depressive symptoms 
at baseline (n=36). We used Cox’ proportional-hazards models to calculate hazard ratios 
(HR) for incident depressive symptoms or syndromes associated with brain imaging 
markers. Persons were followed until onset of depressive symptoms or syndromes, loss to 
follow-up, or October 1st 2005, whichever came fi rst.
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Results
Table 1 shows the baseline characteristics of the study population. Th irty-six persons had 
depressive symptoms, of whom 6 had a depressive syndrome. Th e smaller the brain volume 
the more likely persons were to have depressive symptoms (table 2). At the lobar level, 
particularly parietal and temporal lobe atrophy were associated with depressive symp-
toms. Th e likelihood of having depressive symptoms increased with increasing volume of 
WML, especially in the frontal lobe and deep central region, and with presence of brain 
infarcts. Parietal lobe atrophy and deep white matter lesions were also related to CES-D 
continuously (table 2). Numbers were too small to perform separate analyses for prevalent 
depressive syndromes (n=6).
During 3,373 person-years of follow-up (mean 7.5 years) a total of 92 persons devel-
oped depressive symptoms, of whom 35 suff ered from a depressive syndrome. Neither 
global nor lobar brain tissue volumes were associated with incident depressive symptoms 
or syndromes (table 3 and 4). Furthermore, neither WML nor brain infarcts were associ-
Table 1 Baseline characteristics of the study population
N 479
Age, yr 73.4 (7.8)
Women 50%
Primary education only 30%
MMSE, score 27.7 (2.1)
Current smokers 18%
Former smokers 54%
Systolic blood pressure, mmHg 146 (21)
Diastolic blood pressure, mmHg 77 (12)
Diabetes mellitus 5.0%
Body mass index, kg/m2 26.2 (3.5)
Intima media thickness, mm 0.87 (0.14)
MRI markers
Whole brain volume, %ICV 77.4 (3.6)
Frontal lobe volume, %ICV 27.4 (1.9)
Parietal lobe volume, %ICV 15.8 (1.1)
Occipital lobe volume, %ICV 9.0 (0.7)
Temporal lobe volume, %ICV 15.5 (0.9)
Deep central region*, %ICV 9.7 (0.5)
Grey matter, %ICV 46.6 (4.1)
Normal white matter, %ICV 29.5 (6.3)
Total white matter, %ICV 30.8 (5.7)
White matter lesions, %ICV 1.33 (1.51)
Brain infarcts 28%
Values are percentages or means (standard deviation); MMSE stands for Mini-Mental State Examination, ICV for Intra-cranial volume; * 
The deep central region includes the corpus callosum, insular cortex, basal ganglia, and the white matter surrounding the basal ganglia.
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ated with incident depressive symptoms or depressive syndromes. Additional adjustment 
for cardiovascular risk factors did not change the results.
Discussion
In this population-based cohort study of elderly persons we found that structural markers 
of vascular brain disease were cross-sectionally related to presence of depressive symptoms. 
However, we did not fi nd any association between structural brain markers and incident 
depressive symptoms or depressive syndromes.
Strengths of our study include the population-based setting, and the cross-sectional as 
well as longitudinal design of the study with more than seven years of follow-up. More-
over, contrary to other studies we investigated various markers of vascular brain disease 
using automated quantifi cation techniques. A limitation is that we lacked reliable data on 
depression before baseline. Th erefore, some persons may already have had a depression 
before baseline. However, given that persons with a history of depression have an increased 
risk of recurrent depression, together with the strong cross-sectional association between 
Table 2 Cross-sectional association between brain tissue volumes and prevalent depressive symptoms (n=36), including 
depressive syndromes (n=6)
Brain tissue volumes* Odds-ratio of being CES-D positive (score 
of 16 is taken as cut-off )
Diff erence in CES-D score (using CES-D 
score continuously)
Global brain tissue volumes
Whole brain volume 0.52 (0.31-0.87) -0.71 (-0.15; 0.03)
Grey matter 0.95 (0.67-1.33) -0.02 (-0.58; 0.54)
Normal white matter 0.70 (0.46-1.07) -0.52 (-1.16; 0.13)
Total white matter 0.80 (0.53-1.21) -0.30 (-0.92; 0.32)
Lobar brain tissue volumes†
Frontal lobe 0.68 (0.43-1.07) -0.65 (-1.32; 0.03)
Parietal lobe 0.56 (0.35-0.90) -0.65 (-1.30; -0.01)
Occipital lobe 0.87 (0.60-1.26) -0.09 (-0.66; 0.48)
Temporal lobe 0.65 (0.43-0.98) -0.33 (-0.96; 0.31)
Deep central region 1.08 (0.75-1.53) 0.36 (-0.20; 0.93)
WML volume‡ and brain infarcts
Global WML 1.56 (0.98-2.46) 0.41 (-0.20; 1.02)
Frontal WML 1.68 (1.07-2.62) 0.45 (-0.14; 1.04)
Parietal WML 1.30 (0.85-1.99) 0.11 (-0.47; 0.68)
Occipital WML 1.45 (0.94-2.23) 0.37 (-0.22; 0.95)
Temporal WML 1.36 (0.89-2.08) 0.38 (-0.22; 0.96)
Deep WML 1.83 (1.13-2.96) 0.72 (0.12; 1.32)
Brain infarcts (yes versus no) 2.35 (1.12-4.91) 0.82 (-0.46; 2.09)
WML stands for white matter lesion, CES-D for Center for Epidemiological Studies Depression Scale; * expressed per standard deviation 
increase; † these volumes included grey matter and total white matter together; ‡ all white matter lesion volumes were natural log 
transformed.
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vascular brain disease and depression, longitudinal analyses would overestimate any true 
eff ect. Another limitation is possible selection-bias due to diff erential follow-up. If persons 
with vascular disease compared to those without were more prone to seek medical help, 
estimates from longitudinal analyses could easily overestimate eff ects. Conversely, if these 
persons are less likely to report depressive symptoms, it would lead to an underestimation. 
A fi nal consideration is that we excluded persons who used anti-depressants at baseline. 
However, post hoc analyses including these persons in either the depressed or non-depressed 
group yielded unchanged results.
In our cross-sectional analyses we found brain atrophy, brain infarcts and WML to 
be related to depressive symptoms (including depressive syndromes). Th is fi ts well with 
various previous studies.4,8,9 Furthermore, our results concur with published data showing 
that particularly atrophy in the parietal and frontal lobes, and frontal and deep WML are 
related to depression.4,10,19
In contrast, longitudinally we found no association between MRI-markers and incident 
depression. Although we have to be cautious to interpret these as null associations because 
of the relatively wide confi dence intervals, the HR are pretty close to 1 and do not suggest 
Table 3 Risk of depressive symptoms and syndromes associated with brain tissue volumes
Brain tissue volumes* Hazard ratio (95% CI) for incident 
depressive symptoms (including 
depressive syndromes)
(N=92)
Hazard ratio (95% CI) for incident 
depressive syndromes
(N=35)
Global brain tissue volumes
Whole brain volume 1.06 (0.79-1.42) 0.89 (0.55-1.42)
Grey matter 0.92 (0.75-1.14) 0.97 (0.69-1.37)
Normal white matter 1.10 (0.86-1.41) 0.93 (0.62-1.40)
Total white matter 1.10 (0.87-1.40) 0.98 (0.66-1.44)
Lobar brain tissue volumes†
Frontal lobe 0.89 (0.69-1.16) 0.90 (0.59-1.38)
Parietal lobe 1.05 (0.83-1.34) 0.90 (0.60-1.33)
Occipital lobe 1.08 (0.87-1.34) 1.09 (0.78-1.53)
Temporal lobe 1.15 (0.91-1.45) 0.88 (0.60-1.30)
Deep central region 1.10 (0.89-1.38) 1.00 (0.69-1.46)
WML volume‡ and brain infarcts
Global WML 0.88 (0.71-1.10) 0.83 (0.59-1.18)
Frontal WML 0.87 (0.71-1.08) 0.84 (0.60-1.17)
Parietal WML 0.88 (0.72-1.07) 0.87 (0.64-1.19)
Occipital WML 0.88 (0.71-1.09) 0.87 (0.62-1.22)
Temporal WML 0.92 (0.74-1.14) 0.87 (0.62-1.22)
Deep WML 0.92 (0.74-1.16) 0.89 (0.62-1.27)
Brain infarcts (yes versus no) 0.86 (0.51-1.44) 0.88 (0.36-2.11)
Values are adjusted for age, sex, and education. Persons were censored at onset of depressive syndrome, onset of depressive symptoms, 
date last known to be alive in case of loss to follow-up, or October 1st 2005, whichever came fi rst.
CI stand for confi dence interval, WML for white matter lesion; * expressed per standard deviation increase; † these volumes included 
grey matter and total white matter together; ‡ all white matter lesion volumes were natural log transformed.
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any major eff ect. If anything, most are in the opposite direction of what is expected based 
on the vascular depression hypothesis, namely that larger brain volume is associated with a 
decreased risk of depression (HR below 1), and WML with an increased risk of depression 
(HR above 1).
Several explanations for null associations in our longitudinal analyses need to be consid-
ered. Firstly, our study design implies a time delay between baseline vascular damage and 
onset of depression. However, it is possible that vascular injury directly leads to depressive 
symptoms without any delay. A second explanation might be that the causal pathway 
works the other way around, i.e. depression causes vascular brain disease. Based on only 
limited data on progression of white matter lesions, we did not fi nd any such association in 
the Rotterdam Scan Study (data not shown). However, two studies have reported a larger 
increase in WML in depressed compared with non-depressed persons.9,12 Th ough it is not 
established how depression could lead to vascular brain disease and brain atrophy, pos-
sible mechanisms include platelet dysfunction, hypotensive episodes, unhealthy lifestyle 
Table 4 Risk of depressive symptoms and syndromes associated with brain tissue volumes, based on only survey data.
Brain tissue volumes* Hazard ratio (95% CI) for incident 
depressive symptoms (including 
depressive syndromes)
(N=35)
Hazard ratio (95% CI) for incident 
depressive syndromes
(N=18)
Global brain tissue volumes
Whole brain volume 1.24 (0.76-2.01) 1.30 (0.67-2.53)
Grey matter 0.82 (0.59-1.14) 0.85 (0.53-1.34)
Normal white matter 1.34 (0.59-1.14) 1.29 (0.74-2.25)
Total white matter 1.32 (0.90-1.93) 1.31 (0.77-2.23)
Lobar brain tissue volumes†
Frontal lobe 1.19 (0.77-1.84) 1.35 (0.75-2.45)
Parietal lobe 1.06 (0.70-1.58) 1.05 (0.60-1.83)
Occipital lobe 1.10 (0.79-1.54) 1.07 (0.67-1.70)
Temporal lobe 1.08 (0.72-1.48) 1.04 (0.61-1.80)
Deep central region 1.03 (0.72-1.48) 1.05 (0.63-1.75)
WML volume‡ and brain infarcts
Global WML 0.76 (0.53-1.08) 0.79 (0.48-1.29)
Frontal WML 0.76 (0.55-1.04) 0.78 (0.50-1.22)
Parietal WML 0.82 (0.60-1.13) 0.86 (0.55-1.35)
Occipital WML 0.89 (0.63-1.27) 0.86 (0.53-1.38)
Temporal WML 0.87 (0.61-1.23) 0.92 (0.56-1.52)
Deep WML 0.79 (0.55-1.23) 0.89 (0.53-1.50)
Brain infarcts (yes versus no) 0.75 (0.33-1.73) 0.83 (0.26-2.70)
Values are adjusted for age, sex, and education. Persons were censored at onset of depressive syndrome, onset of depressive symptoms, 
date last known to be alive in case of loss to follow-up, or October 1st 2005, whichever came fi rst.
CI stands for confi dence interval, WML for white matter lesion; * expressed per standard deviation increase; † these volumes included 
grey matter and total white matter together; ‡ all white matter lesion volumes were natural log transformed
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choices, and elevated cortisol levels in the brain, which in turn can cause glucocorticoid-
mediated neurotoxicity.1,5,20 However, it is unclear why depression would cause vascular 
disease only in specifi c areas in the brain, e.g. frontal and deep central WML. Th irdly, it 
is possible that vascular brain injury does not relate to incidence of fi rst depression, but 
to persistent, chronic, relapsing, or recurrent depression. To test these possibilities, future 
studies should seek to discern more clearly fi rst-ever depressions from possible recurrent 
events and accurately establish the duration of the depressive episode. Finally, a common 
etiology, e.g. genetic predisposition, could link depression with vascular brain disease 
cross-sectionally, but not necessarily longitudinally. Indeed, a twin study showed that the 
co-occurrence of cardiovascular disease and depression is partly explained by common 
genetic risk factors.21
In conclusion, we found that MRI-markers of vascular brain disease were strongly 
associated with depression cross-sectionally. However, our study emphasizes that a cross-
sectional association does not necessarily demonstrate causation, as we found no evidence 
for the ‘vascular depression’ hypothesis relating these brain markers to incident depression. 
Still, more longitudinal studies are needed to precisely elucidate this hypothesis. After 
all, even a non-causal relation of vascular disease with depression might point towards 
possibilities for prevention and treatment that thus far have remained unexplored.
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Abstract
Context. Depression after stroke is common. Like stroke, transient ischemic attacks (TIAs) 
are manifestations of long-term atherosclerotic damage to the brain. However, the risk of 
developing a depression after a TIA is unknown.
Objective. To study whether TIAs increase the risk of incident late-life depression.
Design, setting and participants. A cohort study of 5,095 inhabitants of Rotterdam, the 
Netherlands. Participants were aged 56 years or older and free of depression at baseline. 
Follow-up duration was on average 8 years. 
Data assessment methods. TIAs and depressions were identifi ed through regular standard-
ized examinations and continuous monitoring of medical and pharmaceutical records. 
Attacks that presented with focal symptoms only (focal attacks) were distinguished from 
attacks that were accompanied by nonfocal symptoms (mixed attacks), and attacks that 
presented with nonfocal symptoms only (nonfocal attacks). Depressive episodes were 
categorized as (1) DSM-IV defi ned depressive disorders, (2) other depressive syndromes, 
and (3) clinically relevant depressive symptoms.
Main Outcome Measure. We estimated hazard ratios (HR) with time-varying Cox regres-
sion analyses, adjusting for socio-demographic and health related factors, such as incident 
stroke. 
Results. TIAs were signifi cantly associated with the risk of incident depressive disorders and 
other syndromes (HR 1.68; 95% CI 1.12-2.51), and depressive disorders only (HR 2.42; 
95% CI 1.26-4.67). We also found an almost three-fold increased risk of DSM-defi ned 
depressive disorders in persons without a history of depression at baseline (HR 2.91; 95% 
CI 0.96-8.81). In contrast to focal and mixed attacks that comprise TIAs, nonfocal attacks 
were not related to depression. Including depressive symptoms in the case defi nition of 
depression diluted the estimated risk of TIAs. 
Conclusions. TIAs are independently associated with an increased risk of incident depres-
sion. Our fi ndings suggest that symptomatic cerebrovascular disease, in particular when 
located in cortical brain regions, may predispose to late-life depression. 
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Transient ischemic attacks
Introduction
Stroke is a common major vascular event in late-life. It often results in permanent damage 
to the brain and reduced functional status. Up to 50% of patients develop depression in 
the fi rst month after a stroke (1, 2), and the risk of depression remains high in the follow-
ing year (3). Depression after stroke not only decreases the quality of life for the patient 
but can substantially contribute to the burden of disease for primary care givers (4). Like 
stroke, transient ischemic attacks (TIAs) are common clinical manifestations of long-term 
atherosclerotic damage to the brain, but, per defi nition, TIAs do not give rise to permanent 
functional disabilities. Rather, TIAs are characterized by sudden neurological symptoms 
that completely resolve within 24 hours (5). Th e possible risk of depression after a TIA has 
received far less attention than the risk conveyed by stroke. To our knowledge, investiga-
tions of TIAs and depression are limited to cross-sectional studies. In a clinical study, the 
prevalence of major depressive disorder in patients with carotid stenosis and TIA (40%) 
was signifi cantly higher than in the control group (0%) (6). Th is fi nding was confi rmed in 
a small population-based study (7). Although studies using a cross-sectional design cannot 
rule out that the observed depressions occurred prior to the cerebrovascular attack (8-10), 
longitudinal studies based on accurate assessments of the onset of depression are lacking.
Th e vascular depression hypothesis posits that cerebrovascular disease may predispose, 
precipitate or perpetuate late-life depression (11, 12). Atherosclerotic lesions to brain 
circuits responsible for aff ective regulation are assumed to form the central pathology 
(13). Th e hypothesis was formulated when multiple imaging studies showed that lesions 
in gray matter, frontal deep white matter, and basal ganglia, as well as atrophy were more 
prevalent in depressed patients than in controls (14). An association between TIAs and 
incident depression would support the vascular depression hypothesis. 
In the traditional defi nition, TIAs present with focal neurological symptoms (5), but 
transient neurological attacks that are characterized by focal and nonfocal symptoms 
are often diagnosed by neurologists and general practitioners as a TIA as well (15, 16). 
Recently, it has been proposed to defi ne a more encompassing classifi cation of transient 
neurological attacks that distinguishes between transient neurological attacks with focal 
symptoms, nonfocal symptoms, or a mix of both for scientifi c and clinical purposes. Non-
focal attacks have been associated with stroke and dementia (15), like TIAs (17) , although 
earlier studies indicated a more benign prognosis (18-23). Moreover, in contrast to TIAs 
(24), nonfocal attacks have not been associated with myocardial infarction or mortality 
(15). Mixed attacks seem to have the poorest prognosis in terms of vascular morbidity and 
mortality (15). Th e prognostic diff erences between the attacks may originate from varia-
tion in pathogenesis or localization. Distinguishing between TIAs and nonfocal attacks 
might provide further insight into the etiology of late-life depression. 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Chapter 9 
108
Th e aim of the present study was to assess whether TIAs like stroke are associated 
with an increased risk of developing depression. In addition, we assessed the association 
between attacks with focal symptoms, nonfocal symptoms or a mix of both and incident 
depression. Th e study was performed in a large cohort of community-dwelling elderly 
persons free of depression at baseline. During the follow-up period, which was 8 years 
on average, participants were continuously monitored for the occurrence of TIAs and 
incident depression.
Methods
Setting 
Th is study was embedded in the Rotterdam Study, a prospective study that started in 1989 
among 7,983 inhabitants of Ommoord, a district of Rotterdam (25). Participants were 55 
years of age or older. Th e study focuses on the occurrence and determinants of chronic 
diseases in the elderly. Th e Medical Ethics Committee of Erasmus Medical Center Rotter-
dam approved the study and written informed consent was obtained from all participants. 
Until 2004 four examination rounds took place, during which participants underwent 
an extensive interview and a physical examination. In addition, continuous monitoring 
for major events, such as TIA and depression, took place from baseline onwards through 
automated linkage with the medical fi les from the general practitioners. Information on 
vital status was obtained bimonthly from the municipal authorities in Rotterdam. 
Study population
Th e study population for analysis consisted of persons at risk of incident depression and 
was selected as follows. During the second examination round, the baseline of the current 
analysis, 5769 participants were screened for depressive symptoms. Participants fi lled out 
either the validated Dutch version of the Center for Epidemiologic Studies Depression 
Scale (CES-D) or the validated Dutch version of the Hospital Anxiety and Depression 
Scale (HADS) (26, 27). Persons with a score of 16 or higher on the CES-D or 9 or higher 
on the HADS were considered screen-positive. At baseline, we excluded 549 persons 
with depressive symptoms, 105 persons with dementia, 9 persons with bipolar disorder, 
2 persons lost to follow-up directly after screening, and 9 persons with unknown stroke 
status. Th is resulted in a study population of 5095 persons free of depression at baseline. 
Assessment of incident depression
Assessment of depression has been described in detail before (28). Information on the 
occurrence of incident depressions during follow-up was obtained from (1) psychiatric 
examinations, (2) self-reported histories of depression, and (3) medical records. Th e psy-
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chiatric examination during examination rounds consisted of a screening with the CES-D. 
Subsequently, a trained clinician conducted a semi-structured interview (Schedules for 
Clinical Assessment in Neuropsychiatry) in the screen-positive participants to obtain 
DSM-IV defi ned diagnoses (29),(30). Th e self-reported history of depression, solicited 
during examination rounds, included standardized questions to ascertain whether and 
when participants had suff ered from a depressive episode, and if so whether they had 
been treated. Trained research-assistants scrutinized the general practitioners’ medical 
records and copied the information about a potential depression. Two research physicians 
independently assessed this information according to a predefi ned protocol, and discussed 
discordant assessments.
Based on these sources, we categorized depressive episodes as either:
(1) depressive disorders, that is DSM-IV-defi ned major depressive disorder or dysthymia 
as diagnosed by a psychiatrist or another mental health professional; 
(2) ‘other depressive syndromes’, that is a depression recorded by a general practitioner, 
self-reported depression for which the participant consulted a health professional, or 
DSM-IV-defi ned minor depression; or,
(3) ‘clinically relevant depressive symptoms’, if at least one clinically relevant core symp-
tom of major depression had been reported. 
We defi ned the date-of-onset as the day of the fi rst report of symptoms according to 
one of the sources described above, or the fi rst prescription date of an antidepressant drug, 
whichever came fi rst. 
Assessment of TIAs and stroke
Assessment procedures for TIAs and stroke have been described elsewhere in detail (15). 
Prevalent and incident TIAs were ascertained by a research physician who screened all 
participants by asking for transient neurological symptoms during examination rounds. 
In addition, research physicians reviewed the information from the medical fi les, and if 
available brain imaging results from hospital records. An experienced neurologist verifi ed 
all diagnoses. Follow-up for all events was completed until October 1, 2005, for 96 % of 
potential person-years.
To ascertain a TIA, focal symptoms had to have set in suddenly and to have cleared up 
within seconds to a maximum of 24 hours. Attacks that presented with focal symptoms 
only were classifi ed as ‘focal attacks’, attacks accompanied by focal and nonfocal symptoms 
were classifi ed as ‘mixed attacks’, and attacks with nonfocal neurological symptoms only 
as ‘nonfocal attacks’ (15). A stroke was diagnosed if a patient had typical symptoms that 
lasted longer than 24 hours (31). 
Focal brain symptoms included hemiparesis, hemihypesthesia, dysphasia, dysarthria, 
amaurosis fugax, hemianopia, hemiataxia, diplopia, or vertigo. Th e nonfocal brain 
symptoms included decreased consciousness, unconsciousness, confusion, amnesia, un-
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steadiness, nonrotatory dizziness, positive visual phenomena, cardiac or vegetative signs, 
paresthesias, bilateral weakness, or unwell feelings. Th e date-of-onset of an incident attack 
was determined with the information from the sources described above. History of TIA at 
baseline was positive if a TIA had occurred before baseline interview. Participants that had 
a history of stroke at baseline or an incident stroke after baseline could not be identifi ed 
with a TIA anymore.
Covariables
Th e following baseline covariates were considered potential confounders: age, sex, socio-
economic status, disability in activities of daily living, history of depression, smoking, 
and hypertension. In addition, diabetes mellitus, history of cardiovascular disease, atrial 
fi brillation, and current use of antihypertensive medication were included as time-varying 
covariables. 
Socio-economic status was determined in terms of the combination of highest educa-
tion attained and net income (32). Disability in activities of daily living was assessed with 
the Modifi ed Stanford Health Assessment Questionnaire (33). Self-reported smoking use 
was categorized into none, former, and current. Th e average of the two blood pressure 
measurements in sitting position was used for our analysis. Th e criteria for diabetes mel-
litus were: fasting plasma glucose level of 7.0 mmol/l or over, non-fasting glucose or an 
oral glucose tolerance test result of 11.1 mmol/L or over, or treatment with an antidiabetic 
medication or diet (34). History of cardiovascular disease encompassed angina pectoris 
and claudicatio intermittens, both established with the Rose questionnaire, as well as a 
history of myocardial infarction, coronary artery bypass graft, percutaneous transluminal 
coronary angioplasty and peripheral artery bypass graft, as verifi ed in the medical fi les 
(35). Information on the use of antihypertensive medication was obtained from the 
online pharmaceutical database described above. We included diuretics, beta-blockers, 
angiotensin-converting enzyme inhibitors, and a miscellaneous group including reserpine, 
methyldopa and clonidine. We distinguished between non-use and current use on the day 
an event occurred. 
Statistical analysis
To study the eff ect of TIAs on the risk of incident depression, we estimated hazard ratios 
with Cox proportional hazards analyses. We performed the analyses with three increasingly 
stringently defi ned outcomes: time to depressive syndromes and symptoms (categories 1, 
2 and 3), depressive syndromes (categories 1 and 2), and depressive disorders (category 
1). Th e exposure of having had a TIA or stroke compared to no cerebrovascular event was 
entered in the model as a time-varying variable. For each outcome defi ned above, we fi tted 
a model that included the exposure and the confounders described above. We thus obtain 
risk estimates that refl ect the direct eff ects of TIAs on the risk of depression, not through 
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stroke. Additionally, in order to further ascertain the chronological relationship between 
TIAs and depression, we repeated the models in persons without a history of depression 
at baseline. 
Finally, we fi tted a model in which each fi rst occurrence of a focal, mixed or nonfocal 
attack was entered as a time-varying exposure variable, again adjusted for intermediate 
stroke and all confounders.
In all analyses, each participant contributed person-years from baseline date until 
follow-up ended when a depression occurred, dementia, death, loss-to-follow, or the end 
of study period on October 1, 2005. Two-sided p-values of <0.05 were considered statisti-
cally signifi cant. For all statistical analyses we used SPSS for Windows, version 13.0.
Results
Table 1 presents the baseline characteristics of the study population. Th e average age was 
70 years with a range of 56 to 101 years and 58 % of the participants were female. Th e 
most prevalent cardiovascular risk factor was history of smoking with 51% former smok-
ers and 17 % current smokers. At baseline, 1641 participants had a history of depression. 
One or more TIAs were diagnosed in 86 participants before baseline, and in 239 persons 
during follow-up. 
Table 1 Baseline characteristics of study population (n=5095)
Descriptives
Age, mean (SD) 70.0 (8.3)
Female sex, n (%) 2939 (57.7)
Education, primary school only, n (%) 934 (18.3)
Income, median (range) 2690 (750-7000)
Disability, mean (range) 1.3 (1.0-4.0)
History of depression, n (%) 1641 (32.2)
Smoking, 
- former smoker, n (%)
- current smoker, n (%)
2598 (51.0)
868 (17.0)
Diastolic blood pressure, mean (range) 77 (40-128)
Systolic blood pressure, mean (range) 141 (70-242)
Body mass index, mean (range) 26.5 (14.7-48.0)
Total cholesterol, mean (range) 6.6 (2.2-18.0)
HDL cholesterol, mean (range) 1.4 (0.4-6.3)
Diabetes, n (%) 537 (10.5)
History of cardiovascular disease, n (%) 1006 (19.7)
Chronic heart failure, n (%) 206 (4.0)
Use of antihypertensives, n (%) 1558 (30.6)
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In our study population, a total of 736 incident depressions occurred during 42,090 
person-years. Of these episodes, 407 were depressive syndromes including 103 DSM-
defi ned depressive disorders. Th e mean time between the (fi rst) TIA and a depressive 
syndrome was 3.3 years (SD 2.9), counting cases of TIA present at baseline from that time 
onward. For incident TIAs only, the mean time to a depressive syndrome was 3.1 years 
(SD 2.6). Th e mean time based on the last (incident) TIA was only a few months short 
of the mean time based on fi rst (incident) TIA. Figure 1 shows the Kaplan-Meier survival 
curves for depressive syndromes in persons with and without a TIA. After 12 years of 
follow-up, twice as many participants with a TIA had developed a depressive syndrome.
Table 2 shows the risk of incident depression associated with TIAs and stroke. TIAs were 
more strongly associated with depression the more stringently depression was defi ned: the 
risk of depressive symptoms and syndromes combined was 1.30 (95% CI 0.94-1.80), the 
risk of depressive syndromes 1.68 (95% CI 1.12-2.51), and the risk of depressive disorders 
2.42 (95% CI 1.26-4.67). Like TIAs, stroke was also related to depressive syndromes (HR 
1.52; 95% CI 1.01-2.27) and to depressive disorders (HR 3.35; 95% CI 1.82-6.18). Th e 
hazard ratios showed the same pattern in the subsample of persons without a history of 
depression at baseline. In fact, the risk of depressive disorders after TIA was as high as 2.91 
(95% CI 0.96-8.81). 
Additionally, we assessed the risk of incident depression related to focal, mixed and 
nonfocal attacks. Table 3 shows the results. Focal attacks did not increase the risk of 
depressive symptoms and syndromes combined (HR 1.22; 95% CI 0.86-1.74), but sig-
nifi cantly increased the risk of depressive syndromes (HR 1.55; 95% CI 1.00-2.39), and 
Figure 1 Cumulative survival for incident depressive syndromes by TIA status
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depressive disorders (HR 2.17; 95% CI 1.05-4.46). Mixed attacks in particular conveyed 
an increased risk of depressive symptoms and syndromes combined (HR 2.25; 95% CI 
1.11-4.55), and depressive syndromes (HR 3.14; 95% CI 1.39-7.12). Th e risk estimate of 
mixed attacks for depressive disorders was not statistically signifi cant (HR 2.88; 95% CI 
0.68-12.3), probably as a result of the small number of cases. In contrast, nonfocal attacks 
were not associated with depression.
Discussion
In this population-based cohort, TIAs were associated with an increased risk of incident 
depression. Nonfocal attacks did not increase the risk of incident depression. Th e risk of 
TIAs for depression was similar to that of stroke. Although TIAs, like stroke, are clinical 
indicators of long-term atherosclerotic damage to the brain and occur frequently, the risk of 
TIAs for depression has, to the best of our knowledge, not been studied prospectively before.
 Table 2 TNAs and the risk of incident depression using Cox’ proportional hazard models*
Type of attack Depressive syndromes and 
symptoms (n=736)
N      HR (95%CI)      p-value
Depressive syndromes only
(n=407)  
N      HR (95%CI)      p-value
Depressive disorders only
(n=103)
N      HR (95%CI)      p-value
Complete study population (n=5095)
Focal attacks|| (263)    34     1.22 (0.86-1.74)     .27     23     1.55 (1.00-2.39)     .05    9     2.17 (1.05-4.46)     .04
Nonfocal attacks (226)    23     1.00 (0.66-1.53)     .98     10     0.79 (0.42-1.49)     .47    2     0.50 (0.12-2.07)     .34
Mixed attacks (42)      8     2.25 (1.11-4.55)     .02       6     3.14 (1.39-7.12)     .01    2     2.88 (0.68-12.29)   .15
Any attack (458) †    59     1.18 (0.90-1.55)     .24     33     1.22 (0.85-1.77)     .28  12     1.53 (0.81-2.89)     .19
Persons without history of depression (n=3454)
Focal attacks (170)   16      1.38 (0.83-2.30)     .22    11     1.88 (1.01-3.50)     .05    3     2.42 (0.70-8.39)     .16
Nonfocal attacks (156)   14      1.29 (0.75-2.23)     .36      6     1.06 (0.46-2.43)     .89    2     1.58 (0.37-6.81)     .54
Mixed attacks (26)     3      2.11 (0.67-6.65)     .20      3     3.70 (1.16-11.77)   .03    1     6.88 (0.90-52.70)   .06
Any attack (319) ‡   29      1.35 (0.91-1.99)     .14    16     1.45 (0.85-2.45)     .17    5     2.29 (0.84-6.22)     .11
* adjusted for age, sex, SES, ADL, history of depression, smoking, diastolic and systolic blood pressure, diabetes, history of 
cardiovascular disease , chronic heart failure, and use of anti-hypertensives, and censored for stroke; † otherwise known as TIA; ‡ 
numbers of individual types of TNAs do not add up to number of all TNAs due to persons with more than one type of TNA
Table 3 Type of attack and the risk of incident depression using Cox’ proportional hazard models (n=5,095)*
Depressive syndromes and 
symptoms (n=736)
HR (95%CI)      p-value
Depressive syndromes only
(n=407)  
HR (95%CI)      p-value
Depressive disorders only
(n=103)
HR (95%CI)      p-value
Focal attacks (n= 263) † 1.22 (0.86-1.74)     .27 1.55 (1.00-2.39)     .05 2.17 (1.05-4.46)     .04
Mixed attacks (n= 42) ‡ 2.25 (1.11-4.55)     .02 3.14 (1.39-7.12)     .01 2.88 (0.68-12.3)     .15
Nonfocal attacks (n= 226) § 1.00 (0.66-1.53)     .98 0.79 (0.42-1.49)     .47 0.50 (0.12-2.07)     .34
* adjusted for age, sex, SES, ADL, history of depression, smoking, hypertension, diabetes, history of cardiovascular disease, chronic heart 
failure, use of anti-hypertensives, and stroke; † focal attacks are transient neurological attacks that present with focal symptoms only, ‡ 
mixed attacks present with focal and nonfocal symptoms, and § nonfocal attacks with nonfocal symptoms only.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Chapter 9 
114
Prospective studies of vascular depression have mostly investigated the association 
between cerebrovascular risk factors and depression, such as smoking, blood pressure, 
diabetes, dyslipidemia, history of cardiovascular disease, or the use of antihypertensives. 
However, none of the risk factors were found to consistently predict depression (36, 37). 
Similarly, composite scores of these risk factors were related to incident depression in 
some studies but not in others (36-40). Results from prospective imaging studies that 
investigated a link between severity of white matter lesions with new-onset depression 
are more consistent, with most fi nding no relationship (41-44). In the study that yielded 
a positive association, prevalent and incident dementia had not been taken into account 
(45). No relationship between progression of white matter lesions and incident depressive 
symptoms has been found either (44). 
Th e association between stroke and subsequent depression has been studied extensively 
(3, 4, 46, 47). Between 10 and 50% of patients develop depression in the fi rst month 
after a stroke, and one-year post-stroke the risk is still higher than 30% (1-3). It remains 
unclear, however, what the direct contribution of the brain lesion is and what the contri-
bution of reduced functional status is to the increased risk of depression. To add to the 
complexity, depression secondary to stroke has been associated with diff erent locations 
and with decreased catecholamine activity in the injured and uninjured brain structures 
(2, 4, 48). 
In our study, we were able to test the vascular depression hypothesis in patients with 
clear clinical manifestations of ischemic brain damage without concomitant permanent 
loss of neurological function. We showed that the risk of depression after TIA is similar to 
that after stroke in a population-based cohort. In a clinical study, the prevalence of major 
depressive disorder in patients with carotid stenosis and TIA was similar to that of patients 
with stroke (6). It is also known that depression can occur long after the index stroke 
(47), like depression after TIA in our study. Cerebrovascular accidents, irrespective of the 
duration of initial symptoms and loss of function, predict new-onset depression over an 
extended period of time. Th us, TIAs, like stroke, require immediate and extensive tests 
to detect underlying pathology, but similarly, also careful long-term follow-up to monitor 
and prevent the onset of depression. 
Th e association of TIAs but not nonfocal attacks with depression strongly suggests a 
role for focal cortical brain damage. However, stroke location has not been associated with 
depression consistently (2, 4, 48), and imaging studies have found that damage to grey 
matter, white matter, and basal ganglia were all associated with depression (14). Moreover, 
transient global amnesia, qualifi ed as a nonfocal attack in our study, was associated with 
a personal or family history of psychiatric diseases in another study  (22). It is possible, 
that the heterogeneity of the group of nonfocal attacks in our study explains the apparent 
contrast with TIAs. For instance, syncope, which made up 25% of the nonfocal attacks in 
our study (15), tends to have multiple causes in elderly patients (49). 
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We found that TIAs are associated with incident depression, like stroke. Th is suggests 
that not the functional impairment but rather the atherosclerotic process underlies the 
depression. Yet, MRI-visualized subclinical cerebrovascular disease has not been associated 
with depression consistently (41-45). Moreover, we cannot rule out that the clinical event 
provokes depression. TIAs usually occur out of the blue and may forebode potentially 
life-threatening stroke. Th is may provoke a reactive depression (4), possibly in already 
vulnerable persons (50), although in the present study most depressions occurred several 
years after the event.
Strengths and limitations
Our study was based on a large population-based cohort and long follow-up period. Data 
were gathered prospectively and without prior knowledge of the research hypothesis. 
Participants were monitored continuously for incident depression and interviews were 
conducted by clinicians who used DSM-IV criteria to diagnose depressions. In addi-
tion, detailed information on the occurrence of TIAs was also collected with systematic 
repeated interviews and continuous monitoring of medical fi les. However, some TIAs 
may have been missed or misclassifi ed, because the diagnoses were primarily derived from 
medical records. Th ere is often disagreement, even between neurologists, about whether a 
given patient has had a TIA (51). In order to minimize misclassifi cation in our study, each 
potential TIA was classifi ed according to a stringent protocol by multiple raters.   
To rule out that depression was already present when a TIA occurred, the dates-of-onset 
of the depressions needed to be precise. We used all available information from interviews, 
prescriptions, and medical records. Moreover, the mean time-lag between the occurrence 
of a TIA and the onset of depression was more than three years. Another advantage of the 
available information on dates-of-onset was that we could perform time-varying analyses, 
including TIAs that had occurred after baseline.
Finally, we minimized potential confounding by adjusting for a considerable number of 
socio-demographic and health related confounders. Some residual confounding may have 
occurred because we did not have baseline data on carotid stenosis (52).
Conclusion
TIAs increase the risk of incident depression in the elderly. Th e high risk for post-TIA 
depression, a frequently debilitating disease, justifi es greater attention for this long-term 
psychiatric outcome in daily medical practice of patients presenting with TIA. Research 
is needed to clarify the eff ect of TIAs on the disease course and treatment response in 
depressed patients. 
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Exploring the results
Th e aim of this thesis was to examine the association of cardiovascular and cerebrovascular 
disease with incident late-life depression in a population-based setting. Previous studies 
have often been performed in clinical populations, such as in patients with cardiac disease 
or primary care patients (1-5), which reduces the external validity of the results. Th e fi nd-
ings of our studies apply to the heterogeneous population of community-dwelling elderly 
persons. Moreover, most previous studies had cross-sectional designs. Th e prospective 
nature of our studies enabled us to examine the longitudinal association of cardiovascular 
and cerebrovascular disease with depression. Whether heart failure, atrial fi brillation, or 
transient neurological attacks relate to incident depression had not been studied before.
Th e studies for this thesis were embedded in the Rotterdam Study, a large ongoing 
cohort study (6). Since 1989, 7,983 inhabitants of Ommoord, a district of Rotterdam, 
have participated in it. Every four years they underwent an extensive home interview 
and a physical examination. Detailed information on the occurrence of cardiac disease, 
cerebrovascular risk factors and depression was collected continuously from the medical 
records. Furthermore, all drugs dispensed to the participants by pharmacies in the Om-
moord region were prospectively registered. In addition, a sample of 563 participants 
of the Rotterdam Study underwent brain MRI-scanning in 1995-1996 as part of the 
Rotterdam Scan Study (7).
In order to study risk factors of incident late-life depression, we needed to identify 
incident depressive episodes that occurred in the study population during follow-up. 
Depressive episodes were categorized as mutually exclusive DSM-IV defi ned depressive 
disorders, other depressive syndromes, and clinically relevant depressive symptoms. Due 
to the high incidence of episodes with clinically relevant depressive symptoms and to 
recurrence of depressive syndromes in elderly with a history of depression, the incidence 
of depression was high in our elderly study population. 
Vascular heart disease and late-life depression  
Cross-sectional studies have shown an association of heart failure and atrial fi brillation 
with depression (4, 5). Although depression has been established as a risk factor for inci-
dent cardiovascular disease (8-10), it is also possible that the cross-sectional associations 
can (in part) be explained by heart failure and atrial fi brillation as risk factors for incident 
depression. Heart failure gives rise to reduced cardiac output that can lead to insuffi  cient 
cerebral perfusion. Disturbances of heart rate and heart-rate variability can interrupt 
healthy brain function (11). Another explanation for the cross-sectional association be-
tween these cardiac disease and depression, can be that patients often use beta-blockers. 
Th ese drugs are often used in heart failure and atrial fi brillation and physicians have been 
concerned about a depressogenic eff ect ever since the introduction on the market in late 
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60s. However, the potential bias introduced by the use of cardiovascular medication has 
received little attention (12-14). 
We found that heart failure was associated with an increased risk of incident depressive 
syndromes. In participants with heart failure, the use of loop-diuretics in persons was 
associated with a decreased risk of depressive syndromes. Atrial fi brillation, on the other 
hand, did not convey an increased risk of either depressive symptoms or syndromes. To 
our knowledge, no studies have been published before that investigated the longitudinal 
relationship of these heart diseases with incident late-life depression.
We found that beta-blockers in general did not increase the risk of depressive symptoms 
or syndromes. However, lipophilic beta-blockers with serotonergic affi  nity, in our study 
mostly propranolol, were associated with depressive symptoms in the fi rst three months of 
use. Our fi ndings confi rm previous results for propranolol from case reports and observa-
tional studies (15-17). Th ere are however also two cohort studies and two meta-analyses 
of trials have yielded null fi ndings for lipophilic beta-blockers (16, 18-20). However, 
lack of systematic and timely assessment of depression, sometimes resulting in very small 
numbers of cases, may well have contributed to insuffi  cient power of these studies (21). 
Propranolol is hardly ever prescribed for cardiovascular disease, but primarily for anxiety, 
migraine, alcoholism, and thyroid disease.
Th e results of our studies suggest that loss of daily functioning is an important interme-
diate factor in the relation between cardiovascular disease and incident depression. Heart 
failure is related to loss of daily functioning, whereas uncomplicated atrial fi brillation 
is not. Moreover, we found that use of loop-diuretics in persons with heart failure was 
associated with a decreased risk of depression. Loop-diuretics can provide quick relief of 
the debilitating symptoms of heart failure, such as breathlessness. Other chronic disease 
with low quality of life such as rheumatoid arthritis and chronic obstructive pulmonary 
disease bear a high risk of depression as well (22). Another non-biological explanation of 
our fi ndings could be that experiencing the symptoms of a (life) threatening disease, such 
as heart failure, may provoke a psychological reaction, and when coping mechanisms fail, 
a patient may become depressed. In contrast, atrial fi brillation has a far better prognosis 
than heart failure and thus it will not provoke such a psychological reaction easily. 
Vascular brain disease and late-life depression
An abundance of cross-sectional studies has shown an association between cerebrovascular 
disease and depression (23, 24). Th ese fi ndings have been confi rmed in the Rotterdam 
Study (25, 26). High rates of depression in cerebrovascular disease might be explained by 
an increased risk of cerebrovascular disease in individuals with depression, by an increased 
risk of depression in individuals with cerebrovascular disease, or by both. Indeed, depres-
sive symptoms have been linked to development of atherosclerosis, incident coronary heart 
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disease, incident stroke and total mortality in apparently healthy elderly persons (27-30). 
Th e question remains whether cerebrovascular disease is a risk factor for depression.
In 1997, the vascular depression hypothesis was originally formulated as: “cerebrovas-
cular disease can predispose, precipitate, or perpetuate a depressive syndrome in older 
adults” (31). Th e authors further argued that “direct testing of the vascular depression 
hypothesis is not possible since the mechanisms of depression are unknown”. In other 
words, cerebrovascular disease was suggested to catalyze other depressogenic mechanisms. 
Indeed, it has been shown that stressful life events carry a greater risk of depression in the 
presence of vascular risk factors (32), and that MRI-visualized brain lesions are associated 
with persistence and worsening of depressive symptoms over one year (33), but more 
population-based studies on these topics are still lacking. Th e majority of prospective 
studies published to date, like the studies presented in this thesis, assessed whether cere-
brovascular disease increased the risk of incident depression in the elderly. Th e implicit 
hypothesis is that atherosclerotic brain disease has a distinct etiological role in late-life 
depression (34). A variety of risk factors has been investigated, ranging from individual 
cerebrovascular risk factors, composite scores of these risk factors, extra cerebrovascular 
damage, MRI visualized brain damage to clinical cerebrovascular disease. Th e results of 
the studies in this thesis and other population-based studies are discussed below.
In our study about cerebrovascular risk factors, smoking and the use of antihypertensive 
drugs were the only individual risk factors related to incident depressive symptoms, and 
diabetes the only one associated with incident depressive syndromes. All other individual 
risk factors, i.e. cholesterol, diastolic and systolic blood pressure, a history of cardiovascu-
lar disease, atrial fi brillation, left ventricular hypertrophy, or the use of statins and anti-
coagulants were not related to either incident depressive symptoms or syndromes. Apart 
from an ischemic eff ect on cerebral small vessels, smoking, diabetes and anti-hypertensive 
drugs have also been hypothesized to cause abnormalities in neurotransmitter metabolism. 
Moreover, the association between diabetes and depressive disorders may be explained by 
obesity, a risk factor for diabetes and depression (35), for which we did not adjust.  Other 
population-based studies about cerebrovascular risk factors have yielded similar results 
(32, 36-44). Th e only exceptions were that serum total cholesterol, HDL cholesterol, 
diabetes and history of heart disease were found to be associated with incident depression 
after two years of follow-up (36, 38). However, the eff ects of these risk factors were esti-
mate in models that were unadjusted for other risk factors, such as smoking and obesity.
With respect to composite score of vascular risk factors, we found that the Framingham 
stroke risk score predicted depressive disorders, but not depressive symptoms. As the 
Framingham stroke risk score was developed to identify persons at substantially increased 
stroke risk resulting from their vascular risk profi le (45), this fi nding seems to support the 
‘vascular depression’ hypothesis. However, the score includes diabetes and heart failure 
that may be associated with incident depressive disorders not just through cerebrovascular 
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mechanisms such as stroke, as mentioned before. Other population-based studies found 
no relationship with cumulative scores for vascular burden (32, 46).
Two studies assessed the risk that extra cerebral damage on the risk of incident depres-
sion. We found that diminished retinal microcirculation, whether indicated by smaller 
arteriolar or larger venular calibers, was not associated with incident depressive symptoms 
or syndromes. Aterosclerosis in terms of carotid plaques, aortic calcifi cations, peripheral 
arterial disease, intima-media thickness of the right and left common carotid artery, a 
composite measure of these four measures, and fi nally coronary calcifi cation were also not 
predictive of incident depressive symptoms or incident depressive syndromes (47).
White matter lesions have always been at the heart of the vascular depression hypothesis 
(34, 48, 49). In our MR-imaging study, however, there was no association between base-
line volume of white matter lesions and incident depressive symptoms or syndromes (50). 
Moreover, similar results were yielded by a study in an American general population (33). 
In a French general population, on the hand, higher baseline volume of white matter lesions 
was related to a higher the risk of developing depressive symptoms during a follow-up of 
four years (51). An important diff erence with the two other before mentioned studies was, 
however, that prevalent and incident dementia had not been taken into account. No re-
lationship between progression of white matter lesions and incident depressive symptoms 
has been found either (52). Another remarkable fi nding of our imaging study was that 
brain infarcts were not associated with incident depressive symptoms or syndromes (50). 
Around 85% of these infarct consisted of so-called silent, or unrecognized, strokes (53). 
Other structural brain changes, such as cortical atrophy, and hippocampal and amygdalar 
volumes have not been related to incident depressive symptoms or syndromes in the Rot-
terdam Scan Study either (50, 54). 
Stroke and transient neurological attacks represent clearly recognizable clinical 
manifestations of long-term atherosclerotic damage to the brain. In our study of transient 
neurological attacks, we found that focal attacks and mixed attacks were associated with an 
increased risk of incident depressive syndromes and disorders. Nonfocal attacks were not 
related to depression. A meta-analysis showed that one third of stroke patients developed 
depression in the year following the stroke (55).  In a clinical study, patients with transient 
ischemic attacks had signifi cantly less severe depressive symptoms than stroke patients 
measured one year after the attack (56).
Overall, the studies in this thesis and those from other population-based settings show 
that individual cerebrovascular risk factors, composite scores of these risk factors, extra 
cerebral aterosclerosis, changes in retinal microcirculation, and MRI visualized brain dam-
age are not related to incident depression. Only clinical cerebrovascular diseases, such as 
strokes and transient neurological attacks, seem to be associated with incident depression 
(24, 55). Th is is more compatible with a psychological than with a biological role of 
cerebrovascular disease in the etiology of incident late-life depression. Stroke and tran-
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sient cerebrovascular attacks usually occur out of the blue and may forebode potentially 
life-threatening re-occurrences. Patients might experience them as a sword of Damocles 
hovering over their head. Alternatively, functional consequences of cerebrovascular disease 
may be the causal pathway by which vascular brain lesions are associated with depressive 
symptomatology. In a meta-analysis, besides stroke severity, physical disability and cogni-
tive impairment were risk factors for post-stroke depression (55).  
Where do all these results leave us? Th e lack of an association of unsymptomatic 
cerebrovascular disease and risk factors with the occurrence of new depression suggests 
that vascular changes observed at the time of the initial assessment have exerted their 
eff ect on mood by that time (33). Clearly, longitudinal studies are needed to examine the 
relationship between incident vascular disease and depression so that the time course can 
be examined more precisely. In addition, the observation that individuals with unsymp-
tomatic cerebrovascular disease who were not depressed at baseline did not tend to become 
depressed during follow-up raises the question whether they may have protective factors 
(biological, psychological, or social) that insulate them from depression. Future studies 
should address this possibility. 
Methodological issues
Causal inference of results from observational studies requires reliable and valid results. 
Reliability, or repeatability, requires suffi  cient power, and validity requires lack of bias. Be-
low, I will discuss how we tried to optimize reliability and validity of the studies presented 
in this thesis. 
Reliability
A study’s reliability depends primarily on its power, given that in an epidemiological study 
the possibility of a false-positive fi nding is usually a priori set to 5% given a priori formu-
lated hypotheses. Power of an epidemiological study depends on the size of the eff ect that 
is examined, the number of cases in the exposed and unexposed group, and the precision 
with which the outcome is measured. Sample size was already determined at the off set of 
the studies in this thesis. Th e validity (sensitivity and specifi city) and reliability of the tests 
that were used to establish the cases, is discussed below. 
Identifying incident episodes of depression has been a particular challenge. Unlike for 
instance schizophrenia or dementia, depression is a remitting and often recurring disease. 
In other words, it is not a disease that once it has occurred will not go away and can 
be identifi ed even long after it has occurred. Most prospective studies that have been 
published previously were based on sequential examinations rounds. An example of this 
design is our study on cerebrovascular risk factors. At baseline and during the follow-up 
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rounds, participants were screened by trained interviewers with the CES-D, which has 
been validated in elderly populations, and has a sensitivity of 100% and specifi city of 
88% using a cut-off  of 16 (57). Subsequently, experienced and carefully trained clini-
cians interviewed screen-positive participants with the Present State Examination (58). 
However, when depressive episodes are identifi ed during sequential examination rounds 
only, episodes that have developed and remitted in the interval between rounds may be 
missed. Th is will occur especially if the periods between rounds are long, relative to the 
median duration of episodes. 
In order to enhance the number of incident depressions identifi ed, information was 
collected with additional assessment methods. Th e self-reported history of depression, 
solicited during the visits, included standardized questions to ascertain whether and when 
participants had had a depressive episode, and if they had been treated. However, episodes 
will still be missed, because people tend to forget or undervalue past depressive episodes, 
particularly if they occurred more than 5 years ago (59). Even episodes of depression for 
which they received inpatients are sometimes forgotten. Th e longer the periods between 
assessments are relative to people’s memory, the more episodes will remain undetected. 
We also used continuous monitoring of medical records to identify depressions. Trained 
research-assistants scrutinized the medical records of the general practitioners (GPs) and 
copied the information about a potential depression using a list of predefi ned cue words. 
Two research physicians independently assessed this information according to a predefi ned 
protocol, and discussed discordant assessments. Continuous surveillance of medical re-
cords is seldom used in psychiatric epidemiology. Underdetection of psychiatric diseases in 
daily medical practice, record keeping by physicians and retrieving the information from 
those records may all be imperfect. General practitioners diagnose between 30 to 60% 
of depression, with lower recognition for milder cases (60-62). However, when a general 
practitioner diagnoses a depression, this most probably refl ects actual depressions (63). 
Moreover, the reports from mental health professionals to the GPs were often elaborate, 
and substantiated the DSM-classifi ed diagnoses.
Th e last source of information consisted of the automatic and digitalized registration 
of all antidepressants dispensed to the participants to identify incident depressions. Th e 
pharmaceutical records have high reliability and the information from the records is 
particularly useful to specify the date-of-onset of episodes. However, modern antidepres-
sants are commonly prescribed for other indications such as anxiety disorders, sleeping 
disorders, migraine, or neuropathic pain (64, 65). Population surveys and family practices 
studies have shown that 43-56% of patients receiving an antidepressant do not fulfi ll the 
criteria of depression (64, 66-68). 
Th e main rationale for using data from other sources, albeit with diff erent diagnostic 
certainty and reliability, was to ensure that detection of (incident and recurrent) depres-
sions was as high as possible. Increasing the number of cases increases the power of a study. 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Chapter 10 
128
Power is also enhanced by establishing specifi c DSM-IV defi ned diagnoses. In most other 
population-based studies, cases have been defi ned as a score above a pre-specifi ed cut-off  
on a screening instrument for depressive symptoms, mostly the CES-D, or as indicated by 
the use of anti-depressant medication (18, 19, 33, 51). Both CES-D and anti-depressant 
drug use have low specifi city with only around 20% of screen-positives and 50% of users 
of anti-depressant medication having in fact a DSM-defi ned depression (44, 57, 64, 66-
68). (An illustration of loss of power as a result of error in the assessment of depression is 
provided in our study about heart failure: even though the total number of cases of depres-
sive symptoms and syndromes combined (any depression) is almost twice as high as the 
number of depressive syndromes only, the confi dence intervals are wider.) In our study, 
the mental status of CES-D screen-positives was further assessed in a psychiatric interview, 
as explained before. A great advantage of this method is that it provides accurate DSM-IV 
defi ned diagnoses. To take into account the lower levels of diagnostic certainty from the 
medical records, we categorized the information on depressive episodes conservatively. 
Moreover, we regarded antidepressant use without a verifi ed diagnosis from one of the 
other sources as a marker of depressive symptoms in the incidence study, but not in the 
other studies presented in this thesis.
What can be learned from our experience with identifying new occurrence of depression? 
As depicted in fi gure 1, the psychiatric assessments contributed more than the monitoring 
of medical records to the number of identifi ed depressions. Moreover, the most sensitive 
and specifi c of the assessments methods that we used was the two-step procedure with 
CES-D and psychiatric interview in screen-positives during examination rounds. Perhaps 
it would have been more effi  cient to administer this assessment more frequently than every 
four to fi ve years instead of continuously monitoring medical fi les. As late-life depres-
sion recovers in 60% of patients in one year and in 70-80% in two years, an assessment 
Figure 1 Distribution of depressions identifi ed from psychiatric assessments and medical records 
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every two years would probably have been suffi  cient (69-76). A self-report CES-D or 
a 10-item CES-D could have been used for relatively quick and inexpensive screening 
in the interval between examination rounds. To determine the history of depression, a 
validated questionnaire or interview method administered during home interviews by 
trained interviewers could have been used.
Validity
As mentioned before, the major threats to the validity of observational studies are confound-
ing, information bias, and selection bias. Causal diagrams may facilitate discussions about the 
presence of bias in epidemiological studies (see fi gure 2-4). In a causal diagram, the assumed 
causal relationships between exposure (A), outcome (Y) and other variables of interest can 
be schematically illustrated (77, 78). Nodes are used to depict the variables and arrows the 
causal eff ect of one node on another. Variables that merely mediate are usually omitted from 
the diagram. As causes precede their eff ects, the diagrams are acyclic: one can never start from 
one variable and, following the direction of the arrows, end up at the same variable (78). 
Information bias, or measurement bias, is traditionally described as bias resulting from 
error in the measurement of the exposure and disease status. To illustrate information 
bias in a causal diagram, additional nodes are required: A* for measured exposure, Y* 
for measured outcome, and node U for unmeasured variable(s).  Figure 2 presents the 
three mechanisms by which measurement error may give rise to information bias in a 
prospective study (ref ). 
Figure 2 Information bias in prospective studies
     Present (baseline)              Follow-up period 
  
 
                                        
                                              A Y* 
 
A* Y 
U 
Differential information bias: dotted arrow present 
Independent information bias: one dashed arrow out of U present  
Dependent information bias: both dashed arrows out of U present 
A stands for true exposure status, A* for measured exposure status, Y for true outcome status, Y* for measured exposure status, and U 
for unmeasured variables. Boxes around nodes indicate that the variables that are controlled for in the analysis.
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To decrease error in the measurement of the exposure in the studies of this thesis, 
detailed data was collected about cardiovascular and cerebrovascular disease. Again, data 
from the examination rounds and medical fi les were used to establish cases of cardiac 
and cerebrovascular disease. For the imaging study, an MRI was made in a subgroup of 
more than 500 participants. Th e relevance of accurate information on exposure is that 
information bias (and confounding) is reduced. 
Although the information on exposure and outcome were collected independently of 
each other, by diff erent groups of researchers, some diff erential information bias might 
still have occurred. If persons with heart failure or transient neurological attack visited 
their GP or cardiologist more frequently, this will increase the probability that depressions 
were identifi ed. Th us, analyzing these exposures as time varying variables, like we did, may 
reduce independent nondiff erential information bias on the one hand, but induce some 
diff erential information bias on the other. However, given the mean time-lag of more 
than three years between these diseases and depression, the bias is probably small. Similar 
diff erential bias could have occurred in our study about beta-blockers, because physicians 
have been shown before to err in the direction of falsely calling beta-blocker users cases 
than users of other drugs (18).
Confounding occurs when a common cause of the exposure and outcome is not controlled 
for, even if the exposure has no causal eff ect on the outcome (see fi gure 3) (78, 79). Th is 
is shown in fi gure 3 by the presence of the so-called backdoor path (or association) from 
A through L to Y, independent of an arrow between A and Y. 
In the studies of this thesis, confounding was minimized by adjusting for factors that 
were assumed to be common causes of cardio- or cerebrovascular disease as well as depres-
sion according to content knowledge. An abundance of information on socio-demographic 
and health related factors is available in the Rotterdam Study. If the number of baseline 
confounders was relatively high, the factors that hardly changed the risk estimate were 
sometimes not included in the analysis in order to preserve power. In addition, given that 
depression is a risk factor for vascular disease (ref ), we rerun the analyses in the subsamples 
of persons without a history of depression. We also used the time-varying information 
that was available about the occurrence of confounders such as diabetes and myocardial 
infarction. Th us, we were able to extensively adjust for confounding. 
Some residual confounding may still have occurred. We lacked data on thyroid disease 
related to atrial fi brillation, on severity of heart failure in users of loop-diuretics (we did 
not have information on New York Heart Association (NYHA classes I-IV), or cholesterol 
levels when studying transient neurological attacks. Moreover, in pharmaco-epidemiolog-
ical studies confounding by indication may occur. Propranolol, the most commonly used 
high lipid-soluble beta-blocker, is often prescribed for symptoms that are closely related 
to depression such as anxiety, alcoholism, and thyroid disease. Finally, overadjustment 
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Figure 3 Confounding
L A Y
A stands for exposure, Y for outcome, and L for common causes of A and Y, i.e. potential confounder(s) that should be controlled for. 
Boxes around nodes indicate that the variables that are controlled for in the analysis.
may have occurred. In the study on cerebrovascular risk factors, we made one model 
that included all factors, while some factors are not confounders of others. In order to 
avoid overadjustment in the Cox’ regression models of the other studies, we adjusted for 
confounders that are also intermediates by only taking their baseline status into account. 
Selection bias occurs when a common eff ect of the exposure and the outcome is adjusted 
for in the design or analysis (see fi gure 4) (80). Th e box around the common eff ect in 
fi gure 4 depicts that it is adjusted for. 
A major advantage of using multiple sources to identify depression, like we did, is that 
selection bias is reduced. Depressions in participants who are lost to follow-up are less 
easily missed. In the study about cerebrovascular risk factors, for instance, the probability 
that a participant drops out is higher if he has more vascular health problems at baseline 
and if he is depressed at the time of the follow-up measurement (the common eff ect being 
participation in follow-up round). Th is could have lead to underestimation of the true 
risk. (When we later rerun the analysis on our data set with incident cases from multiple 
sources, it yielded similar results.) 
A potential source of selection bias might have occurred as a result of censoring for 
death, because depression in patients with heart or brain disease is often related to higher 
mortality. If patients with heart or brain disease died before their depression was diag-
nosed and recorded, risks will be underestimated. Th e higher baseline age of the study 
population and thereby the death rate, the larger this selection bias may be (81). In our 
dataset, for instance, stroke has a protective eff ect on incident depression. Th is is however 
Figure 4 Selection bias
A Y L
A stands for exposure, Y for outcome, and L for common eff ects of A and Y which should not be controlled for in the study. Boxes 
around nodes indicate that the variables that are controlled for in the analysis.
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implausible, given the abundance of literature showing that stroke actually carries a high 
risk of depression (55). Consequently, adjusting for intermediate (time-varying) stroke has 
possibly led to overestimation of the true risk of transient neurological attacks. 
Recommendation: from associations to causal eff ects
Currently, progression of longitudinal epidemiological studies is primarily sought by 
extending data collection. More and more advanced techniques are used to measure more 
exposure and outcomes, and measure them more accurately. In addition, large population-
based cohorts are observed over long periods. Th e Rotterdam Study, from which the 
data for this thesis have been drawn, is an example of this practice. Unmistakably, these 
initiatives have greatly expanded epidemiological knowledge. However, in many of these 
longitudinal studies conventional statistical methods to control for bias are used, such as 
matching and regression analyses (82, 83). Th ese methods do not allow causal inference of 
the associations that have been examined, because adjustment for common causes that are 
also common eff ects of exposure and outcome introduces selection bias. New methods to 
control for bias should be used. 
As the most realistic interventions often take place over time, statistical methods that 
appropriately handle time-varying exposures and adjust for time-varying confounders to 
estimate their causal eff ect are required. Marginal structural models make use of inverse 
probability weighting to appropriately adjust for measured time-varying confounders af-
fected by prior exposure (84, 85). For example, myocardial infarction can precede the use 
of beta-blockers and the occurrence of depression, but the use of beta-blockers diminishes 
the risk of recurrent myocardial infarction. Conventionally, time-varying confounders are 
adjusted for by adding them in the regression or survival model, but this yields the partial 
eff ect of the exposure on the outcome only. Moreover, selection bias can be introduced 
when the confounder is also a common eff ect. Although the assumption of no residual 
confounding is hard to check, marginal structural models have been shown to yield risk 
estimates comparable to those found in randomized controlled trials (84, 86). In some 
instances, an instrumental variable analysis could be used to diminish bias. Mendelian 
randomization makes use of genetic variants as a randomizer (instrumental variable) to 
estimate unbiased associations in observational studies (87, 88). Th e analysis requires the 
identifi cation of a genetic variant that robustly predicts the exposure of interest, and does 
not predict the outcome except through this exposure (88). For instance, the association 
between obesity and depression may be estimated using genes that predict body mass 
index or waist circumference. 
Finally, some recommendations may be made that relate to daily medical practice. 
We found that heart failure and transient neurological attacks were associated with an 
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increased risk of incident depression. Th ere was no association between atrial fi brilla-
tion, structural brain changes (brain atrophy, brain infarcts and white matter lesions) or 
diminished retinal microcirculation and incident depression. Physicians should take into 
account the role of heart failure and transient neurological attacks in depressed patients. 
In non-depressed patients, treating these conditions as eff ectively as possible in order to 
optimize physical health, might possibly also prevent depression. Our fi ndings require 
further if the goal is to inform public health policy or medical practice. Often we do not 
know the actual procedure by which each subject achieved the exposure of interest, such 
as a cardiac condition (89). Th erefore, an observed diff erence in risk between exposed and 
unexposed participants cannot be translated into a well-defi ned causal eff ect. Studies are 
needed that focus on the eff ect that modifi able lifestyle behaviors, such as exercise and 
smoking, have on depression. All analytic methods for causal inference from observational 
data (stratifi cation/regression, matching, inverse probability weighting, instrumental vari-
able methods) yield eff ect estimates that are only as well defi ned as the interventions that 
are being compared. 
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Summary
Depression occurs frequently. Almost one out of fi ve persons develops a depression at 
least once in his lifetime. Besides genetic predisposition, several external risk factors, such 
as traumatic life events, poverty, female sex, and somatic diseases. Th e aim of the studies 
presented in this thesis was to assess the longitudinal relationship between vascular heart 
and brain disease and the risk of new-onset depression. Th e studiew were embedded in 
the Rotterdam Study. Th is a prospective study among 7983 inhabitans of Ommoord, 
a district of Rotterdam. At the start of the study in 1989 they were 55 years or older. 
During 4-yearly examination rounds, they were interviewed and received multiple tests 
to establish their health status. Health related factors that could infl uence the relationship 
between vascular diseases and depression, and that could bias the results of the studies 
were measured as well. 
We used several sources to identify participants with a depression. Since 1993 par-
ticipants are screened with questionnaire for depressive symptoms during examination 
rounds. Since 1997, screen-positive persons are invited to participate in a psychiatric 
interview. Additionally, medical fi les of general practitioners were continuously monitored 
and pharmacies provided online information on the use of  anti-depressant medication. 
We also used the self-reported histories of depression to identify depressions that had 
occurred before the start of the study and in-between examination rounds. We categorized 
the depressions as depressive syndromes, including DSM-IV defi ned major depression, 
or clinically relevant depressive symptoms. In our study among more than 5000 elderly 
persons new-onset depressions occurred frequently (chapter 2). Th is was due to the high 
incidence of episodes with clinically relevant depressive symptoms and to recurrence of 
depressive syndromes in elderly with a history of depression.  
Subsequently, we studied the association between vascular heart diseases and depression 
and the role of cardiovascular medication in this association. Heart failure is a condition 
in which a problem with the structure or function of the heart impairs its ability to supply 
suffi  cient blood fl ow to meet the body’s needs. In our study, heart failure was not associ-
ated with depressive symptoms, but it was associated with an increased risk of incident 
depressive syndormes (chapter 3). We also found that use of loop-diuretics, which can 
provide quick relief of breathlessness and swollen ankles, was associated with a decreased 
risk of depression. Th ere was no association between atrial fi brillation and late-life depres-
sion. We also studied the risk of depression as a result of atrial fi brillation, the most 
common cardiac arrythmia. When we took diff erences in age and gender between people 
with and without atrial fi brillation into account, atrial fi brillation seemed associated with 
an increased risk of depression (chapter 4). However, this association disappeared when we 
adjusted for diff erences in health status. 
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Beta-blockers are often used for various cardiovascular diseases, such as hypertension, 
myocardial infarction, heart failure, and atrial fi brillation. Our study showed that use of 
beta-blockers in general is not associated with depression (chapter 5). However, in the 
fi rst three months of use, beta-blockers with high lipi-solubility, that penetrate the brain 
relatively easily, are associated with depressive symptoms. In our studypopulation, this 
consisted mostly of propranolol, a beta-blocker usually prescribed for anxiety disorders, 
alcoholism, or thyroid disease. Given the association of these diseases with depression, 
could explain the association of propranolol with depressive symptoms.
Next, we studied the association between cerebrovascular risk factors and diseases and 
new-onset depression. Th is builds on international studies about the ‘vascular depression 
hypothesis’ that proposes that vascular damage to the brain predisposes to late-life depres-
sion. First, we studied wether risk factors for cerebrovascular disease are associated with 
depression. We found that smoking, and the use of antihypertensive drugs, diabetes and 
the Framingham stroke risk score, a composite score indicating the risk of stroke, were as-
sociated with depression (chapter 6). Th e other risk factors, that is high serum cholesterol, 
blood pressure, history of cardiovascular disease, atrial fi brillation, and the use of statins 
and anticoagulants, were not related to depression.
In addition, we studied more direct measures of vascular brain damage. Th e volume 
of retinal vessels refl ect the status of brain vessels. In our study, there was however no 
association between this measure and new-onset depression (chapter 7). Vascular damage 
to the brain can also be measured on MRI-scan in terms of the volume of grey and white 
matter, and the presence of infarcts. In a subsample of our study population such scans 
have been made. Again, we did not fi nd an association: the volume of grey and white 
matter, nor infarcts were related to developing depression (chapter 8). Finally, we studied 
the risk of depression after a transient neurological attack (TIA). Th is is a clinical indicator 
of long-term atherosclerotic damage to the brain. TIAs, like stroke, conveyed an increased 
risk of depression (chapter 9).
We conclude that vascular heart and brain disease with severe or life-threatening symp-
toms, such as heart failure and TIAs, increase the risk of depression. Despite many studies 
showing a cross-sectional associations between subclinical cardio- and cerebrovascular 
disease and depression, we did not fi nd a longitudinal association in our study. Possibly, 
loss of daily functioning and psychological eff ects of vascular heart and brain disease have 
a greater eff ect on the riks of new-onset late-life depression, than the vascular damage 
itself. We close with the recommendation to use statistical randomisation techniques in 
future epidemiological cohort studies to minimize bias.
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Samenvatting
Depressie is een veel voorkomende aandoening. Ongeveer 15-20% van de mensen ontwikkelt 
tenminste één keer in zijn leven een depressie. Behalve een vermoedelijke genetische aanleg, 
bestaan er verscheidene externe risicofactoren, zoals traumatische gebeurtenissen, armoede, 
vrouwelijk geslacht en lichamelijke ziekten. Het doel van het onderzoek in dit proefschrift 
was de longitudinale relatie tussen vaatziekten van hart en hersenen en de ontwikkeling van 
depressie bij oudere mensen te onderzoeken (hoofdstuk 1). Het onderzoek maakte deel uit 
van het Erasmus Rotterdam Gezondheid Onderzoek (ERGO), internationaal bekend als 
‘the Rotterdam Study’. Dit is een prospectief onderzoek waaraan 7983 inwoners van de wijk 
Ommoord in Rotterdam deelnamen. Bij de start van de studie in 1989 waren zij 55 jaar of 
ouder. Tijdens 4-jaarlijkse onderzoeksronden werden zij geïnterviewd en werd een lichame-
lijk onderzoek verricht om hun gezondheidstoestand te bepalen. Gezondheidsfactoren die 
de relatie tussen vasculaire ziekten en depressie kunnen beïnvloeden en de resultaten van het 
onderzoeken zouden kunnen vertekenen werden ook gemeten.
Wij gebruikten verschillende bronnen om deelnemers met een depressie te identifi ceren 
(hoofdstuk 2). Sinds 1993 worden de deelnemers tijdens de onderzoeksronden met een 
vragenlijst gescreend op depressieve symptomen, en sinds 1997 is daar een psychiatrisch 
interview aan toegevoegd voor de mensen die veel depressieve klachten rapporteerden 
tijdens de screening. Verder gebruikten wij medische dossiers van huisartsen inclusief 
de daarin aanwezige correspondentie van specialisten, en ook informatie van apotheken 
over het gebruik van antidepressiva. Daarnaast werd de medische voorgeschiedenis van 
de deelnemers uitgevraagd tijdens de onderzoeksronden om depressies voor het begin van 
de studie en depressies tussen de onderzoeksronden in vast te stellen. Wij onderscheiden 
episoden met depressieve klachten van depressieve syndromen, die ofwel voldeden aan de 
daarvoor algemeen geldende criteria (DSM-IV) of door een arts of een psycholoog waren 
gediagnosticeerd. In ons onderzoek bij meer dan 5000 oudere mensen traden vaak nieuwe 
depressieve episoden op (hoofdstuk 2). Dit bleek te zijn toe te rekenen aan episoden van 
depressieve symptomen en aan terugkerende depressies bij ouderen met een voorgeschiede-
nis van depressie. 
Vervolgens onderzochten we de associatie tussen verschillende cardiovasculaire ziekten en 
depressie en de rol van cardiovasculaire medicatie in deze relatie. Hartfalen treedt op als het 
hart als gevolg van een hartaandoening niet meer in staat is de hoeveelheid bloed rond te 
pompen die het lichaam vraagt. Hartfalen was in ons onderzoek niet geassocieerd met het 
ontwikkelen van depressieve symptomen, maar wel met het ontwikkelen van depressieve 
syndromen (hoofdstuk 3). Patiënten met hartfalen gebruiken vaak lisdiuretica, waardoor 
de klachten van benauwdheid en gezwollen enkels in korte tijd kunnen verminderen. 
De patiënten die deze medicijnen gebruikten hadden een verlaagd risico op depressieve 
syndromen. Ook hebben we het risico op depressie onderzocht als gevolg van boezemfi bril-
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leren, een veel voorkomende hartritmestoornis. Als alleen rekening gehouden werd met 
verschillen in geslacht en leeftijd tussen de mensen met en zonder boezemfi brilleren leek een 
verhoogd risico op depressie te bestaan (hoofdstuk 4). Dit verband bleek echter niet meer 
aanwezig te zijn als ook rekening gehouden werd met verschillen in gezondheidstoestand. 
Beta-blokkers worden vaak gebruikt bij allerlei hart- en vaatziekten, waaronder hoge 
bloeddruk, hartaanval, hartfalen, en boezemfi brilleren. Ons onderzoek toonde aan dat 
gebruik van beta-blokkers in het algemeen niet geassocieerd was met depressie (hoofdstuk 
5). Echter, in de eerste drie maanden van gebruik waren beta-blokkers met een hoge 
vetoplosbaarheid, die relatief gemakkelijk in de hersenen kunnen binnendringen, wel 
geassocieerd met depressieve symptomen. In onze onderzoekspopulatie betreft dat meestal 
propranolol, een middel dat meestal gegeven wordt bij angststoornissen, alcoholisme of 
schildklieraandoeningen. Aangezien deze ziekten vaak geassocieerd zijn met depressie, is 
het de vraag of propranolol een eigenstandig eff ect heeft op het risico van depressie.
Tevens hebben wij de associatie tussen cerebrovasculaire ziekten en depressie onderzocht. 
Dit sluit aan bij het internationale onderzoek naar de ‘vasculaire depressie’ hypothese die 
stelt dat depressies bij ouderen eerder optreden als sprake is van cumulatieve vasculaire 
schade aan het brein. Eerst hebben wij onderzocht of factoren die het risico op vasculaire 
hersenziekten verhogen geassocieerd zijn met depressie (hoofdstuk 6). Wij vonden dat 
roken, het gebruik van een medicijn tegen hoge bloeddruk, diabetes en de Framingham 
stroke risk score, een risicomaat voor de kans op herseninfarct, geassocieerd waren met het 
ontwikkelen van depressie. Alle andere factoren, zoals hoge bloeddruk, verhoogd choles-
terol, een voorgeschiedenis van vaatziekten van het hart, boezemfi brilleren, of gebruik 
van cholesterolverlagende of bloedverdunnende medicijnen waren niet geassocieerd met 
depressie. Vervolgens onderzochten wij meer directe maten voor vaatschade aan het brein. 
Het volume van de (slag)aders van het netvlies weerspiegelen de toestand van de hersenva-
ten. In ons onderzoek was er echter geen relatie tussen deze maat en het ontwikkelen van 
depressie (hoofdstuk 7). De toestand van de hersenen kan ook gemeten worden met een 
MRI-scan. Het volume van de grijze en witte stof, als mede de aanwezigheid van hersenin-
farcten, vormen een maat voor de vaatschade. In een deel van de onderzoekspopulatie was 
een dergelijke scan gemaakt. Opnieuw vonden wij geen verband: het volume van de grijze 
en witte stof, noch herseninfarcten waren geassocieerd met het ontwikkelen van depressie 
(hoofdstuk 8). Tot slot, onderzochten wij het risico op depressie na een transient ischemic 
attack, ook wel TIA. TIAs kunnen optreden als gevolg van langdurige vaatschade van de 
hersenen. TIAs bleken net als hersenberoertes gepaard te gaan met een verhoogd risico op 
depressie (hoofdstuk 9). 
Wij concluderen dat vaatziekten aan hart en hersenen die gepaard gaan met ernstige of 
bedreigende symptomen zoals hartfalen en TIAs het risico op depressie verhogen (hoofdstuk 
10). Ondanks dat in het verleden in dwarsdoorsnede onderzoek vaak een verband gevon-
den werd met vaatziekten aan hart en hersenen, vonden wij in ons longitudinale onderzoek 
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geen verband tussen vasculaire risicofactoren of ziekten zonder duidelijke symptomen en 
het ontwikkelen van depressie. Mogelijk spelen fysieke beperkingen en psychologische ge-
volgen van vasculaire ziekten aan hart en hersenen een belangrijkere rol in het ontwikkelen 
van depressie, dan feitelijke vaatschade aan de hersenen. Ten slotte bevelen wij aan om voor 
nader onderzoek vaker gebruik te maken van statistische technieken om te randomiseren, 
om zodoende de kans op vertekening van de resultaten nog verder te verminderen.
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Dankwoord
Aan het begin mijn promotie-onderzoek zei ik vaak: “De Rotterdam Study is een rijdende 
trein die velen naar hun bestemming heeft gebracht. Ik heb er het volste vertrouwen in dat 
die trein mij daar ook zal brengen.” Nu dat zover is, wil ik de vele mensen bedanken die 
met hun doorlopende inzet de treinreis mogelijk maakten. 
In de eerste plaats zijn dat mijn promotor prof. dr. Bruno Stricker en co-promotor dr. 
Henning Tiemeier. Beste Bruno, bedankt dat je indertijd met zoveel voortvarendheid mijn 
voorstel oppikte om een GeestKracht subsidie bij ZonMw aan te vragen. Ongelofelijk, hoe 
snel je de aanvraag op papier had staan! Ook wil ik je bedanken voor het eindeloze geduld 
waarmee je keer op keer nieuwe resultaten en concepthoofdstukken van commentaar 
voorzag. Eén daarvan was het ‘hoofdpijnhoofdstuk’ over beta-blokkers. Jouw interventies 
leverde mij als bijwerking maar liefst vier extra concept artikelen op. Beste Henning, ik heb 
veel van je geleerd over de dagelijkse onderzoekspraktijk, de epidemiologie als wetenschap, 
en het reilen en zeilen op een grote vakgroep. Bedankt voor je snelle en tegelijk minutieuze 
beoordelingen van teksten en tabellen. Er was geen betere manier om te leren hoe ik een 
artikel langs de reviewers kan krijgen, dan door die te laten lezen door mijn begeleiders.
Op de tweede plaats bedank ik Armin Voogt, Rob Koning en Wim Moonen, managers 
bij BAVO-Europoort/ Parnassia BAVO Groep, voor de broodnodige ‘BAVO tijd’ die ik 
aan mijn proefschrift mocht besteden. Beste Armin, bedankt voor je bijdrage aan een 
goede afl oop en zeker ook voor je standvastige vertrouwen daarin.
Verder wil ik al die mensen bedanken die al vele jaren (mee)werken aan de Rotterdam 
Study: prof. dr. Bert Hofman (machinist van het eerste uur) en de andere hoogleraren, 
alsmede de datamanagers en ICT-medewerkers van de afdeling Epidemiologie, de mede-
werkers van het Ergo-centrum, de huisartsen en apothekers van Ommoord, en niet in de 
laatste plaats de deelnemers van de Rotterdam Study, die belangeloos honderden vragen 
beantwoordden en allerlei testen ondergingen. Ook de co-auteurs ben ik erkentelijk voor 
hun bijdragen, en vooral dr. Arfan Ikram en dr. Kamran Ikram, allebei eerste auteur van 
een hoofdstuk. 
Prof. dr. Niels Mulder, prof. dr. Peter Koudstaal en prof. dr. Dorly Deeg wil ik bedanken 
voor het plaatsnemen in de kleine commissie en het beoordelen van het manuscript. Prof. 
dr. Miriam Sturkenboom, prof. dr. Roos van der Mast en dr. Paul Jansen bedank ik voor 
hun deelname in de grote commissie. 
Naast goede data en inhoudelijke begeleiding, is een gezellige en motiverende werkom-
geving belangrijk geweest voor het slagen van mijn promotie-onderzoek. In het bijzonder 
wil ik Julia van den Berg en Marieke Dekker noemen. Jullie waren niet alleen mede 
dataverzamelaars en later co-auteurs, maar vooral ook enthousiaste en vriendschappelijke 
kamergenoten. Julia, in het begin van de reis hadden we coupé Ee21-36 zo’n beetje voor 
ons zelf: het was constructief samenwerken en verlokkelijk onderhoudend om niet te 
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werken. Marieke, tegen het einde van de rit, toen ‘bladeren op het spoor’ geregeld voor 
vertraging zorgden, steunde jij mij iedere keer weer. Heel erg bedankt, allebei! Voor hun 
gezelligheid wil ik ook de overige (oud)promovendi van de (pharmaco)epi bedanken, en 
met name kamergenoten Claire Siemens, Karin Hek, Martina Teichert, en Rachel Newson. 
Een speciale plaats nemen de collega’s van de BAVO in. Niet alleen de prettige en leerzame 
samenwerking, maar ook ‘het hart voor het vak’ dat jullie hebben was (en is) inspirerend. 
Dat geldt eveneens voor de sociaal geriaters met wie ik in verschillende contexten intensief 
heb mogen samenwerken: Anne Stroomer-van Wijk, Hugo van Andel, Karel Brühl en 
Mike Verkaaik. I would like to thank Miguel Hernán for his most enlightening work 
and lectures on causal inference in epidemiology, and for enabeling the inspiring stay in 
Boston.
Familie en vrienden wil ik bedanken voor al hun belangstelling. Lieve pa en ma, bedankt 
voor de rustige thuishaven die jullie bieden, en niet op zijn minst voor alle uren die jullie 
voor Zian zorgden zodat ik aan mijn proefschrift kon werken. Ook mijn schoonouders, 
Jacques en Femy, wil ik bedanken voor hun steun en oppashulp. Jullie maakten de enerve-
rende en leerzame ‘vakantie’ in Boston mogelijk. Karla en Karel, paranifmen en vrienden, 
ik ben blij dat jullie net als in de aanloop naar, ook tijdens de verdediging van mijn 
proefschrift naast me willen staan.
Lieve Xander, het is gebruikelijk de partner (en kinderen) als laatste te noemen, maar 
eigenlijk kom jij op de eerste plaats. Als iemand mij geholpen heeft was jij het wel: je gaf 
me keer op keer advies over de analyses, je maakte me wegwijs in STATA, en je stimuleerde 
me als de motivatie even op was. Heel erg bedankt! Lieve Zian, jij leverde de broodnodige 
dagelijkse relativering: ijz is (inderdaad) lekkuh! Lief Federtje, jij hebt nog het minst 
meegekregen van de totstandkoming van dit proefschrift. Laten we dat zo houden: tijd 
voor een nieuwe reis!
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